- 1 Proteomic studies of human placentas reveal partnerships associated with
- 2 preeclampsia, diabetes, gravidity, and labor

- 4 Shannon J. Ho^{1,10}, Dale Chaput^{2,10}, Rachel G. Sinkey¹, Amanda H. Garces³, Erika P.
- 5 New¹, Maja Okuka¹, Peng Sang⁴, Sefa Arlier¹, Nihan Semerci¹, Thora S. Steffensen⁵,
- 6 Thomas J. Rutherford^{1,6}, Angel E. Alsina⁷, Jianfeng Cai⁴, Matthew L. Anderson^{1,6},
- 7 Ronald R. Magness¹, Vladimir N. Uversky⁸, Derek A. T. Cummings⁹ & John C. M.
- 8 Tsibris^{1,8 ™}
- ¹Department of Obstetrics and Gynecology, University of South Florida, Tampa, Florida,
- 10 USA. ²Department of Cell Biology, Microbiology and Molecular Biology, University of South
- 11 Florida, Tampa, Florida, USA. ³Lisa Muma Weitz Microscopy Laboratory, University of
- 12 South Florida, USA. ⁴Department of Chemistry, University of South Florida, Tampa,
- 13 Florida, USA. ⁵Department of Pathology, Tampa General Hospital, Tampa, Florida, USA.
- 14 ⁶Cancer Center, Tampa General Hospital, Tampa, Florida, USA. ⁷Transplant Surgery
- 15 Center, Tampa General Hospital, Tampa, Florida, USA. 8Department of Molecular
- 16 Medicine, University of South Florida, Tampa, Florida, USA. ⁹Department of Biology and
- 17 Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA. ¹⁰These authors
- 18 contributed equally. [™]e-mail: tsibris@usf.edu

19

2021

Abstract

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

23

VEGFR2 is a central regulator of placental angiogenesis. The study of the VEGFR2 proteome of chorionic villi at term revealed its partners MDMX and PICALM. The oxytocin receptor (OT-R) and vasopressin V1aR receptor were detected in MDMX and PICALM immunoprecipitations. Immunogold electron microscopy showed VEGFR2 on endothelial cell (EC) nuclei, mitochondria, and Hofbauer cells (HC), the tissue-resident macrophages. MDMX, PICALM, and V1aR were on EC plasma membranes, nuclei, and HC nuclei. Unexpectedly, PICALM and OT-R were detected on EC projections into the fetal lumen and OT-R on 20-150 nm clusters therein, prompting the hypothesis that placental exosomes transport OT-R to the fetus and across the blood-brain barrier. Insights on gestational complications were gained by univariable and multivariable regression analyses associating preeclampsia with lower MDMX protein levels in membrane extracts of chorionic villi, and lower MDMX, PICALM, OT-R, and V1aR with spontaneous vaginal deliveries compared to cesarean deliveries before labor. We found select associations between higher MDMX, PICALM, OT-R and either gravidity, diabetes, BMI, maternal age, or neonatal weight, and correlations between PICALM-OT-R (p<2.7x10⁻⁸), PICALM-V1aR (p<0.006), and OT-R-V1aR (p<0.001). These results offer for exploration new partnerships in metabolic networks, tissue-resident immunity, and labor, notably for HC that predominantly express MDMX.

The placenta is a transient organ that performs the functions of major organs of the fetus, such as lungs, liver, and kidney¹, supplies the fetus and in particular the fetal brain with oxygen and nutrients, and facilitates waste disposal and provides immune protection^{2,3}. The genomes of placenta and fetus are identical except in cases of confined placental mosaicism. The vascular endothelial growth factor A (VEGF-A) is a key regulator of vasculogenesis, angiogenesis and placental growth that acts mainly through VEGFR1 and VEGFR2, two tyrosine kinase single-pass transmembrane receptors⁴⁻⁶.

Preeclampsia is a serious complication of human pregnancy occurring in 5-7% of all gestations with newly-onset hypertension and proteinuria as its primary clinical characteristics^{2,7}. Preeclampsia is a multisystemic syndrome of different subtypes associated with serious health problems to mother and child even after pregnancy⁸. Lipid bilayer-enclosed extracellular vehicles (EV) transport extracellular nucleic acids, proteins, lipids, and metabolites⁹⁻¹². Cancer cells deploy EV to activate VEGF signaling in endothelial cells¹². Exosomes are EV measuring 20–150 nm in diameter. Placental-derived exosomes released in the maternal circulation are associated with pregnancy disorders and parturition¹¹.

Tissue-based maps of the human proteome of many organs, including placentas, have been published, 13-16 but great challenges remain to discover which among the hundreds of detected proteins regulate key metabolic networks, specifically, during normal and complicated pregnancies and labor. To obtain such information, we chose to immunoprecipitate VEGFR2, an ideal target as an extensively documented regulator of placental angiogenesis. To deploy a wide net for the membrane partners of VEGFR2, we analyzed the pellets obtained after high-speed centrifugation of chorionic villi homogenates. Uterine blood in the maternal intervillous space exchanges substances with fetal blood at the villous tree. Although the villi are physically separated from uterine blood^{1,3}, the pellets contain cells and EV from it. To preserve protein complexes, we extracted the pellets with ASB-14 (amidosulfobetaine-14), an efficient non-denaturing detergent. The extracts were immunoprecipitated with the bait antibody (Ab) charged on magnetic beads knowing that extraction of membrane proteins from their native environment could alter their structure and protein links. Mass spectrometry identified proteins immunoprecipitated with VEGFR2, especially its newly discovered placental

partners, the multifunctional MDMX (Double minute 4 protein) and PICALM (Phosphatidylinositol-binding clathrin assembly protein).

MDMX, also known as MDM4 and HDMX, is a zinc-binding protein and a p53 inhibitor acting in coordination with MDM2, a zinc-dependent E3 ubiquitin ligase¹⁷. MDMX and MDM2 have numerous p53-independent activities. In preeclampsia, p53 is upregulated in villous trophoblasts¹⁸. PICALM is a nuclear and plasma membrane protein that interacts with phosphatidylinositol to recruit clathrin and adaptor protein-2, initiates endocytosis of clathrin-coated vesicles, internalizes ligand-receptor complexes, and participates in iron and cholesterol homeostasis 19,20. PICALM is a genetic risk factor for late-onset Alzheimer's disease that participates in amyloid-β transcytosis and processing of amyloid precursor protein (APP). Human placentas express APP and APP-processing enzymes which are increased in preeclampsia²¹. Oxytocin is a hydrophilic neuropeptide and Pitocin, a synthetic oxytocin, is prescribed in the USA to induce labor and decrease postpartum hemorrhage. The oxytocin receptor (OT-R, OXTR) is a magnesium-dependent G protein-coupled receptor²² that activates a phosphatidylinositol-calcium second messenger system²³. OT-R participates in numerous activities ranging from parturition to lactation and mother-child bonding^{22,23}. OT-R functions as a homodimer and in heterocomplexes with vasopressin receptors V1aR (AVPR1A)24, V2R, and other receptors. V1aR is the most abundant among vasoactive receptors in human arteries²⁵.

Here, among the newly detected partners of VEGFR2 we focused on MDMX and PICLAM based on their documented biochemical functions, and their partners OT-R and V1aR. Finding OT-R in exosome-size clusters in the fetal lumen led to the hypothesis that placental OT-R is carried to the fetus in exosomes, potential transporters of future therapeutic agents. MDMX, PICALM, OT-R, and V1aR protein levels, estimated by western blots and relative to an internal control sample, were associated with clinical characteristics of the 44 patients we studied. Potential insights on the molecular mechanisms of placental MDMX and PICALM were gained, respectively, from the cancer and Alzheimer's disease literature.

Results

Immunoprecipitations (IP). Key prerequisite for this study was that VEGFR2 protein complexes withstood tissue freezing and extraction by ASB-14. Since Blue-Native electrophoresis (BN) resolves protein mixtures under non-denaturing conditions, we fractionated placental extracts by BN followed by VEGFR2 immunostaining which revealed streaks extending up to 800 kDa. VEGFR2 monomers appear at 220 kDa in western blots. Apparently, ASB-14 stabilized the extracted protein complexes of VEGFR2. Several proteins described in this study were efficiently extracted by ASB-14 (see Methods). New VEGFR2 partners, MDMX and PICALM, were also selected for IP.

Fig. 1 shows western blots of the fractions eluted from the magnetic beads and used to select the fraction for mass spectrometric analysis. Representative fractions are identified by the patient's assigned letter-number code shown on Table 1. Magnetic beads retained all of the applied VEGFR2 (**A**) as none was detected in the flow-through fraction, but the MDMX and PICALM antibodies charged on the beads retained only a fraction of their target protein as shown, respectively, in **E** and **F**. All target proteins were greatly enriched in the eluted fraction-E relative to the applied placental extract, fraction-X. OT-R co-immunoprecipitated with MDMX (**G**, right side) and with PICALM (**G**, left side), but not with VEGFR2 (**D**). V1aR co-immunoprecipitated with MDMX (**H**, left side) and with PICALM (**H**, right side), but not with VEGFR2 (**C**). Eluted MDMX appeared smaller in the VEGFR2 IP (**B**) and MDMX IP (**E**), whereas PICALM (**F**), OT-R (**G**) and V1aR (**H**) appeared larger. The size of eluted VEGFR2 was the same as in the extracts (**A**).




Fig. 1. Protein elution profiles in VEGFR2, MDMX and PICALM IP. Detergent-extracted villous sample X was incubated with magnetic bead suspension charged with the target Ab (see Methods). E denotes eluted protein fractions. Western blots detected the target proteins eluted in the uniformly performed IP experiments. A. VEGFR2 in VEGFR2-IP. B. MDMX in VEGFR2-IP. C. V1aR in VEGFR2-IP. D. OT-R in VEGFR2-IP. E. MDMX in MDMX-IP. F. PICALM in PICALM-IP. G. Left-side, OT-R in samples from PICALM-IP, and right-side OT-R in samples from MDMX-IP. H. Left-side, V1aR in samples from MDMX-IP, and right-side samples from PICALM-IP. Panel C shows the membrane in B reprobed for V1aR without stripping.

Proteomic analysis. Results of the immunoprecipitations of VEGFR2 (samples O4, O5, O7, U1), MDMX (samples O1, O4, O6, Q1, Q4, R4), and PICALM (samples N3, O1, R4, Q1, Q4, U1) are listed in Tables 2-4. The peptide coverage was not consistent among the placental extracts in each immunoprecipitation group due to different clinical characteristics of the patients whose tissues we tested, and potential differences in post-translational modifications, such as acetylation, and ubiquitination. Soluble proteins in villous homogenates having an affinity for membrane proteins would be retained on the pellets obtained after centrifugation at 100,000*g* for 1h.

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

Select proteins that co-immunoprecipitated with VEGFR2 (Table 2). VEGFR2 was retained on the beads by an Ab raised to the cytoplasmic tail of VEGFR2 exposing extracted proteins to its extracellular, VEGF-binding, domain (see Methods). Therefore, most VEGFR2 partners must have interacted, even after VEGFR2 internalization, with its extracellular rather than its intracellular tyrosine kinase domain, and in binary associations while fewer would bind via some intermediate protein partners. In principle, VEGFR2, MDMX, and PICALM isoforms post-translationally modified at the target sequence of the immunoprecipitating antibodies, are unlikely to be retained on the beads. Our experimental design provided only an estimate of peptide levels in each placental sample. Very basic proteins, such as VEGF-A (pl=9.2), were not detected due to excessive trypsin digestion of these mostly intrinsically disordered proteins prior to mass spectrometric analysis. For example, more than 65% of the VEGF-A residues are expected to be disordered. Nevertheless, western blot analysis showed that VEGF-A co-immunoprecipitated in VEGFR2 IP, and that OT-R (pl=9.6) and V1aR (pl=9.5) co-immunoprecipitated in MDMX and PICALM IP. p53 and MDM2 were detected in IP eluates only by western blots. Under our protocol, proteins larger than 220 kDa were, most likely, identified by peptides from their smaller forms in the placenta.

The E3 ubiquitin ligase TRIM21 (tripartite motif-containing protein 21) coimmunoprecipitated with VEGFR2 and in MDMX and PICALM IP (Tables 2-4). TRIM21, a member of the large TRIM family, contains a zinc-binding as well as other motifs. TRIM21 is found in the cytosol and nucleus and is unique among all proteins as the highest-affinity Fc receptor in humans²⁶. TRIM21 does not distinguish free from bound antibodies. Another VEGFR2 partner was PDC-E2 (*DLAT*), the E2 component of pyruvate dehydrogenase (Table 2). The association of PDC-E2 with VEGFR2 probably occurs in the nuclei²⁷ and mitochondria, as discussed later, and is shown in the vasculature of the villi (video). Other VEGFR2 partners were complement components (Table 2) revealing complement activation known to occur in placental dysfunctions²⁸. Immunoglobulin heavy constant alpha 1 (*IGHA1*), an autoantibody antigen and signature protein of plasma cells²⁹, was among the large amounts of immunoglobulins detected that are carried by placental endothelial cells³⁰ and maternal blood cells. A smaller than 220 kDa form of the giant protein titin was also detected in VEGFR2 and PICALM IP (Tables 2, 4).

Select proteins that co-immunoprecipitated with MDMX and PICALM (Tables 3, 4).

VEGFR2 was not detected in MDMX and PICALM IP, probably because of the limited binding capacity of the MDMX and PICALM antibody charged on the beads. Among the proteins that co-immunoprecipitated with MDMX were PICALM, annexins, arginase-1, RNA-binding protein HNPNPA2B1³¹ and others that immunoprecipitated also in VEGFR2 and PICALM IP (Tables 2, 4). Protein-glutamine gamma-glutamyltransferase 2 (*TGM2*), which co-immunoprecipitated with MDMX and PICALM (Tables 3, 4), catalyzes protein cross-linking, is considered a bridge between inflammation and hypertension, and is upregulated in preeclampsia³². We indicated in Table 3 the few proteins common in VEGFR2, MDMX and PICALM immunoprecipitations, and many more that co-immunoprecipitated only with MDMX, likely members of the HC proteome. After an initial statistical analysis associated MDMX with the mode of delivery, we were prompted to study the OT-R, which is activated in the myometrium causing uterine contractions²², and its partner V1aR, after validating two commercial antibodies (Figure 10).

Immunohistochemistry and whole mount immunofluorescence. VEGFR2 strongly stained the endothelium of the villous capillaries (Fig. 2A). TRIM21 staining is seen in the cytoplasm of villous trophoblasts and stronger staining in intervillous maternal leukocytes (Fig. 2B, arrows). MDMX is predominantly expressed (Fig. 2, C and D) on Hofbauer cells (HC)³³⁻³⁷ that are targets of Zika and other viruses³⁸. Strong MDMX staining was limited to the cytoplasm of HC, easily identified within the villous stroma, some within stromal channels (Fig. 2C). CD163^{33,39}, a marker for placental macrophages⁴⁰, stained the




Fig. 2. Immunohistochemical staining of placental sections. **A.** VEGFR2 immunostaining is strongly positive in villous endothelial cells (patient Q3). **B.** TRIM21 is uniformly positive in villous trophoblast (patient N4). Very strong staining is seen of maternal leukocytes (arrows). **C.** MDMX is strongly positive in the cytoplasm of HC and moderately positive in endothelial cells (patient W2). **D.** CD163 is strongly positive in the cytoplasm of the HC (patient U1). **E.** PICALM is strongly positive in the trophoblast (patient R4). **F.** PICALM positivity seen in the villous endothelial cells and fetal blood leukocytes (patient R4). Magnifications in A-F were 10x, 20x and 40x.

The co-localization of VEGFR2 (red) and PDC-E2 (green) in endothelial cells of the villous vasculature of a normotensive patient is shown on the video obtained from reconstructed stacked images of whole mount immunofluorescence. Nuclei were stained blue with DAPI.

Immunogold electron microscopy (IGEM). VEGFR2 was localized along segments of endoplasmic reticulum, and in mitochondria (Fig. 3). MDMX was localized diffusely within the cytoplasm of an HC and was seen clustering in the nucleus and cytosol. Clusters ran along the nuclear membrane and appeared associated with mitochondrial and endoplasmic reticulum membranes (Fig. 4). PICALM was localized to endothelial cell junctions, along endothelial cell plasma membrane, in cytoplasmic projection into the lumen and adjacent stroma and fetal blood (Fig. 5). OT-R was detected in endoplasmic reticulum and cytoplasmic "peninsulas" of endothelial cells extending into the lumen and on clusters (Fig. 6). V1aR was localized to endothelial cell membrane, nucleus, and stroma. V1aR was also seen on a fetal RBC (Fig. 7). Details are seen in Figures 3-7.




Fig. 3. Detection of VEGFR2 by IGEM in chorionic villi of placenta Ho-73 (preeclamptic). A. Top left micrograph shows a villous capillary. P: pericyte, E: RBC, SC: stromal cells. Bottom image details area outlined on the top micrograph and shows endothelial cell (EC) cytoplasm, pericyte (P), tight junction (*), collagen fibers in villous stroma (VS), and capillary lumen (L). Image at right: Enlargement of area outlined on the bottom left shows VEGFR2 in mitochondria (arrows). B. Micrograph on top left shows villous capillary, stroma (S), luminal RBC (E), and Hofbauer cell (HC). Enlargement of rectangle at bottom shows prominent nucleolus, mitochondria, and endoplasmic reticulum of HC. Micrographs on the right show enlargement of areas outlined on the bottom left

micrograph that detail clusters of VEGFR2 (arrows) in the cytosol (C), along segments of endoplasmic reticulum (ER), and mitochondria (M). Enlargement of image at bottom right shows diffuse localization of VEGFR2 clusters throughout the nucleoplasm (arrows). **C.** Top left micrograph: Villus stroma depicting a fibroblast (Fb), and a pericyte (P) associated with fetal capillary in partial profile, RBC (E), and EC cytoplasm. Bottom left is enlargement of area outlined on the top graph and shows fibroblast cytosol, mitochondria (M), and villous stroma (S). To the right, enlargement of two areas show VEGFR2 in cytoplasm and in partial profiles of mitochondrial matrix (white arrow heads). **D.** A TEM micrograph after osmication provided a better outline of mitochondria in an EC, compared to **A, B** and **C** panels. **E.** Fetal capillaries with luminal RBC (E) are shown in the top left image, IS: intervillous space; mE: maternal RBC. Bottom: enlargement of outlined area shows a fetal macrophage in greater detail; a syncytiotrophoblast (SCT) is also present. Right micrograph: enlargement of area in bottom left micrograph, points to VEGFR2 labelling in an incomplete profile of a mitochondrion. Dashed arrows outline the outer double membrane of the labeled and unlabeled mitochondria. The gold particle diameter is 6 nm.




Fig. 4. Detection of MDMX by IGEM in chorionic villi of placentas Ho-71 (normotensive) and Ho-73 (preeclamptic). A. Left micrograph: Nucleus (N) of endothelial cell (EC) from Ho-73. Arrow heads point to small MDMX clusters, parallel to the inner aspect of the EC plasma membrane. Area outlined, top left: EC junction; P: pericyte process; E: RBC in capillary lumen, S: stroma. This area is enlarged on the top right graph and shows MDMX clusters along the junction (Ju), and endoplasmic reticulum

(ER). Bottom right: enlargement of outlined area shows diffuse pattern of MDMX clusters throughout the nucleoplasm. **B.** Top left micrograph shows an outline of apoptotic macrophage in the lumen of fetal capillary (cap) from Ho-71. P: pericyte, F: partial profile of fibroblast (F) and HC partially marked by a white outline. Enlargement on the top right image shows diffuse MDMX localization in the vacuolated cytoplasm of luminal macrophage. Image at bottom left is enlargement of area outlined in white and shows MDMX clustering in the nucleus (N) and cytosol of the HC. Clusters, averaging 50-100 nm in diameter, run along the nuclear membrane and appear to be associated with mitochondrial and endoplasmic reticulum membranes. Bottom right: enlarged area shows MDMX clusters of approximately 100 nm. The gold particle diameter is 6 nm.




Fig. 5. Detection of PICALM in chorionic villi of placentas Ho-71 (normotensive) and Ho-73 (preeclamptic). A. Top IGEM micrograph: partial profile of villus capillary from Ho-71. EC: endothelial cells; E: RBC; stroma. Bottom images: enlargement of two selected areas of endothelium show PICALM localization (arrows) at EC junctions (Ju), along EC plasma membrane, in cytoplasmic projections into lumen (L) and adjacent stroma (S). B. Top micrograph: the nuclei of endothelium of a villus capillary from Ho-71, and the adjacent pericyte (P) are patent. Bottom image: enlargement of nucleus, shows PICALM in

nucleoplasm near chromatin, on EC cytoplasmic membrane (white arrows) and in luminal space (black arrow). **C.** Top micrograph: HC in stroma of Ho-73. E: RBC in capillary. At bottom: enlargement shows PICALM in HC nucleus (arrows). **D.** Top micrograph: HC cell in the stroma of placenta Ho-71. Bottom image: enlargement shows PICALM in nucleoplasm in association with chromatin. **E.** PICALM is shown (arrows) at the junction (Ju), and plasma membrane of EC and in adjacent stroma (S) of fetal capillary from Ho-73. **F.** PICALM is shown (arrows) in cytoplasm and plasma membrane of EC of capillary from Ho-71, and in basal lamina (BL), stroma (S) and capillary lumen. The gold particle diameter is 10 nm.




Fig. 6. Detection of Oxytocin Receptor (OT-R) in chorionic villi of placentas of normotensive Ho-71, and preeclamptic Ho-73 patients. A. Top IGEM micrograph: Villus capillary from Ho-71. P: pericyte adjacent to the endothelial cell (EC); L: lumen. White arrow shows cluster of PICALM on P. Bottom: enlargement shows OT-R in endoplasmic reticulum (ER) and cytoplasm projections of EC into the lumen. (arrows). **B.** Top micrograph: Partial view of villus capillary from Ho73, E: RBC; S: stroma. Bottom graph shows EC junction (J) and OT-R clusters on J, EC cytoplasm, and lumen (arrow). **C.** OT-R is seen in the nucleus of an EC from Ho-73. The gold particle diameter is 10 nm.




Fig. 7. Detection of Vasopressin Receptor V1aR in chorionic villus of placenta Ho-72 (diabetic). A. Composite IGEM image shows nucleus of HC in stroma on the left and enlargements of three demarcated regions of its nucleus on the right. V1aR clusters, 20-100 nm, in the nucleus are indicated by arrows. **B.** Top micrograph shows EC aspect of a villus capillary. Bottom image is enlargement that shows V1aR on EC membrane, nucleus, and stroma (arrows). **C.** Top micrograph shows aspect of EC of villus capillary; an RBC is seen in the lumen. Bottom image is enlargement that shows several 20-100 nm clusters of V1aR on surface of the RBC (arrows). The gold particle diameter is 10 nm.




Fig. 8. Transmission electron microscopy of osmicated chorionic villus from placenta Ho-73 (preeclamptic). A. An exosome⁹ is shown in the lumen with the characteristic lipid bilayer adjacent to RBC (E). B. A dense particle with a lipid bilayer, perhaps an exomere¹², is shown in the lumen next to an RBC (E). Scale in A and B is 50 μ m.

Statistical analysis of protein levels in placental extracts. To estimate the protein levels of MDMX, PICALM, OT-R and V1aR, we analyzed by western blots 25 µg protein from each of the 44 placental extracts (Table 1). The intensity of the native-protein band, shown at the top of the representative western blots in Fig. 9, is relative to an internal control sample (Q1 or V1) taken as 100% (Table 5). Violin plots show the analysis of the mean protein levels (Fig. 9) among different clinical conditions. Precluded from the statistical analysis were VEGFR2, since its protein levels did not differ significantly among the 44 placentas analyzed in this study, and TRIM21 due to extensive degradation of its native 50-kDa form in our placental extracts.




Fig. 9. Representative western blots (A) of MDMX, PICALM, OT-R, and V1aR, and violin plots of their relative protein levels associated with diabetes, gravidity, labor, neonatal weight, preeclampsia, BMI, or maternal age, as indicated in B-E. Western blots show the molecular mass (kDa) and the placental extracts identified by a letternumber code shown in Table 1. Internal control for MDMX and PICALM was sample Q1, and sample V1 for OT-R and V1aR.

Next, we performed univariable and multivariable analyses, shown in Tables 6-12, to test whether the mean protein levels of MDMX, PICALM, OT-R and V1aR, represented by western blot band intensity of placental extracts and relative to an internal reference sample Q1 or T1, varied as a function of maternal age, gravidity, gestational age, body mass index, race, preeclampsia, diabetic status, delivery mode, neonatal sex, and neonatal weight. Preeclamptic patients were compared to non-preeclamptic, and diabetic to non-diabetic patients.

Univariable analysis of protein levels. Protein expression units are the percent values relative to an internal control sample taken as 100% (Table 5).

MDMX protein levels were associated with diabetes with an increase of 47.63 units (95% CI 14.27, 90.00) among those with Type II diabetes and 47.91 (95% CI 5.51, 90.32) among those with gestational diabetes mellitus (GDM) compared to those without diabetes, and gravidity with an increase of 9.66 (95% CI 3.59, 15.70) with each unit increase in gravidity, neonatal weight (an increase of 0.03 (95% CI 0.01, 0.06) for each increase in grams), and preeclampsia (-44.13 (95% CI -71.63, -16.64). Regarding the mode of delivery, cesarean delivery, CD, prior to the onset of labor was associated with an increase of 56.16 (95% CI 24.13, 88.18) compared to those with SVD. See Table 6 for full results. Recently, CD163 expression in Hofbauer cells was associated with BMI, gravidity, and fetal birthweight⁴¹.

Increased PICALM levels were associated with maternal age with an increase of 3.68 (95% CI 0.28, 7.08) in intensity for each year increase, and body mass index with an increase of 2.06 (95% CI 0.66, 3.45) for each unit increase. Regarding the mode of delivery, CD prior to the onset of labor had an increase of 59.96 (19.24, 100.68) compared to those with SVD. See Table 7 for full results.

OT-R protein levels were associated with maternal age, an increase of 1.56 (95% CI 0.13, 2.99) for each year of age, and diabetes with an increase of 24.16 (95% CI 5.47, 42.85) among those with Type II diabetes compared to those without diabetes. Neonatal weight was associated with an increase of 0.01 (95% CI 8.36x10⁻⁴, 0.03) for each increase in grams. See Table 8 for full results.

V1aR protein levels were statistically significantly associated with mode of delivery, CD prior to onset of labor 20.36 (95% CI 10.58, 30.13) compared to SVD. See Table 9 for

full results. No associations were found for race, neonatal sex, or gestational age between 35-42 weeks for any outcome.

Multivariable analysis of protein levels. A multivariable model considered simultaneously all variables that were statistically significant in univariable analysis. MDMX protein levels showed a statistically significantly association with gravidity 7.19 (95% CI 1.24, 13.14), and preeclampsia -40.61 (95% CI -66.18, -15.04) as shown on Table 10. There were no significant associations for PICALM or OT-R as shown in Tables 11-12. The best fit model for V1aR included only an intercept (no covariate).

To account for the spread in the replicate measurements of MDMX, PICALM, OTand V1aR (Table 5), we carried out the bootstrapping analysis shown in Tables 14-19. The statistical results were robust to bootstrapped resampling (n=1000) of data points included in the analyses.

We also looked at the correlation of MDMX, PICALM, OT-R and V1aR protein levels with each other and found significant correlations between PICALM and OT-R (0.72 95% CI 0.54, 0.84, p<2.7x10⁻⁸), PICALM and V1aR (0.41 95% CI 0.12, 0.63, p<0.006), and OT-R and V1aR (0.47 95% CI 0.20, 0.67, p<0.001). MDMX was not correlated with PICALM, OT-R or V1aR.

Discussion

Mass spectrometry placed VEGFR2, MDMX and PICALM and their partners in the molecular landscape of chorionic villi of placentas at term. The co-immunoprecipitated proteins represent the most prevalent and stable complexes. IGEM provided a detailed map of VEGFR2, MDMX, PICALM, OT-R and V1aR in the villi, and hints about protein traffic, specifically, of placental exosomes transporting OT-R to the fetus. In future studies, IGEM can show if two proteins are within 10-20 Å of each other, with secondary antibodies labeled with gold particles of different size⁴², such as 6 nm and 12 nm, even though larger particles may occasionally eclipse the smaller ones.

A comprehensive statistical analysis of 44 placental extracts associated MDMX, PICALM, OT-R and V1aR protein levels with labor at term and a number of clinical parameters and gestational complications. Further studies may assign their binary protein

interactions into networks of signaling partnerships among patient groups with normal gestation and gestational complications.⁴³ The predominant expression of MDMX on fetal macrophages (HC)³⁷ and the association of MDMX levels in the villi with most of the clinical characteristics we tested, suggest that MDMX has a central role in comorbidities, that originate from deficient trophoblast proliferation,⁴⁴ and are linked to pre-existing conditions and environmental exposures.⁴⁵

MDMX immunoprecipitations. We were puzzled that the immunoprecipitated MDMX had a molecular mass of 50 kDa, instead of 75 kDa in the placental extracts (Fig. 1, B and E). A possible explanation was offered by the discovery⁴⁶ that MDMX interacts with TRPM7. a bi-functional cation channel protein fused with a kinase domain. TRPM7 is a master regulator of the cellular balance of divalent cations, that mediates the uptake of Zn²⁺, Mg²⁺ and Ca²⁺,⁴⁷ and senses oxidative stress to release Zn²⁺ from intracellular vesicles⁴⁸. TRPM7 regulates MDMX levels by modulating Zn²⁺ concentration, and induces the formation of faster moving forms of MDMX on SDS-PAGE gels⁴⁶. These forms depend on the channel function of TRPM7 and proteasomal degradation. We hypothesize that placental TRPM7, which is downregulated in preeclampsia, 49 interacted with MDMX during the overnight incubation with the immunoprecipitation beads stripping MDMX of Zn²⁺. Proteasomal degradation was prevented by including MG-132 in our tissue-extraction and IP buffer. We missed detecting TRPM7 because it did not enter the top section of the 4-12% Bis-Tris NuPAGE gels we used to fractionate the IP proteins with and submit the 25-220 kDa strips for proteomic analysis (see Methods). TRPM7 has a theoretical mass of 213 kDa and pl 8.1, but on SDS-PAGE gels it is shown at 230 kDa and was reported at 245 kDa in BN electrophoresis.

Autoantibody antigens and TRIM21. Although our patients did not show symptoms of autoimmune diseases, a few of the immunoprecipitated proteins listed on Table 20 were also among the autoantigens detected by Neiman *et al.* in healthy adults⁵⁰, such as the extensively studied autoantigens TRIM21/Ro(SS-A) and PDC-E2, also an autoantigen in primary biliary cholangitis and other autoimmune diseases. PDC-E2 would be held on the beads as a partner of VEGFR2. TRIM21 is also extracted from intervillous maternal

leucocytes based on their staining with TRIM21 (Fig. 2B). Maternal autoantigen-autoantibody complexes, with an affinity for proteins in the villous membrane fraction, would be trapped on the beads by Fc-receptor TRIM21 based on its high affinity for IgG²⁶. Since TRIM21 has broad species specificity, it could bind to the sheep anti-rabbit Ab on the Dynabeads and the IP-bait, the anti-rabbit Ab the beads were charged with. If TRIM21 clusters on the beads remain catalytically active, they could, in principle, retain VEGFR2, MDMX and PICALM, as substrates of ubiquitin ligases, along with other proteins, many not *in vivo* TRIM21 substrates, detected by mass spectrometry. Consequently, TRIM21 can confound immunoprecipitations, performed according to our protocol, by retaining proteins unrelated to the bait-Ab. Based on the extensive TRIM21 literature, placental TRIM21 could participate in metabolic pathways as an E3 ubiquitin ligase, ^{51,52} and as Fc receptor defending against infections.

Immunohistochemistry and immunogold electron microscopy. The distribution of VEGFR2, MDMX and PICALM in the villi was shown by IHC (Fig. 2) and by IGEM which also showed the distribution of OT-R and V1aR (Figures 3-7). VEGFR2 was detected in the nucleus, as previously reported^{27,53}, and in mitochondria, a novel observation to the best of our knowledge (Fig. 3, panels A, B and C). Translocation in the other direction, mitochondria to the nucleus, was shown for the entire pyruvate dehydrogenase complex to supply acetyl-CoA for histone acetylation⁵⁴. VEGFR2 is distributed through relay networks in lipid rafts and endosomal trafficking⁵⁵ and SUMOylation holds VEGFR2 at the traffic control Golgi apparatus⁵⁶. Gradients in receptor concentration may exist along the placental vascular tree, as was shown for the purinergic P2Y₂ receptor (pl=9.7)⁵⁷. Distortion of receptor gradients in preeclampsia and diabetes could affect protein traffic and even expose proteins to degradation. Regarding the latter, it may be pertinent to consider the mechanism of action of estrogen receptor antagonists that decreased the estrogen receptor intra-nuclear mobility and subsequently induced its turnover⁵⁸.

MDMX appeared in nuclear clusters (Fig. 4, A and B). PICALM was detected in nuclei (Fig. 5, B and C). The very basic OT-R and V1aR were also detected (Figures 6 and 7). Surprisingly, clusters of V1aR became clearly visible on a fetal RBC after increasing gamma (Fig. 7, C). Since vasopressin receptors participate in erythropoiesis⁵⁹

their presence on RBC was not very surprising. We hypothesize that in addition to non-traditional functions, such as critical immune sensors,⁶⁰ RBC transport V1aR to the endothelial cells of the villi²⁵.

PICALM and OT-R were detected on endothelial cell projections into the fetal lumen (Figures 5A, 6A) where OT-R clusters were also observed (Fig. 6, A and B) matching the dimensions of microvesicles-exosomes^{10,11}. Although we cannot prove that OT-R clusters are inside exosomes with the characteristic bi-lipid membranes, as seen in standard EM cellular morphology, we propose that fetal exosomes carry to the fetus the OT-R and other proteins produced in the placenta. A limitation of IGEM, from the exosome perspective, is that bi-lipid layers are greatly impaired during the processing of tissues because OsO4 is omitted in a post-fixation step used to increase the visualization of such membranes. OsO4 reacts strongly with lipid complexes, and while it enhances contrast for standard EM cell morphological imaging, it can oxidize many antigen epitopes in IGEM. Fig. 8 shows representative intraluminal vesicles⁹ seen in the fetal capillary of the placenta sample that was processed with the OsO₄ post-fixational step included. Membranes are more clearly defined here, compared to the IGEM sample, representing exosomes or microvesicles⁹ in the fetal lumen (Fig. 8, A and B). We noticed similarities between our IGEM Figures 5 and 6 and transmission electron microscopy images in a study at two polluted cities in Mexico showing that environmental nanoparticles of Fe, Ti, Cu, Hg and Sn accumulated in HC and endothelial cells of chorionic villi sampled at term⁶¹.

Statistical analysis of protein levels and clinical presentations. Our search for the function of the newly detected placental membrane proteins MDMX, PICALM, and of OTR and V1aR, was accelerated by a statistical analysis of their protein levels, which revealed numerous associations with clinical characteristics of the 44 patients. MDMX, located predominantly in HC (Fig. 2C), took center stage based on its association with most of the clinical characteristics we tested. Although many of our statistical associations from 44 placentas are highly unlikely to be observed by chance, our conclusions could change by testing a larger number of placenta samples and integrating, after further research, protein isoforms and post-translational modifications of the newly detected proteins. But to what extent did proteins from intervillous blood, reflecting also the maternal

immune system,⁴⁵ contribute to the observed clinical associations? An initial answer was provided for MDMX by the statistical analyses showing that tissue-resident HC contributed most extensively since they predominantly express MDMX (Fig. 2).

Diabetes. In diabetic patients, higher MDMX levels (Table 6) seem to correspond to the higher number of cells stained with CD163⁶², a marker of HC³⁹. It is not known if MDMX upregulation and higher HC numbers mark a metabolic shift towards diabetes. A diabetic atherosclerosis rat model showed upregulation of MDMX mRNA and protein levels⁶³. MDMX was shown in cell cultures to serve as a nutrient sensor by inhibiting mTORC1⁶⁴. HC could facilitate nutrient transportation in the villous stroma³⁴ linking placental MDMX to nutrient levels and metabolic networks. OT-R levels are higher in Type 2 diabetes (Table 8), and there is an association of *OXTR* variants with insulin sensitivity and Type 2 diabetes⁶⁵.

Preeclampsia. Villous trophoblasts in pregnancies complicated by preeclampsia had higher p53 and lower MDM2 levels 18 . Although MDMX was not measured, we believe it would have been decreased also. Lower MDMX levels (Tables 6, 10) could reflect the decreased numbers of HC in preeclampsia 40,41 . What can cause the decrease of HC? In cancer, abnormal vascularity disrupts the penetration of immune cells, 66 and their function is hindered by the tumor microenvironment 67,68 . Here, defective placental vascularity and increased placental stiffness 69 , both changing the architecture of the villi, could have an adverse effect on HC levels. In preeclampsia, placental stiffness could be increased by higher levels of tissue transglutaminase/TGM2 (Tables 3, 4) which catalyzes protein crosslinking 32 . MDMX could be involved in the reprogramming of fetal macrophages (HC) during preeclampsia and other gestational complications and labor. Drawing from the breast cancer literature 70 , downregulation of placental MDMX in preeclampsia could be linked to estrogen receptor- α^{71} and lower estrogen levels 72,73 .

In preeclampsia large quantities of magnesium sulfate are prescribed to prevent seizures. A potentially relevant study of a blood-brain barrier (BBB) model of primary endothelial cells from human brain 74 , showed that TRPM7 mediated the entry of extracellular Mg²⁺ into cells and that high Mg²⁺ levels speeded up the clearance of A β to

the blood side via BBB transcytosis and upregulation of PICALM and LRP-1 that is also expressed in HC⁷⁵. It was shown recently that TRPM7 kinase activity induces amyloid- β degradation and clearance⁷⁶. Among other mechanisms, the accumulation of placental A β ²¹ could be related to TRPM7 and limiting PICALM-dependent transcytosis.

Gravidity. Univariable and multivariable regression analysis found a significant association of gravidity with MDMX levels (Tables 6, 10). Gravidity was recently associated with HC levels determined by CD163 immunostaining⁴¹. While multigravida women have shorter telomeres and increased DNA methylation age,⁷⁷ a role of p53 and MDMX on telomere length is not established in normal human tissues, to the best of our knowledge. DNA methylation age is associated with MDMX and prenatal smoke exposure⁷⁸. The gravidity-MDMX association, which registers in the villi, could reflect the cost of multiple pregnancies to the mother⁷⁹.

PICALM, **OT-R** and **V1aR**. The association of placental PICALM levels with BMI (Table 7) is intriguing because the placenta functions in the absence of adipocytes. A potential precedent for such association was provided by a study on gastric bypass surgery where PICALM mRNA levels in the blood were decreased after a significant drop of BMI⁸⁰. Furthermore, among the Alzheimer's risk nucleotide polymorphisms (SNP), a PICALM SNP is associated with obesity⁸¹.

The strong correlation of protein levels of PICALM with OT-R (p<2.7x10⁻⁸), PICALM with V1aR (p<0.006), and OT-R with V1aR (p<0.001) point to fundamental interactions by yet unknown mechanisms. MDMX was not correlated with PICALM, OT-R or V1aR.

Downregulation of OT-R in spontaneous vaginal deliveries (SVD) relative to CD prior to the onset of labor (Table 8), would be consistent with the higher oxytocin levels in SVD than CD. It is not known to what extend extravillous blood cells and exosomes may have supplied OT-R, and V1aR, detected in placental membrane extracts. Nevertheless, IGEM images of the chorionic villi support the hypothesis that the lipid-covered exosomes carry a cargo of the very basic, magnesium-dependent OT-R across the blood-brain barrier to interact also with fetal microglia⁸²⁻⁸⁴, the resident immune cells of the brain⁸⁵. OT-R protein levels in venous and arterial blood from the umbilical cord may reveal differences

in bi-directional OT-R traffic in normal, preterm and postterm deliveries. In that case, OT-R protein levels and epigenetic modifications⁸⁶ may lead to therapeutic interventions with exosomes⁸⁷ prepared, ideally, with the transmembrane orientation¹² of OT-R in villous exosomes.

Labor. The decrease of MDMX in the membrane fraction of chorionic villi in SVD vs. CD prior to the onset of labor (Table 6), could be related to the decrease of immune cells in peripheral maternal blood with approaching labor⁸⁸, and the molecular signature of the "immune clock". 45,89 Lower MDMX levels could also indicate a molecular switch in late gestation, locally, to energy-preserving measures or other mechanisms involving uterine macrophages⁹⁰. MDMX, PICALM, OT-R and V1aR could be components of the fetal and maternal immune system during pregnancy and as the fetus develops immunity in preparation for birth. 91,92 Concomitant downregulation of MDMX, PICALM, OT-R and V1aR occurred only in SVD compared to CD prior to the onset of labor (Tables 6-9) signifying a potential convergence of metabolic networks to prepare the uterus for the final act in pregnancy, delivery of the fetus.

Materials and methods

Human Subjects. All patients signed consent forms prior to their inclusion in the study according to the protocol approved by the Institutional Review Board of the University of South Florida and Tampa General Hospital. Placental samples were obtained from 44 patients with singleton pregnancies, aged 19-40 and gestational ages ranging from 35-42 weeks based on the dating criteria from the American College of Obstetricians and Gynecologists (ACOG) (https://pubmed.ncbi.nlm.nih.gov/28426621/) for women who delivered vaginally or by cesarean delivery (CD), between 7 AM to 4 PM, based on obstetric indications (Table 1). Patients were excluded if they had active viral infections or fetal growth restriction, defined as estimated fetal weight of <10th% per the Hadlock growth curve. Preeclampsia was diagnosed according to the criteria established in 2013 by ACOG (DOI: 10.1097/01.AOG.0000437382.03963.88). Low risk pregnancy was defined by the absence of maternal co-morbidities including chronic hypertension defined as

hypertension prior to pregnancy or systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg prior to 20 weeks' gestation, pregestational or gestational diabetes, smoking, renal disease, and autoimmune disease. Patients with preeclampsia with severe features defined by the 2013 ACOG Guidelines received magnesium sulfate for seizure prophylaxis during induction of labor or CD through 24*h* postpartum. The demographic Table 21 shows that 91% of study participants were 18-34 years old and 75% were multiparous. Most participants (91%) were ≥37 weeks' gestation. There was no risk of bias in the selection of placentas which was at random. Sample/patient IDs (e.g., H-1, J-1, etc.) are not known to anyone outside the research group, and are assigned identifiers not using any personally identifiable information.

Reagents. Most of the reagents were purchased from Thermo Fisher Scientific (Waltham, MA, USA), MMP-200 metalloprotease inhibitor III, proteasome inhibitor MG-132, protease inhibitor cocktail III, marimastat, Hammarsten-grade casein, detergent ASB-14, Novagen S-protein HRP conjugate 69047-3, Novex 4-12% BT SDS-PAGE gels, CL-XPosure film, magnetic Dynabeads M-280 charged with sheep anti-rabbit antibodies, Maxisorp Nunc C-bottom 8-well strips, protein assay Pierce BCA 562 nm kit 23225 (Pierce, Rockford, IL), and Protein Perfect HRP MW markers 69079-3/ Millipore-Calbiochem (Billerica, MA). Additional reagents are provided in the sections below.

Antibodies (Protein target/vendor). VEGFR2 (55B11) no. 2479/Cell Signaling (Danvers, MA), MDMX A300-287A/Bethyl Laboratories (Montgomery, TX), PDC-E2 SC-365276/Santa Cruz Biotechnology (Santa Cruz, CA), PICALM Prestige HPA019053, OT-R ABN1735/Millipore (Temecula, CA), V1aR Sigma MBS176788/MyBiosource (San Diego, CA), CD163 MA5-33091/InVitrogen-Thermo Fisher Scientific, TRIM21 Novus NBP1-33548 (Centennial, CO), Alexa-488 (green) and Alexa-64 (red) goat anti-rabbit/mouse conjugated secondary antibodies/Life Technologies (Eugene, OR), immunogold donkey-anti-rabbit secondary antibodies 25702 (6 nm) and 25705 (10 nm) (Electron Microscopy Sciences (Hatfield, PA).

Placenta tissue collection, homogenization, and protein extraction with ASB-14 Within 15 min of the delivery of the placenta, samples were obtained from the fetal side of the placental bed at 4-5 cm from the umbilical cord and were placed on dry ice and then

stored at -80°C. Tissues were also fixed in formalin for IHC or in paraformaldehyde-tannic acid for IGEM. Frozen tissue samples were finely cut and placed, at 150 mg per mL, in homogenization buffer containing 50 mM sodium phosphate pH 7.6, 50 mM NaCl, 50 µM sodium o-vanadate, 10 mM NaF, 20 µM proteasome inhibitor MG-132, 10 µM marimastat and 6 µL protease inhibitor cocktail-III per mL. After homogenization at 4°C by three 15s bursts of a homogenizer with one-minute cooling in between, the homogenates were centrifuged for 1h at 100,000g. On top of the pellets was a thin pink fluffy layer, presumably of RBC membranes, which was included when the pellets were suspended in homogenization buffer containing 1% ASB-14 and then extracted overnight, due to logistical reasons, at 6-8°C by end-over-end rotation. The zwitterionic detergent ASB-14 was superior in solubilizing membrane proteins to CHAPSO or n-octyl β-D-maltoside. After centrifugation at 100,000g for 1h, the supernatant solution was used in immunoprecipitations and western blots. We refrained from washing the membrane pellets in order to capture weak protein complexes. Protein levels of the membrane extracts were determined in quadruplicate at two dilutions with the Pierce BCA 562 nm kit. Final yield: 10-15 mg of detergent-extracted proteins per g wet tissue. To determine the efficiency of protein extraction by ASB-14, the post-ASB-14 100,000g pellets were solubilized in SDS-DTT at 95°C and then probed in western blots. Extraction yield was 100% for VEGFR2, MDMX and PICALM, 86% for PDC-E2 and 64% for TOMM20, a marker for inner mitochondrial membranes.

637

638

639

640

641

642

643

644

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632


633

634

635

636

Peptide synthesis to validate the OT-R and V1aR antibodies. Fig. 10 shows OT-R peptides EGNRTAGPPRRNEA (within the OT-R immunogen range given for this antibody), AEAPEGAAAGDGGRVA (outside the OT-R immunogen range) and V1aR immunogen peptide HPLKTLQQPARRSRLMIAA to validate the OT-R Millipore ABN1735 (0.5 μ g/ μ L) and V1aR MyBioSourse MBS176788 (0.5 μ g/ μ L) antibodies. The peptides were synthesized on 100 mg Rink Amide-MBHA resin (0.65 mmol/g) at room temperature under air using standard solid phase peptide synthesis protocol.



647 Fig. 10. Validation of OT-R and V1a

Fig. 10. Validation of OT-R and V1aR antibodies. The synthesized peptides and their pl are shown next to the scans of the coated Nunc C-bottom strips probed with the antibodies being validated.

Validation method for OT-R and V1aR antibodies. Maxisorp Nunc C-bottom strips were coated overnight at 4°C with the indicated amounts of synthetic peptides (Fig. 10) dissolved in sodium carbonate buffer pH 9.6°3. After blocking, as in western blot experiments, the OT-R and V1aR antibodies were added for 2h at room temperature at the indicated dilution followed by the secondary anti-rabbit antibody conjugated with horseradish peroxidase. Detection of bound OT-R or V1aR antibodies was conducted by ECL on films exposed for the indicated times. The OT-R and V1aR antibodies bound only to peptide sequences used to raise them.

Immunoprecipitations. Each immunoprecipitation of the 4-6 placental extracts, shown in Table 3-5, was carried out in one batch. Half mL of pellicular support M-280 Dynabeads was washed in homogenization buffer containing 1% ASB-14 and charged separately at room temperature for 2h with 0.9 μg VEGFR2, 15 μg MDMX or 7.5 μg PICALM antibody. Three mg of ASB14-extracted placental membranes from each placenta were mixed separately with the beads, overnight for logistical reasons, at 6-8°C. Most proteins adhering to the beads were removed by washing four times with homogenization buffer

containing 1% ASB-14 and once with detergent-free buffer. Bound proteins were eluted at 95°C with 100 mM Tris-HCl pH 7.6, 4% SDS (w/v) and 100 mM DTT. Eluted proteins were fractionated on 4-12% Bis-Tris NuPAGE gels. After Coomassie blue staining, gel strips from 25-220 kDa were submitted for mass spectrometric analysis.

Mass spectrometry. Samples were submitted and analyzed in a double-blinded fashion. Immunoprecipitated proteins were digested with Trypsin/Lys-C overnight at 37° C as described⁹⁴. Each group of immunoprecipitated samples was analyzed with a new trap and HPLC column. Peptides were dried in a vacuum concentrator and resuspended in 0.1% formic acid for LC-MS/MS analysis. Peptides were separated with a C18 reversed-phase-HPLC column on an Ultimate3000 UHPLC with a 60-min gradient and analyzed on a Q-Exactive Plus using data-dependent acquisition. Raw data files were processed in MaxQuant (www.maxquant.org) and searched against the UniprotKB human protein sequence database. Search parameters included constant modification of cysteine by carbamidomethylation and the variable modification, methionine oxidation. Proteins were identified using the filtering criteria of 1% protein and peptide false discovery rate.

Western blot analysis. 25 µg of protein from placental extracts were resolved on 4-12% Bis-Tris NuPAGE gels, transferred to PVDF membranes and blocked overnight at room temperature in 1% Hammarsten-grade casein or 5% Difco skimmed milk powder. MDMX, PICALM, OT-R or V1aR primary antibody dilutions ranged from 1:800 to 1:10000. PVDF membranes incubated with ECL reagents were exposed to film for 1-20s. Films were scanned in the transmittance mode (Epson Perfection 3200 Photo, Epson America, Los Alamitos, CA, USA). The intensity of the top band (Fig. 9) was measured with Li-Cor Image Studio Lite software (Lincoln, Nebraska, USA) and chosen from a film exposed at the linear portion of the correlation between band intensity and film exposure time before films were overexposed. In the statistical analyses we used the mean intensity from 3.6 blots, on the average, and relative to an internal control sample Q1 or V1 (Table 5).

Immunohistochemistry. 4 μm formalin-fixed paraffin embedded tissue sections were processed for IHC and stained with VEGFR2 (1:50), MDMX (1:500) or PICALM (1:1000)

antibodies. Slides were exposed with diaminobenzidine tetrahydrochloride dehydrate as a chromogen and counterstained with hematoxylin before permanent mounting.

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

697

698

Immunogold electron microscopy. Tissue samples were promptly fixed in buffered 4% paraformaldehyde and kept overnight at 4°C and then immersed in 0.75% buffered solution of tannic acid for 2h at room temperature. Samples were rinsed in filtered glassdistilled water, dehydrated through a series of increasing ethanol concentration, infiltrated, and embedded in LRW acrylic resin. Selected blocks were sectioned at 90-100 nm and mounted on formvar coated copper grids. The immunogold reaction was performed by incubating grids in standard blocking solution for 30 min at room temperature and transferring to either 1:100 MDMX rabbit Ab, 1:400 PICALM rabbit Ab, 1:100 VEGFR2 rabbit Ab or 1:600 OT-R or V1aR rabbit Ab for an overnight incubation at 4°C. After washing in PBS, gold-conjugated donkey anti-rabbit Ab 25703 (Electron Microscopy Sciences, Hatfield, PA), was applied at 1:50 dilution for 90 min at room temperature. The diameter of the gold particles (Electron Microscopy Sciences, Hatfield, PA) was 6 nm in VEGFR2 and MDMX and 10 nm in PICALM and OT-R experiments. Excess secondary antibody was removed by washing with glass-distilled water and the grids were further treated with 2% aqueous uranyl acetate added for contrast. In control experiments excluding the primary antibody, 1-2 gold particles were detected throughout the grids. In morphological analysis by transmission electron microscopy, tissues were fixed in 2% OsO4, after 2.5% glutaraldehyde fixation and prior to the dehydration and resin infiltration steps. Images were obtained with a JEM-1400 transmission electron microscope (JEOL, Peabody, MA) and Orius-832 camera (Gatan Inc., Pleasanton, CA).

720721

722

723

724

725

726

727

Whole mount immunofluorescence (WMIF). Small samples (2x2x2 mm) of placental tissues, were fixed in 1 mL 90% methanol for 2h at 4°C according to Bushway et al. 95 with modifications. After washing with PBS, the samples were blocked for 2h at 4°C with 1% Hammarsten-grade casein in PBS containing 0.02% Thimerosal. After washing with 0.5% Casein in PBS, antibodies to VEGFR2 and PDC-E2 were added at 1:400 dilution and incubated overnight at 4°C, followed by washing with 0.5% Casein-PBS containing 0.3% Triton-X and incubation with the secondary antibodies at 1:100 dilutions. WMIF slides were

observed with a Leica TCS SP5 AOBS laser scanning confocal microscope through a 40X/1.3NA Plan Apochromat oil immersion objective lens (Leica Microsystems CMS GmbH, Germany). 405 Diode, Argon 488 and He-Ne 647 laser lines were applied to excite the samples and tunable emissions were used to minimize crosstalk between fluorochromes. Images were captured with photomultiplier detectors and prepared with the LAS AF software version 2.7 (Leica Microsystems CMS GmbH, Germany). A 3D projected image was created by Z-stack of images taken at 1.0-0.5-micron intervals to create a movie by Imaris version 7.6 (Bitplane AG, Switzerland) (video).

Statistical analysis. The protein levels of MDMX, PICALM, OT-R and V1aR were analyzed for univariable and multivariable associations by linear regression using the R statistical program (https://www.r-project.org, 4.1.3). Parsimonious multivariable models were selected using Akaike's Information Criteria with a stepwise selection procedure (StepAIC in the MASS package of R) and were run with covariates that were identified as statistically significant in univariable analysis. A p-value of less than 0.05 was considered statistically significant. Violin plots were made by R statistical program, and data Figures and graphs were assembled using Fiji ImageJ, GraphPad Prism 9.4.0, Adobe Illustrator and Windows Office365 software. To test the robustness of results to the specific datapoints included in the analysis, bootstrapped resampling (with replacement) was used to generate 1000 replicate datasets, upon which regression analyses were redone. Results of bootstrapped resampled analyses were summarized and compared to the full dataset to characterize consistency of point estimates and patterns of statistical significance. Pearson correlation coefficients were used to characterize correlation of protein measurements with each other.

Acknowledgements

This study was supported by the Department of Obstetrics and Gynecology at the University of South Florida and research funds from Tampa General Hospital (AEA) and the Teasley Foundation (TJR). The WMIF images were obtained by the Analytic Microscopy Core Facility at the H. Lee Moffitt Cancer Center & Research Institute, an NCI designated Comprehensive Cancer Center (P30-CA076292). We thank Umit A. Kayisli for

advice on IHC, and Santo V. Nicosia and Greg Arsenis for reading the manuscript and comments.

761

762

Author contributions

763 JCMT conceived the study, performed most wet chemistry experiments, and wrote the first 764 draft of the manuscript in consultation with VNU and RRM. SJH, RGS, and EPN recruited 765 patients, collected, and interpreted clinical data in consultation with TSS, TJR, AEA, and 766 MLA. DC performed proteomic analyses. MO assisted in the analysis of western blot data 767 and confocal and WMIF experiments. SA and NS performed IHC experiments. AG 768 performed and interpreted IGEM. PS and JC synthesized OT-R and V1aR peptides. DATC 769 performed analyses and statistical data presentation. All authors critically read and 770 approved the manuscript.

771

772

Competing interests

DATC declares a grant from Merck for research unrelated to this manuscript. The remaining authors declare no competing interests.

775

776

Data availability

- 777 The video of the chorionic villi is deposited at
- 778 https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fzenodo.org%2Frecord%2
- 779 F8160169%3Ftoken%3DevJhbGciOiJIUzUxMilsImV4cCl6MTY5MiMwOTU5OSwiaWF0ljoxNig5
- 780 Njk3NDQzfQ.eyJkYXRhljp7InJIY2lkljo4MTYwMTY5fSwiaWQiOjM1ODEzLCJybmQiOjJjMTlkOT
- 781 M2NCJ9.2OSYKMRxBpqO7afBKem S8HdQJgmbtnahLFTgJ 5hoiK3wxcbB2fvuygEPJ0PeTtF r
- 782 9f9Zuocr6LcfXPs2-
- 783 gw&data=05%7C01%7Ctsibris%40usf.edu%7C02564875fb61480dab4f08db87ae6fdb%7C741bf
- 784 7dee2e546df8d6782607df9deaa%7C0%7C0%7C638252955485880125%7CUnknown%7CTWF
- 785 pbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7
- 786 C3000%7C%7C%7C&sdata=iukZjlFOvoliQAdfd566alnMH33jLMz3TV%2BDqPv5Trk%3D&reser
- 787 ved=0.
- 788 All MS raw files and corresponding results files will be deposited to the ProteomeXchange
- 789 Consortium via the PRIDE partner repository.

791
792 REFERENCES

793

- Burton, G. J. & Fowden, A. L. The placenta: a multifaceted, transient organ. *Philos Trans R Soc Lond B Biol Sci* **370**, 20140066 (2015). https://doi.org:10.1098/rstb.2014.0066
- Burton, G. J., Redman, C. W., Roberts, J. M. & Moffett, A. Pre-eclampsia: pathophysiology and clinical implications. *BMJ* **366**, I2381 (2019). https://doi.org/10.1136/bmj.I2381
- Aplin, J. D., Myers, J. E., Timms, K. & Westwood, M. Tracking placental development in health and disease. *Nat Rev Endocrinol* **16**, 479-494 (2020). https://doi.org:10.1038/s41574-020-0372-6
- Shibuya, M. VEGFR and type-V RTK activation and signaling. *Cold Spring Harbor perspectives in biology* **5**, a009092 (2013). https://doi.org:10.1101/cshperspect.a009092
- Peach, C. J. *et al.* Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2.

 Int J Mol Sci **19** (2018). https://doi.org:10.3390/ijms19041264
- Simons, M., Gordon, E. & Claesson-Welsh, L. Mechanisms and regulation of endothelial VEGF receptor signalling. *Nature reviews. Molecular cell biology* **17**, 611-625 (2016). https://doi.org:10.1038/nrm.2016.87
- 807 7 Qu, H. & Khalil, R. A. Vascular mechanisms and molecular targets in hypertensive pregnancy and 808 Physiol Heart Circ Physiol preeclampsia. Аm J 319, H661-H681 (2020).809 https://doi.org:10.1152/ajpheart.00202.2020
- 810 8 Roberts, J. M. *et al.* Subtypes of Preeclampsia: Recognition and Determining Clinical Usefulness. 811 *Hypertension* **77**, 1430-1441 (2021). https://doi.org:10.1161/HYPERTENSIONAHA.120.14781
- Mincheva-Nilsson, L. Immunosuppressive Protein Signatures Carried by Syncytiotrophoblast-Derived Exosomes and Their Role in Human Pregnancy. *Front Immunol* **12**, 717884 (2021). https://doi.org:10.3389/fimmu.2021.717884
- Ormazabal, V., Nair, S., Carrion, F., McIntyre, H. D. & Salomon, C. The link between gestational diabetes and cardiovascular diseases: potential role of extracellular vesicles. *Cardiovasc Diabetol* 21, 174 (2022). https://doi.org:10.1186/s12933-022-01597-3
- Morelli, A. E. & Sadovsky, Y. Extracellular vesicles and immune response during pregnancy: A balancing act. *Immunol Rev* (2022). https://doi.org:10.1111/imr.13074
- Kugeratski, F. G., Santi, A. & Zanivan, S. Extracellular vesicles as central regulators of blood vessel function in cancer. *Science signaling* **15**, eaaz4742 (2022). https://doi.org:10.1126/scisignal.aaz4742
- Uhlen, M. *et al.* Proteomics. Tissue-based map of the human proteome. *Science* **347**, 1260419 (2015). https://doi.org:10.1126/science.1260419
- Wang, D. *et al.* A deep proteome and transcriptome abundance atlas of 29 healthy human tissues.

 Mol Syst Biol **15**, e8503 (2019). https://doi.org:10.15252/msb.20188503
- Di Meo, A. *et al.* Proteomic Profiling of the Human Tissue and Biological Fluid Proteome. *J Proteome Res* **20**, 444-452 (2021). https://doi.org:10.1021/acs.jproteome.0c00502
- Manna, S. *et al.* A proteomic profile of the healthy human placenta. *Clin Proteomics* **20**, 1 (2023). https://doi.org:10.1186/s12014-022-09388-4
- Klein, A. M., de Queiroz, R. M., Venkatesh, D. & Prives, C. The roles and regulation of MDM2 and MDMX: it is not just about p53. *Genes Dev* (2021). https://doi.org:10.1101/gad.347872.120
- Sharp, A. N. *et al.* Preeclampsia is associated with alterations in the p53-pathway in villous trophoblast. *PLoS One* **9**, e87621 (2014). https://doi.org:10.1371/journal.pone.0087621
- Tebar, F., Bohlander, S. K. & Sorkin, A. Clathrin assembly lymphoid myeloid leukemia (CALM) protein: localization in endocytic-coated pits, interactions with clathrin, and the impact of

- 837 overexpression on clathrin-mediated traffic. *Mol Biol Cell* **10**, 2687-2702 (1999). 838 https://doi.org:10.1091/mbc.10.8.2687
- Ando, K. *et al.* PICALM and Alzheimer's Disease: An Update and Perspectives. *Cells* **11** (2022). https://doi.org:10.3390/cells11243994
- 841 21 Buhimschi, I. A. *et al.* Protein misfolding, congophilia, oligomerization, and defective amyloid processing in preeclampsia. *Science translational medicine* **6**, 245ra292 (2014). https://doi.org:10.1126/scitranslmed.3008808
- Meyerowitz, J. G. *et al.* The oxytocin signaling complex reveals a molecular switch for cation dependence. *Nat Struct Mol Biol* (2022). https://doi.org:10.1038/s41594-022-00728-4
- Jurek, B. & Neumann, I. D. The Oxytocin Receptor: From Intracellular Signaling to Behavior. *Physiol Rev* **98**, 1805-1908 (2018). https://doi.org:10.1152/physrev.00031.2017
- Dekan, Z. *et al.* Nature-inspired dimerization as a strategy to modulate neuropeptide pharmacology exemplified with vasopressin and oxytocin. *Chem Sci* **12**, 4057-4062 (2021). https://doi.org:10.1039/dosc05501h
- Liu, X., Luo, D., Zhang, J. & Du, L. Distribution and relative expression of vasoactive receptors on arteries. *Sci Rep* **10**, 15383 (2020). https://doi.org:10.1038/s41598-020-72352-5
- Zeng, J. *et al.* Target-induced clustering activates Trim-Away of pathogens and proteins. *Nat Struct*Mol Biol **28**, 278-289 (2021). https://doi.org:10.1038/s41594-021-00560-2
- Domingues, I., Rino, J., Demmers, J. A., de Lanerolle, P. & Santos, S. C. VEGFR2 translocates to the nucleus to regulate its own transcription. *PLoS One* **6**, e25668 (2011). https://doi.org:10.1371/journal.pone.0025668
- Collier, A. Y., Smith, L. A. & Karumanchi, S. A. Review of the immune mechanisms of preeclampsia and the potential of immune modulating therapy. *Hum Immunol* **82**, 362-370 (2021). https://doi.org:10.1016/j.humimm.2021.01.004
- Streicher, K. *et al.* The plasma cell signature in autoimmune disease. *Arthritis & rheumatology* (Hoboken, N.J.) **66**, 173-184 (2014). https://doi.org:10.1002/art.38194
- Gafencu, A., Heltianu, C., Burlacu, A., Hunziker, W. & Simionescu, M. Investigation of IgG receptors expressed on the surface of human placental endothelial cells. *Placenta* **24**, 664-676 (2003). https://doi.org:10.1016/s0143-4004(03)00041-9
- Hu, L. *et al.* Identification of a novel heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) ligand that disrupts HnRNPA2B1/nucleic acid interactions to inhibit the MDMX-p53 axis in gastric cancer. *Pharmacol Res* **189**, 106696 (2023). https://doi.org:10.1016/j.phrs.2023.106696
- Liu, C., Kellems, R. E. & Xia, Y. Inflammation, Autoimmunity, and Hypertension: The Essential Role of Tissue Transglutaminase. *Am J Hypertens* **30**, 756-764 (2017). https://doi.org:10.1093/ajh/hpx027
- Reyes, L. & Golos, T. G. Hofbauer Cells: Their Role in Healthy and Complicated Pregnancy. *Front Immunol* **9**, 2628 (2018). https://doi.org:10.3389/fimmu.2018.02628
- Zulu, M. Z., Martinez, F. O., Gordon, S. & Gray, C. M. The Elusive Role of Placental Macrophages:
 The Hofbauer Cell. *J Innate Immun* 11, 447-456 (2019). https://doi.org:10.1159/000497416
- Semmes, E. C. & Coyne, C. B. Innate immune defenses at the maternal-fetal interface. *Curr Opin Immunol* **74**, 60-67 (2021). https://doi.org:10.1016/j.coi.2021.10.007
- Fakonti, G., Pantazi, P., Bokun, V. & Holder, B. Placental Macrophage (Hofbauer Cell) Responses to Infection During Pregnancy: A Systematic Scoping Review. *Front Immunol* **12**, 756035 (2021). https://doi.org:10.3389/fimmu.2021.756035
- Ning, J., Zhang, M., Cui, D. & Yang, H. The pathologic changes of human placental macrophages in women with hyperglycemia in pregnancy. *Placenta* **130**, 60-66 (2022). https://doi.org/10.1016/j.placenta.2022.11.004

- Girsch, J. H. *et al.* Host-Viral Interactions at the Maternal-Fetal Interface. What We Know and What We Need to Know. *Frontiers (Boulder)* **2** (2022). https://doi.org:10.3389/fviro.2022.833106
- 886 39 Lasch, M. *et al.* Isolation of Decidual Macrophages and Hofbauer Cells from Term Placenta-887 Comparison of the Expression of CD163 and CD80. *Int J Mol Sci* **23** (2022). 888 https://doi.org:10.3390/ijms23116113
- Mercnik, M. H., Schliefsteiner, C., Fluhr, H. & Wadsack, C. Placental macrophages present distinct polarization pattern and effector functions depending on clinical onset of preeclampsia. *Front Immunol* **13**, 1095879 (2022). https://doi.org:10.3389/fimmu.2022.1095879
- Mittelberger, J. *et al.* The programmed cell death protein 1 (PD1) and the programmed cell death ligand 1 (PD-L1) are significantly downregulated on macrophages and Hofbauer cells in the placenta of preeclampsia patients. *Journal of reproductive immunology* **157**, 103949 (2023). https://doi.org:10.1016/j.jri.2023.103949
- Zinn, V. Z., Khatri, A., Mednieks, M. I. & Hand, A. R. Localization of cystic fibrosis transmembrane conductance regulator signaling complexes in human salivary gland striated duct cells. *Eur J Oral Sci* **123**, 140-148 (2015). https://doi.org:10.1111/eos.12184
- Maron, B. A. *et al.* Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes. *Nat Commun* **12**, 873 (2021). https://doi.org:10.1038/s41467-021-21146-y
- 902 44 Burton, G. J. & Jauniaux, E. The human placenta: new perspectives on its formation and function during early pregnancy. *Proc Biol Sci* **290**, 20230191 (2023). https://doi.org:10.1098/rspb.2023.0191
- 905 45 Ozen, M. *et al.* Omics approaches: interactions at the maternal-fetal interface and origins of child health and disease. *Pediatr Res*, 1-10 (2022). https://doi.org:10.1038/s41390-022-02335-x
- Wang, H. *et al.* The ion channel TRPM7 regulates zinc depletion-induced MDMX degradation. *J Biol Chem*, 101292 (2021). https://doi.org:10.1016/j.jbc.2021.101292
- 909 47 Nadezhdin, K. D. *et al.* Structural mechanisms of TRPM7 activation and inhibition. *Nat Commun* **14**, 2639 (2023). https://doi.org:10.1038/s41467-023-38362-3
- 911 48 Abiria, S. A. *et al.* TRPM7 senses oxidative stress to release Zn(2+) from unique intracellular vesicles. 912 *Proc Natl Acad Sci U S A* **114**, E6079-E6088 (2017). https://doi.org:10.1073/pnas.1707380114
- 913 49 Yang, H., Kim, T. H., Lee, G. S., Hong, E. J. & Jeung, E. B. Comparing the expression patterns of placental magnesium/phosphorus-transporting channels between healthy and preeclamptic pregnancies. *Mol Reprod Dev* 81, 851-860 (2014). https://doi.org:10.1002/mrd.22353
- 916 50 Neiman, M. *et al.* Individual and stable autoantibody repertoires in healthy individuals. 917 *Autoimmunity* **52**, 1-11 (2019). https://doi.org:10.1080/08916934.2019.1581774
- 918 51 Cheng, J. *et al.* TRIM21 and PHLDA3 negatively regulate the crosstalk between the PI3K/AKT pathway and PPP metabolism. *Nat Commun* **11**, 1880 (2020). https://doi.org:10.1038/s41467-020-15819-3
- 921 52 Park, J. S. *et al.* Mechanical regulation of glycolysis via cytoskeleton architecture. *Nature* **578**, 621-922 626 (2020). https://doi.org:10.1038/s41586-020-1998-1
- 923 Silva, J. A. F., Qi, X., Grant, M. B. & Boulton, M. E. Spatial and temporal VEGF receptor intracellular trafficking in microvascular and macrovascular endothelial cells. *Sci Rep* **11**, 17400 (2021). https://doi.org:10.1038/s41598-021-96964-7
- 926 54 Sutendra, G. *et al.* A nuclear pyruvate dehydrogenase complex is important for the generation of 927 acetyl-CoA and histone acetylation. *Cell* **158**, 84-97 (2014). 928 https://doi.org:10.1016/j.cell.2014.04.046
- 929 55 Kofler, N. *et al.* The Rab-effector protein RABEP2 regulates endosomal trafficking to mediate vascular endothelial growth factor receptor-2 (VEGFR2)-dependent signaling. *J Biol Chem* **293**, 4805-4817 (2018). https://doi.org:10.1074/jbc.M117.812172

- Shou, H. J. *et al.* SUMOylation of VEGFR2 regulates its intracellular trafficking and pathological angiogenesis. *Nat Commun* **9**, 3303 (2018). https://doi.org:10.1038/s41467-018-05812-2
- 934 57 Buvinic, S. *et al.* P2Y1 and P2Y2 receptor distribution varies along the human placental vascular tree: role of nucleotides in vascular tone regulation. *The Journal of physiology* **573**, 427-443 (2006). 936 https://doi.org:10.1113/jphysiol.2006.105882
- Guan, J. *et al.* Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility. *Cell* **178**, 949-963 e918 (2019). https://doi.org:10.1016/j.cell.2019.06.026
- 939 59 Mayer, B. *et al.* Vasopressin stimulates the proliferation and differentiation of red blood cell precursors and improves recovery from anemia. *Science translational medicine* **9** (2017). https://doi.org:10.1126/scitranslmed.aao1632
- 942 60 Lam, L. K. M. *et al.* DNA binding to TLR9 expressed by red blood cells promotes innate immune activation and anemia. *Science translational medicine* **13**, eabj1008 (2021). https://doi.org:10.1126/scitranslmed.abj1008
- 945 61 Calderon-Garciduenas, L. *et al.* Environmental Nanoparticles Reach Human Fetal Brains. 946 *Biomedicines* **10** (2022). https://doi.org:10.3390/biomedicines10020410
- 947 62 Kerby, A. *et al.* Placental Morphology and Cellular Characteristics in Stillbirths in Women With 948 Diabetes and Unexplained Stillbirths. *Arch Pathol Lab Med* **145**, 82-89 (2021). 949 https://doi.org/10.5858/arpa.2019-0524-OA
- 950 63 Li, Y. *et al.* MicroRNA profiling of diabetic atherosclerosis in a rat model. *Eur J Med Res* **23**, 55 (2018). https://doi.org:10.1186/s40001-018-0354-5
- 952 64 Mancini, F. *et al.* MDM4 actively restrains cytoplasmic mTORC1 by sensing nutrient availability. 953 *Mol Cancer* **16**, 55 (2017). https://doi.org:10.1186/s12943-017-0626-7
- 954 65 Amin, M., Wu, R. & Gragnoli, C. Novel Risk Variants in the Oxytocin Receptor Gene (OXTR) Possibly 955 Linked to and Associated with Familial Type 2 Diabetes. *Int J Mol Sci* **24** (2023). 956 https://doi.org:10.3390/ijms24076282
- Huang, Y. et al. Improving immune-vascular crosstalk for cancer immunotherapy. *Nat Rev Immunol* 18, 195-203 (2018). https://doi.org:10.1038/nri.2017.145
- 959 67 Kao, K. C., Vilbois, S., Tsai, C. H. & Ho, P. C. Metabolic communication in the tumour-immune microenvironment. *Nat Cell Biol* **24**, 1574-1583 (2022). https://doi.org:10.1038/s41556-022-01002-x
- 268 Zheng, W. et al. Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of antiangiogenesis and immune checkpoint blockade. Front Immunol 13, 1035323 (2022). https://doi.org:10.3389/fimmu.2022.1035323
- 966 Spiliopoulos, M. *et al.* Characterizing placental stiffness using ultrasound shear-wave elastography in healthy and preeclamptic pregnancies. *Arch Gynecol Obstet* **302**, 1103-1112 (2020). https://doi.org:10.1007/s00404-020-05697-x
- 969 70 Mancini, F., Giorgini, L., Teveroni, E., Pontecorvi, A. & Moretti, F. Role of Sex in the Therapeutic 970 Targeting of p53 Circuitry. Front Oncol 11, 698946 (2021). 971 https://doi.org:10.3389/fonc.2021.698946
- 972 71 Swetzig, W. M., Wang, J. & Das, G. M. Estrogen receptor alpha (ERalpha/ESR1) mediates the p53-973 independent overexpression of MDM4/MDMX and MDM2 in human breast cancer. *Oncotarget* **7**, 974 16049-16069 (2016). https://doi.org:10.18632/oncotarget.7533
- 975 72 Berkane, N. *et al.* From Pregnancy to Preeclampsia: A Key Role for Estrogens. *Endocr Rev* **38**, 123- 144 (2017). https://doi.org:10.1210/er.2016-1065
- Jobe, S. O., Tyler, C. T. & Magness, R. R. Aberrant synthesis, metabolism, and plasma accumulation of circulating estrogens and estrogen metabolites in preeclampsia implications for vascular

- 979 dysfunction. *Hypertension* **61**, 480-487 (2013). 980 https://doi.org:10.1161/HYPERTENSIONAHA.111.201624
- Zhu, D., Su, Y., Fu, B. & Xu, H. Magnesium Reduces Blood-Brain Barrier Permeability and Regulates
 Amyloid-beta Transcytosis. *Mol Neurobiol* 55, 7118-7131 (2018). https://doi.org:10.1007/s12035-018-0896-0
- Hentschke, M. R. *et al.* Is the atherosclerotic phenotype of preeclamptic placentas due to altered lipoprotein concentrations and placental lipoprotein receptors? Role of a small-for-gestational-age phenotype. *J Lipid Res* **54**, 2658-2664 (2013). https://doi.org:10.1194/jlr.M036699
- Zhang, S., Cao, F., Li, W. & Abumaria, N. TRPM7 kinase activity induces amyloid-beta degradation to reverse synaptic and cognitive deficits in mouse models of Alzheimer's disease. *Science signaling* eade6325 (2023). https://doi.org:10.1126/scisignal.ade6325
- Ryan, C. P. *et al.* Reproduction predicts shorter telomeres and epigenetic age acceleration among young adult women. *Sci Rep* **8**, 11100 (2018). https://doi.org:10.1038/s41598-018-29486-4
- 992 78 Richmond, R. C., Suderman, M., Langdon, R., Relton, C. L. & Davey Smith, G. DNA methylation as a marker for prenatal smoke exposure in adults. *Int J Epidemiol* **47**, 1120-1130 (2018). 994 https://doi.org:10.1093/ije/dyy091
- 995 79 Ryan, C. P. *et al.* Immune cell type and DNA methylation vary with reproductive status in women: possible pathways for costs of reproduction. *Evol Med Public Health* **10**, 47-58 (2022). https://doi.org:10.1093/emph/eoac003
- 998 80 Ghanim, H. *et al.* Reduction in inflammation and the expression of amyloid precursor protein and other proteins related to Alzheimer's disease following gastric bypass surgery. *J Clin Endocrinol Metab* 97, E1197-1201 (2012). https://doi.org:10.1210/jc.2011-3284
- Hinney, A. *et al.* Genetic variation at the CELF1 (CUGBP, elav-like family member 1 gene) locus is genome-wide associated with Alzheimer's disease and obesity. *Am J Med Genet B Neuropsychiatr Genet* **165B**, 283-293 (2014). https://doi.org:10.1002/ajmg.b.32234
- Behura, S. K. *et al.* The brain-placental axis: Therapeutic and pharmacological relevancy to pregnancy. *Pharmacol Res* **149**, 104468 (2019). https://doi.org:10.1016/j.phrs.2019.104468
- Mairesse, J. *et al.* Oxytocin receptor agonist reduces perinatal brain damage by targeting microglia. Glia **67**, 345-359 (2019). https://doi.org:10.1002/glia.23546
- Shook, L. L., Sullivan, E. L., Lo, J. O., Perlis, R. H. & Edlow, A. G. COVID-19 in pregnancy: implications for fetal brain development. *Trends Mol Med* **28**, 319-330 (2022). https://doi.org:10.1016/j.molmed.2022.02.004
- Lazarov, T., Juarez-Carreno, S., Cox, N. & Geissmann, F. Physiology and diseases of tissue-resident macrophages. *Nature* **618**, 698-707 (2023). https://doi.org:10.1038/s41586-023-06002-x
- 1013 86 Erickson, E. N., Myatt, L., Danoff, J. S., Krol, K. M. & Connelly, J. J. Oxytocin receptor DNA methylation is associated with exogenous oxytocin needs during parturition and postpartum hemorrhage. *Commun Med (Lond)* 3, 11 (2023). https://doi.org:10.1038/s43856-023-00244-6
- 1016 87 Liang, Y., Duan, L., Lu, J. & Xia, J. Engineering exosomes for targeted drug delivery. *Theranostics* **11**, 1017 3183-3195 (2021). https://doi.org:10.7150/thno.52570
- 1018 Stelzer, I. A. *et al.* Integrated trajectories of the maternal metabolome, proteome, and immunome predict labor onset. *Science translational medicine* **13** (2021). https://doi.org:10.1126/scitranslmed.abd9898
- 1021 89 Aghaeepour, N. *et al.* An immune clock of human pregnancy. *Sci Immunol* **2** (2017). https://doi.org:10.1126/sciimmunol.aan2946
- 1023 90 Gomez-Lopez, N. *et al.* Macrophages exert homeostatic actions in pregnancy to protect against preterm birth and fetal inflammatory injury. *JCI Insight* **6** (2021). https://doi.org:10.1172/jci.insight.146089

1026 1027	91	Rackaityte, E. & Halkias, J. Mechanisms of Fetal T Cell Tolerance and Immune Regulation. <i>Front Immunol</i> 11 , 588 (2020). https://doi.org:10.3389/fimmu.2020.00588
1028	92	Miller, D. et al. Single-Cell Immunobiology of the Maternal-Fetal Interface. J Immunol 209, 1450-
1029		1464 (2022). https://doi.org:10.4049/jimmunol.2200433
1030	93	Braitbard, O., Glickstein, H., Bishara-Shieban, J., Pace, U. & Stein, W. D. Competition between
1031		bound and free peptides in an ELISA-based procedure that assays peptides derived from protein
1032		digests. Proteome Sci 4, 12 (2006). https://doi.org:10.1186/1477-5956-4-12
1033	94	Shevchenko, A., Tomas, H., Havlis, J., Olsen, J. V. & Mann, M. In-gel digestion for mass
1034		spectrometric characterization of proteins and proteomes. Nat Protoc 1, 2856-2860 (2006).
1035		https://doi.org:10.1038/nprot.2006.468
1036	95	Bushway, M. E. et al. Morphological and phenotypic analyses of the human placenta using whole
1037		mount immunofluorescence. Biol Reprod 90, 110 (2014).
1038		https://doi.org:10.1095/biolreprod.113.115915

Table 1. Clinical characteristics of 47 patients in the study group.

A. Patient samples were labelled with a code consisting of a letter and 1, 2, 5, 6, 7 for non-preeclamptic, 3, 4 for preeclamptic patients or a Ho-number. **B**. Patients Ho-71, Ho-72 and Ho-73 provided placental samples for immunogold electron microscopy.

A												
Patient	Age Range	Gravida	Gestational Age (weeks)	BMI in L&D	Race	cHTN	Preeclampsia	DM	Delivery Mode	Pitocin pre-delivery	Sex F=1	Neonatal weight (g)
H1	21-25	1	38.0	30.0	6	0	0	0	1	1	1	2,940
H2	21-25	2	37.0	24.0	8	0	0	0	1	NA	2	2,590
H3	31-35	2	37.0	32.0	8	0	1	0	1	NA	1	3,040
I-1	21-25	3	38.0	34.0	2	0	0	0	3	1	2	2,631
I-2	21-25	1	42.0	30.0	1	0	0	0	1	1	2	3,759
I-3	26-30	8	35.0	34.0	2	0	1	2	2	0	2	3,195
I-4	18-20	1	36.6	41.0	8	0	1	0	3	0	1	3,335
J-1	26-30	2	39.0	25.0	8	0	0	0	3	0	2	3,300
J-2	36-40	2	37.4	22.0	1	0	0	0	1	1	1	3,460
J-3	26-30	3	38.5	28.0	1	0	1	3	3	<u>1</u>	2	3,630
L1	21-25	1	39.0	24.0	3	0	0	0	3	0	1	3,147
L2	18-20	1	39.0	29.0	6	0	0	0	1	1	1	2,920
L3	21-25	3	35.0	30.0	2	0	1	0	2	0	2	2,235
L4	26-30	3	40.0	29.0	8	0	1	0	1	NA	1	3,010
M1	21-25	3	40.1	55.0	2	0	0	0	2	0	1	3,795
М3	18-20	2	37.0	31.3	8	0	1	0	2	0	1	3,490
M4	26-30	1	40.1	39.8	8	0	1	0	1	1	2	3,380
N1	31-35	4	39.1	30.0	8	0	0	2	2	0	2	3,800
N2	31-35	2	39.3	32.8	8	0	0	0	2	0	1	3,180
N3	31-35	2	39.0	35.5	8	0	1	0	2	0	2	3,390
N4	18-20	2	36.4	29.5	1	0	1	0	3	1	2	3,510
01	21-25	2	39.3	26.2	1	0	0	0	4	1	1	2,960
02	21-25	1	38.4	34.8	1	0	0	0	1	1	1	2,940
O3	26-30	1	37.1	29.5	1	0	1	0	1	1	1	2,800
04	21-25	3	40.3	52.5	1	0	1	0	3	1	2	3,575
O5	36-40	4	39.1	50.4	8	0	0	3	2	0	2	4,295
07	32-35	12	39.3	35.2	2	0	0	0	2	0	1	3,780
Q1	21-25	2	37.0	47.8	1	0	0	3	2	0	1	3,885
Q2	31-35	4	39.1	35.8	2	0	0	3	2	0	1	3,390
Q3	26-30	2	37.2	66.7	1	1	1	0	3	1	2	3,375
Q4	31-35	4	39.1	77.2	2	0	1	3	2	0	2	3,835
R3	21-25	1	37.6	49.5	1	1	1	0	1	1	2	2,560
R4	26-30	4	39.1	29.8	2	0	1	2	3	1	1	3,960
R5	21-25	6	39.0	30.9	2	0	0	0	2	0	1	3,205
S1	26-30	2	37.4	46.2	8	0	0	2	2	0	2	4,675
S2	26-30	3	37.5	42.2	1	0	0	2	2	0	1	4,600
T1	26-30	5	38.0	41.9	1	0	0	2	2	0	1	3,090
T2	26-30	1	39.1	53.3	1	0	0	2	2	0	2	3,960
U1	31-35	3	37.1	62.6	2	1	0	2	2	0	2	4,440
U2	26-30	3	37.1	52.7	1	1	0	2	2	0	2	5,020
V1	36-40	5	37.1	35.5	2	1	0	0	2	0	2	2,720
V2	36-40	2	38.4	26.1	1	0	0	0	2	0	2	4,150
W1	18-20	1	39.2	30.5	1	0	0	0	2	0	2	3,470
W2	26-30	8	37.0	51.7	2	1	0	0	2	0	1	3,000
3												
Ho-71	31-35	6	37.1	N/A	2	0	0	0	2	0	1	3,195
Ho-72	26-30	1	39.3	29.4	2		0	3	2	NA	1	3,400
Ho-73	26-30	1	37.0	29.1	8	0	1	0	1	1	2	2,780

Abbreviations: *Race*: White 1, Black 2, Asian 3, Hispanic 8, unknown 6. *Chronic hypertension*: cHTN 1. *Preeclampsia* 1. *Diabetes (DM)*: Type-1 1, Type-2 2, Gestational 3. *Delivery mode*: Spontaneous vaginal delivery (SVD) 1, Cesarean delivery (CD) prior to the onset of labor 2, CD after the onset of labor 3, Vaginal birth after CD (VBAC) 4. Pitocin pre-delivery 1. *Fetal sex*: Female 1, Male 2. *L&D*: Labor and delivery suite. *NA*, not available. The number of patients in each category were as follows: Diabetes: 30 no, Type-2 9, Gestational 5. Preeclampsia: 28 no, 16 yes. Delivery Mode: SVD 12; CD prior to the onset of labor 23; CD after the onset of labor 9; VBAC 1.

Table 2 Proteins identified in VEGFR2 immunoprecipitations.

Placental extracts O4, O5, U1, and O7 were immunoprecipitated in one experiment.

Placental extracts O4, O5,	U1, and O7 were immunoprecipitated in one exper	iment.		Internality	Internality	luta na itu	Internality	
Majority Protein ID	Protein	Gene	Total Intensity	Intensity VEGFR2 O4	Intensity VEGFR2 O5	Intensity VEGFR2 U1	Intensity VEGFR2 O7	Peptides
P01857	lg gamma-1 chain C region	IGHG1	24,993,000,000			4,017,600,000		16
O15151-5	Protein Mdm4	MDM4	14,682,000,000	14,638,000,000	0	21,714,000	22,289,000	14
P01834	Ig kappa chain C region	IGKC	11,450,000,000			2,438,900,000		7
A0A0B4J231	Immunoglobulin lambda-like polypeptide 5;lg lam	IGLL5	10,336,000,000	1,336,300,000				4
P01871	Ig mu chain C region	IGHM	4,544,300,000	2,132,500,000	923,280,000	706,680,000	781,900,000	16
P20073-2	Annexin A7	ANXA7	3,045,300,000	1,631,900,000	402,390,000	522,590,000	488,400,000	19 2
P01624 A0A286YES1	Ig kappa chain V-III region POM Ig gamma-3 chain C region	IGKV3D-15 IGHG3	2,885,700,000 2,266,900,000	707,630,000 1,322,900,000	775,800,000 493,150,000	239,480,000	1,381,500,000 211,400,000	2 14
Q9Y6R7	IgGFc-binding protein	FCGBP	1,815,700,000	1,201,900,000	310,570,000	246,590,000	56,630,000	50
J3KT55	Protein-tyrosine-phosphatase;Receptor-type tyro	PTPRM	1,604,700,000	511,350,000	129,960,000	380,380,000	582,970,000	1
P01701	Ig lambda chain V-I region NEW	IGLV1-51	1,311,400,000	193,890,000	242,130,000	234,850,000	640,570,000	3
P50995-2	Annexin A11	ANXA11	984,170,000	401,780,000	125,800,000	283,580,000	173,010,000	18
P01583	Ig kappa chain V-I region AU	IGKV1D-33	948,420,000	223,440,000	220,510,000	138,140,000	366,330,000	2
P01709	Ig lambda chain V-II region MGC;	IGLV2-8	640,270,000	48,724,000	120,690,000	169,210,000	301,660,000	2
P05783	Keratin, type I cytoskeletal 18	KRT18	610,030,000	342,270,000	114,070,000	75,571,000	78,111,000	19
P35968	Vascular endothelial growth factor receptor 2	KDR	571,130,000	132,550,000	167,190,000	146,080,000	125,310,000	28
A0A286YEY4	Ig gamma-2 chain C region	IGHG2	460,180,000	213,440,000	63,593,000	99,658,000	83,492,000	13
A0A286YEY1	lg alpha-1 chain C region Titin	IGHA1 TTN	403,780,000	211,760,000	52,913,000	85,992,000	53,116,000	6
Q8WZ42 A0A075B6K4	Ig lambda chain V-IV region Bau	IGLV3-10	396,070,000 353,630,000	215,440,000 0	31,243,000 105,060,000	97,005,000 0	52,381,000 248,570,000	2 1
P01602	lg kappa chain V-I region HK102	IGKV1-5	352,740,000	23,518,000	98,394,000	83,336,000	147,490,000	1
P07355	Annexin A2;Annexin;Putative annexin A2-like pro	ANXA2	310,810,000	50,471,000	50,738,000	48,427,000	161,170,000	9
P0DP08	Ig heavy chain V-II region NEWM;Ig heavy chain	IGHV4-61	304,360,000	139,200,000	44,252,000	64,988,000	55,917,000	2
A0A4W8ZXM2	Immunoglobulin heavy variable 3-72	IGHV3-72	293,310,000	149,140,000	29,272,000	50,152,000	64,749,000	3
A0A140T8W4	Ras/Rap GTPase-activating protein SynGAP	SYNGAP1	288,030,000	44,004,000	63,931,000	66,499,000	113,600,000	1
P01619	Ig kappa chain V-III region B6	IGKV3D-20	270,720,000	61,855,000	116,270,000	75,359,000	17,241,000	3
A0A0C4DH42	Ig heavy chain V-III region BUT;Ig heavy chain V	IGHV3-66	262,750,000	165,010,000	39,894,000	44,120,000	13,734,000	3
A0A087WW87	Ig kappa chain V-II region FR;Ig kappa chain V-II	IGKV2-40	253,710,000	36,751,000	64,720,000	43,474,000	108,760,000	3
P59666	Neutrophil defensin 3;HP 3-56;Neutrophil defens	DEFA3	216,520,000	69,150,000	64,470,000	3,576,200	79,326,000	3
P69905	Hemoglobin subunit alpha	HBA1	215,170,000	0	0	7,679,400	207,490,000	3
P68871 A0A2R8Y804	Hemoglobin subunit beta;LVV-hemorphin-7;Spinc Catenin beta-1	HBB CTNNB1	212,010,000 209,290,000	31,855,000 166,480,000	0 20,293,000	8,761,200 22,516,000	171,400,000 0	5 1
H0Y2X5	Aldehyde dehydrogenase family 1 member A3	ALDH1A3	208,040,000	81,161,000	28,288,000	92,767,000	5,824,900	1
P0DOY3	lg lambda-6 chain C region;lg lambda-7 chain C	IGLC6	206,310,000	71,942,000	14,393,000	49,459,000	70,513,000	3
P17931	Galectin-3;Galectin	LGALS3	177,750,000	8,812,900	12,846,000	37,357,000	118,730,000	4
P60709	Actin, cytoplasmic 1;Actin, cytoplasmic 1, N-term	ACTB	169,720,000	77,252,000	11,135,000	41,447,000	39,882,000	7
P0DP03	Ig heavy chain V-III region CAM;Ig heavy chain V	IGHV3-23	161,210,000	84,420,000	37,310,000	16,539,000	22,945,000	3
P08670	Vimentin	VIM	138,160,000	72,126,000	18,191,000	31,138,000	16,707,000	14
A0A0A0MRZ8	Ig kappa chain V-III region VG	IGKV3D-11	111,170,000	34,909,000	76,260,000	0	0	1
A0A075B6K5	Ig lambda chain V-III region LOI	IGLV3-9	96,087,000	25,060,000	23,281,000	14,993,000	32,753,000	1
A0A286YFJ8	Ig gamma-4 chain C region	IGHG4	87,485,000	47,260,000	30,192,000	1,565,900	8,467,600	9
A0A075B6Z5	T cell receptor alpha joining 4	TRAJ4	81,903,000	16,074,000	21,003,000	0	44,826,000	1 1
Q96Q89-4 P31942-3	Kinesin-like protein KIF20B Heterogeneous nuclear ribonucleoprotein H3	KIF20B HNRNPH3	80,885,000 80,200,000	35,045,000 14,536,000	8,063,900 9,591,700	37,776,000 10,848,000	0 45,224,000	4
P0DP01	Ig heavy chain V-I region HG3;Ig heavy chain V-I	IGHV1-3	75,366,000	33,904,000	12,319,000	16,686,000	12,457,000	1
C9JA05	Immunoglobulin J chain	JCHAIN	74,956,000	6,239,800	24,681,000	8,971,600	35,063,000	1
A6NJ08	Putative methyl-CpG-binding domain protein 3-lik	MBD3L5	72,585,000	0	0	72,585,000	0	1
O43866	CD5 antigen-like	CD5L	67,251,000	6,765,200	12,049,000	0	48,437,000	3
A0A075B6H9	Immunoglobulin lambda variable 4-69	IGLV4-69	66,271,000	0	23,139,000	15,467,000	27,664,000	1
A0A0C4DH31	Ig heavy chain V-I region V35	IGHV1-18	66,003,000	33,480,000	6,768,000	14,275,000	11,480,000	2
Q8IZ41	Ras and EF-hand domain-containing protein	RASEF	63,614,000	0	0	0	63,614,000	1
Q5JTQ6	Alpha-catulin	CTNNAL1	57,823,000	0	0	0	57,823,000	1
S4R460 P31943	Immunoglobulin heavy variable 3/OR16-9 Heterogeneous nuclear ribonucleoprotein H;Hete	IGHV3OR16-9	55,031,000 53,003,000	38,287,000 27,450,000	3,882,000 6,928,200	8,163,400 12,581,000	4,697,800	3 8
P01700		HNRNPH1 IGLV1-47					6,044,000	2
P69892	Ig lambda chain V-I region HA Hemoglobin subunit gamma-2;Hemoglobin subur	HBG2	52,593,000 51,210,000	4,428,100 4,832,700	9,274,400 6,432,400	10,578,000 4,039,100	28,313,000 35,906,000	2
Q01469	Fatty acid-binding protein, epidermal	FABP5	49,218,000	9,923,200	8,054,700	6,476,700	24,764,000	1
A0A0C4DH38	Immunoglobulin heavy variable 5-51	IGHV5-51	47,777,000	21,306,000	9,176,600	9,526,200	7,768,200	2
P06312	Ig kappa chain V-IV region	IGKV4-1	45,342,000	3,210,900	8,777,500	9,179,900	24,174,000	2
A0A075B7B8	Immunoglobulin heavy variable 3/OR16-12	IGHV3OR16-12	42,463,000	23,390,000	6,964,700	8,836,000	3,272,300	2
D6RF44	Heterogeneous nuclear ribonucleoprotein D0	HNRNPD	42,167,000	25,423,000	6,531,800	3,981,200	6,231,100	2
P12314	High affinity immunoglobulin gamma Fc receptor	FCGR1A	41,035,000	21,744,000	3,306,900	13,766,000	2,217,200	4
A0A075B6I0	Immunoglobulin lambda variable 8-61	IGLV8-61	36,318,000	0	15,369,000	0	20,949,000	1
P01023	Alpha-2-macroglobulin	A2M	34,428,000	24,712,000	0	5,408,900	4,307,000	9
M0R1R1 A0A1C7CYZ1	Serine/threonine-protein kinase PAK 4 Mitogen-activated protein kinase 15	PAK4 MAPK15	33,472,000 33,062,000	0 6,944,400	0 14,185,000	33,472,000 7,347,000	0 4,586,000	1 1
A0A0C4DGL8	Haptoglobin;Haptoglobin alpha chain;Haptoglobi	HP	32,080,000	0,944,400	14,183,000	7,347,000	32,080,000	2
P05109	Protein S100-A8; Protein S100-A8, N-terminally p	S100A8	29,241,000	14,931,000	0	10,002,000	4,308,000	2
Q03135	Caveolin-1;Caveolin	CAV1	28,128,000	0	0	0	28,128,000	2
P01714	Ig lambda chain V-III region SH	IGLV3-19	26,041,000	4,373,400	0	0	21,668,000	1
P19474	E3 ubiquitin-protein ligase TRIM21	TRIM21	25,255,000	18,886,000	4,813,800	1,555,300	0	4
P62979	Ubiquitin-40S ribosomal protein S27a;Ubiquitin;4	RPS27A	25,055,000	1,656,300	2,801,700	7,174,300	13,423,000	2
P81605	Dermcidin;Survival-promoting peptide;DCD-1	DCD	22,842,000	12,716,000	3,502,900	0	6,623,700	2
P52594-2	Arf-GAP domain and FG repeat-containing protei	AGFG1	22,167,000	16,991,000	2,315,700	2,860,400	0	1
A0A0C4DH35	Probable non-functional immunoglobulin	IGHV3-35	20,964,000	12,648,000	3,344,000	2,850,000	2,122,100	1
Q86VF2-5	Isoform 5 of Immunoglobulin-like	IGFN1	20,453,000	0	0	0	20,453,000	1
K7EJT5	60S ribosomal protein L22	RPL22	18,553,000	4,268,800	0	0	14,284,000	2
A0A0A0MSV6 A0A075B6K0	Complement C1q subcomponent subunit B	C1QB	18,258,000	0	6,523,400 4,095,500	3 407 600	11,734,000	2 1
P06702	Ig lambda chain V-IV region Hil;Ig lambda chain \ Protein S100-A9	IGLV3-16 S100A9	18,172,000 17,656,000	10,525,000	4,095,500	3,407,600 7,131,300	10,669,000	2
F8W0I9	Microspherule protein 1	MCRS1	16,973,000	16,973,000	0	7,131,300	0	1
P48741	Putative heat shock 70 kDa protein 7;Heat shock	HSPA7	15,835,000	7,272,600	1,230,000	4,196,900	3,135,800	2

P04430	lg kappa chain V-I region BAN	IGKV1-16	15,155,000	0	1,349,600	3,349,700	10,456,000	1
O75594	Peptidoglycan recognition protein 1	PGLYRP1	14,595,000	2,156,900	2,885,000	0,040,700	9,552,700	1
P01599	Ig kappa chain V-I region Gal	IGKV1-17	14,133,000	1,638,200	1,801,900	5,586,300	5,106,400	1
A0A6Q8PHQ9	Prelamin-A/C;Lamin-A/C	LMNA	13,477,000	10,473,000	0	990,760	2,014,100	3
F8WCU1	Coiled-coil domain-containing protein 150	CCDC150	13,165,000	13,165,000	0	0	0	1
P11021	78 kDa glucose-regulated protein	HSPA5	12,097,000	12,097,000	0	0	0	3
P10515	Dihydrolipoyllysine-residue acetyltransferase cor	DLAT	11,577,000	0	0	0	11,577,000	2
A0A0C4DH73	Ig kappa chain V-I region Daudi;Ig kappa chain V	IGKV1-12	11,157,000	4,228,600	3.358.000	0	3,570,100	1
Q02413	Desmoglein-1	DSG1	11,044,000	6,539,700	4,504,100	0	0	4
A0A2R8Y851	40S ribosomal protein S29	RPS29	10,819,000	0	0	0	10,819,000	1
E9PHT9	Annexin;Annexin A5	ANXA5	10,757,000	0	0	0	10,757,000	2
P01766	Ig heavy chain V-III region BRO	IGHV3-13	9,742,100	6,872,500	2.869.600	0	0	3
I3L0Q1	CREB-binding protein; Histone acetyltransferase	CREBBP	9,408,100	9,408,100	0	0	0	2
A0A0A0MT36	Immunoglobulin kappa variable 6D-21	IGKV6D-21	9,327,900	0	0	0	9,327,900	1
P35030-5	Trypsin-3	PRSS3	8,538,700	4,010,200	0	0	4,528,500	1
P02747	Complement C1q subcomponent subunit C	C1QC	8,466,800	0	6,587,500	1,879,200	0	2
A0A0B4J1V0	Immunoglobulin heavy variable 3-15	IGHV3-15	8,461,900	2,460,400	6,001,500	0	0	2
C9JD14	Guanine nucleotide-binding protein G(I)/G(S)/G(GNB4	8,022,200	0	0	0	8,022,200	1
A0A0C4DH68	Immunoglobulin kappa variable 2-24	IGKV2-24	7,515,800	7,515,800	0	0	0	2
Q5T3N1	Annexin;Annexin A1	ANXA1	7,426,700	1,331,300	0	803,800	5,291,600	2
A0A0A0MRA5	Heterogeneous nuclear ribonucleoprotein U-like	HNRNPUL1	6,653,000	6,653,000	0	0	0	3
P0DP04	lg heavy chain V-III region DOB	IGHV3-43D	6,600,800	0	3,028,100	3,572,700	0	3
P02675	Fibrinogen beta chain; Fibrinopeptide B; Fibrinoge	FGB	6,128,300	6,128,300	0	0	0	2
Q9NZT1	Calmodulin-like protein 5	CALML5	6,023,300	1,202,800	0	4,408,400	412.040	3
A0A0C4DH67	Immunoglobulin kappa variable 1-8	IGKV1-8	5,877,100	2,421,000	3,456,100	0	0	1
A0A2R8YD12	Serpin B6	SERPINB6	5,710,400	5,710,400	0	0	0	1
A0A0A0MRQ5	Peroxiredoxin-2;Peroxiredoxin-1	PRDX1	5,706,700	0	0	2,361,100	3,345,600	1
Q5VVL7	Lipoamide acyltransferase component of branche	DBT	5,612,200	3,395,200	0	2,217,000	0	1
P06310	Ig kappa chain V-II region RPMI 6410	IGKV2-30	5,336,000	0	0	2,017,100	3,318,900	2
P50991	T-complex protein 1 subunit delta	CCT4	4,474,800	0	0	0	4,474,800	1
A0A0C4DH36	Probable non-functional immunoglobulin heavy v	IGHV3-38	4,238,600	0	4,238,600	0	0	2
P47929	Galectin-7	LGALS7	4,195,800	0	0	1,755,800	2,440,000	3
B4E1S2	Annexin; Annexin A4	ANXA4	4,022,500	0	0	0	4,022,500	1
E7ETU5	RNA-binding motif, single-stranded-interacting pr	RBMS1	3,858,200	2,150,500	0	1,707,700	0	2
I3L1P8	Mitochondrial 2-oxoglutarate/malate carrier prote	SLC25A11	3,820,000	0	0	0	3,820,000	1
Q71U36-2	Tubulin alpha-1A chain;Tubulin alpha-1B chain;T	TUBA1A	3,782,000	3,782,000	0	0	0	2
D6R9P3	Heterogeneous nuclear ribonucleoprotein A/B	HNRNPAB	3,571,200	3,120,400	0	450,800	0	2
E9PJT1	Phosphatidylinositol-binding clathrin assembly pr	PICALM	3,561,800	3,561,800	0	0	0	1
A0A0B4J1V6	Immunoglobulin heavy variable 3-73	IGHV3-73	3,460,100	0	1,501,600	1,958,600	0	3
P14923	Junction plakoglobin	JUP	3,261,700	2,178,900	0	0	1,082,900	3
Q5T749	Keratinocyte proline-rich protein	KPRP	3,196,400	3,196,400	0	0	0	2
P15924	Desmoplakin	DSP	2,976,300	0	2,479,300	0	497,000	3
E9PKD2	Nuclear pore complex protein Nup214	NUP214	2,854,500	1,488,400	1,366,100	0	0	1
B3KV94	Lysine-specific demethylase 5B	KDM5B	2,598,600	0	2,598,600	0	0	1
P78406	mRNA export factor	RAE1	2,408,100	2,408,100	0	0	0	1
P17661	Desmin	DES	2,140,500	0	0	1,047,300	1,093,200	4
P31994-5	Low affinity immunoglobulin gamma Fc	FCGR2B	2,042,300	0	2,042,300	0	0	1
A0A087WT15	N-acetylglucosaminyldiphosphodolichol	ALG13	1,878,000	0	1,878,000	0	0	1
P31944	Caspase-14;Caspase-14 subunit p17, mature for	CASP14	880,720	0	880,720	0	0	1
A0A3B3ISA6	Complement C4-A;Complement C4 beta chain;C	C4B	664,880	0	0	0	664,880	1

Table 3
Proteins identified in MDMX immunoprecipitations (IP).
Protein extracts O1, O4, O6, Q1, Q4, and R4 were immunoprecipitated in one experiment.

		Majority protein	Protein	Gene	Total Intensity	Intensity MDMX	Intensity MDMX	Intensity MDMX	Intensity MDMX	Intensity MDMX	Intensity MDMX	Peptides
MDMX IP	to all IP	ID P01857	Ig gamma-1 chain C region	IGHG1		01 22,238,000,000	04	06	Q1 85,828,000,000	Q4	R4 47,830,000,000	17
	Yes	P68871	Hemoglobin subunit beta	HBB	49,360,000,000	2,016,400,000	36,158,000,000	924,450,000	902,880,000	6,065,100,000	3,293,300,000	14
	Yes	P69905 P20073-2	Hemoglobin subunit alpha Annexin A7	HBA1 ANXA7	46,601,000,000 25,375,000,000	3,529,000,000 5,386,800,000	26,425,000,000 1,897,400,000	1,616,500,000 6,836,600,000	1,416,300,000 2,658,100,000	6,485,900,000 3,368,800,000	7,128,000,000 5,226,900,000	15 31
	Yes	Q9Y6R7 P81605	IgGFc-binding protein Dermcidin;Survival-promoting peptide;DCD-1	FCGBP DCD	19,471,000,000 11,575,000,000	6,976,500,000 2,289,500,000	5,284,100,000 1,337,700,000		1,183,900,000 2,832,500,000	470,780,000 985,260,000	3,105,900,000 1,971,800,000	75 9
Yes	Yes	P50995 P01871	Annexin A11 Ig mu chain C region	ANXA11 IGHM	11,312,000,000 10,253,000,000	478,090,000 2.115.600.000	1,687,700,000 3.548,100,000		1,407,600,000 926,840,000		2,827,400,000 1,620,700,000	22 18
		P63261	Actin, cytoplasmic 2	ACTG1	7,787,800,000	669,640,000	2,068,500,000	955,900,000	645,430,000	2,563,700,000	884,630,000	16
Yes	Yes	P69892 P55072	Hemoglobin subunit gamma-2 Transitional endoplasmic reticulum ATPase	HBG2 VCP	7,148,400,000 4,620,000,000	1,386,800,000 185,550,000	780,010,000 758,330,000	795,220,000 1,565,000,000	661,950,000 411,970,000	460,580,000 553,090,000	3,063,800,000 1,146,000,000	12 39
Yes	Yes	P07355 P15924	Annexin A2;Annexin;Putative annexin A2-like Desmoplakin	ANXA2 DSP	4,497,800,000 4,032,200,000	586,000,000 470,760,000	417,330,000 397,430,000	1,170,600,000 777,640,000	722,980,000 503,940,000	573,440,000 1,011,000,000	1,027,400,000 871,340,000	24 71
	Yes Yes	Q02413 P01834	Desmoglein-1 Ig kappa chain C region	DSG1 IGKC	3,842,500,000 3,261,700,000	671,480,000 842,260,000	532,380,000 1,005,100,000	484,300,000 115,500,000	578,340,000 198,480,000	684,390,000 706,400,000	891,590,000 393,970,000	23 8
Yes		P08670 A0A0C4DH90	Vimentin Ig kappa chain V-III region POM	VIM IGKV3OR2-268	3,157,700,000 2,570,200,000	489,550,000 1,897,100,000	337,990,000	734,410,000 13,227,000	251,720,000	392,940,000 225,870,000	951,130,000 434,010,000	25 1
Yes		V9HW50	Alcohol dehydrogenase 1B	HEL-S-117	2,525,500,000	0	2,445,000,000	0	0	80,447,000	0	17
Yes	Yes	P17931 Q08554-2	Galectin-3;Galectin Desmocollin-1	LGALS3 DSC1	2,429,700,000 2,289,200,000	1,214,100,000 409,040,000	169,570,000 260,520,000	378,710,000 496,130,000	177,170,000 269,620,000	77,588,000 267,980,000	412,490,000 585,960,000	8 11
	Yes Yes	P0DOY3 P14923	Ig lambda-1 chain C regions Junction plakoglobin	IGLC1 JUP	2,060,500,000 1,729,100,000	902,940,000 212,940,000	302,390,000 113,640,000	106,470,000 343,050,000	55,564,000 269,710,000	332,740,000 404,730,000	360,390,000 385,000,000	6 15
Yes		Q8N5G2-2 Q5T749	Macoilin Keratinocyte proline-rich protein	MACO1 KPRP	1,581,700,000 1,575,500,000	99,294,000 330,330,000	476,890,000 141,660,000	430,010,000 226,220,000	308,790,000 285,640,000	0 313,090,000	266,730,000 278,590,000	2 12
	Yes Yes	P19474 Q9NZT1	E3 ubiquitin-protein ligase TRIM21 Calmodulin-like protein 5	TRIM21 CALML5	1,493,600,000 1,415,300,000	373,480,000 243,820,000	221,830,000 182,070,000	137,660,000 222,180,000	252,360,000 153,060,000	260,040,000 70,118,000	248,270,000 544,030,000	10 5
	165	P04083	Annexin A1;Annexin	ANXA1	1,402,800,000	51,347,000	99,256,000	209,080,000	80,360,000	733,430,000	229,300,000	12
Yes Yes		P02647 A0A3B3IS80	Apolipoprotein A-I;Proapolipoprotein A-I Fructose-bisphosphate aldolase B	APOA1 ALDOB	1,331,000,000 1,149,700,000	11,399,000 0	117,700,000 1,053,900,000	5,319,000 0	16,475,000 0	1,162,800,000 95,806,000	17,217,000 0	15 15
	Yes	P04406 A0A286YES1	Glyceraldehyde-3-phosphate dehydrogenase Ig gamma-3 chain C region	GAPDH IGHG3	1,024,600,000 1,009,000,000	45,228,000 138,810,000	381,510,000 318,110,000	144,970,000 154,420,000	70,343,000 99,280,000	219,600,000 160,810,000	162,960,000 137,620,000	13 15
	Yes	P02675 A0A5F9ZH78	Fibrinogen beta chain Arginase-1	FGB ARG1	987,840,000 985,040,000	3,484,400 29.882.000	109,660,000 296,130,000	9,669,900 165,080,000	133,750,000	843,190,000 191,750,000	21,839,000 168,450,000	8 7
		P04040 A0A286YEY1	Catalase Ig alpha-1 chain C region	CAT IGHA1	883,310,000	55,685,000	377,410,000	124,610,000	80,278,000	132,340,000	112,980,000	10 11
	Yes	P01023	Alpha-2-macroglobulin	A2M	816,250,000 764,980,000	19,070,000 22,095,000	323,900,000 427,860,000	34,146,000 9,797,400	95,177,000 18,372,000	136,490,000 162,150,000	207,470,000 124,700,000	19
Yes	Yes	Q2L6G8 P11021	Corneodesmosin 78 kDa glucose-regulated protein	CDSN HSPA5	755,530,000 754,080,000	85,379,000 73,659,000	142,160,000 267,450,000	258,560,000 111,330,000	81,346,000 14,914,000	84,291,000 122,090,000	103,800,000 164,640,000	5 19
Yes	Yes	Q14103-3 S4R460	Heterogeneous nuclear ribonucleoprotein D0 Ig heavy chain V-III region BRO	HNRNPD IGHV3OR16-9	743,760,000 737,650,000	190,940,000 77,631,000	159,680,000 167,330,000	172,750,000 68,300,000	62,051,000 164,380,000	75,439,000 145,600,000	82,904,000 114,400,000	7 2
Yes		Q8N257 P02671	Histone H2B type 3-B Fibrinogen alpha chain; Fibrinopeptide A	HIST3H2BB FGA	735,150,000 727,500,000	68,866,000 0	97,720,000 39,906,000	133,440,000	90,551,000	222,990,000 687,600,000	121,590,000	4 20
Yes		H0Y9N0	Alcohol dehydrogenase 4	ADH4 LMNA	720,950,000	0 124,240,000	690,910,000	0	0 16,496,000	30,039,000	0	13
Yes		A0A6Q8PFJ0 P31327	Prelamin-A/C;Lamin-A/C Carbamoyl-phosphate synthase [ammonia], mitochondrial	CPS1	692,900,000 684,130,000	0	137,300,000 639,470,000	102,670,000 0	0	157,450,000 44,655,000	154,750,000 0	15 22
	Yes	P02787 Q01469	Serotransferrin Fatty acid-binding protein, epidermal	TF FABP5	652,910,000 620,650,000	95,889,000	470,270,000 59,613,000	0 208,230,000	97,652,000	146,010,000 68,443,000	36,628,000 90,819,000	17 6
Yes Yes		Q9BTM1 P02042	Histone H2A.J Hemoglobin subunit delta	H2AFJ HBD	616,220,000 608,730,000	134,230,000 5,412,700	164,340,000 569,100,000	41,711,000 0	94,091,000	86,576,000 34,217,000	95,268,000 0	3 11
Yes	Yes	P31943 Q15007	Heterogeneous nuclear ribonucleoprotein H Pre-mRNA-splicing regulator WTAP	HNRNPH1 WTAP	586,320,000 583,670,000	235,200,000 146,160,000	40,807,000 79,564,000	91,509,000 83,145,000	52,962,000 52,450,000	116,480,000 83,328,000	49,360,000 139,020,000	10 11
163		E7ETU5	RNA-binding motif, single-stranded-interacting protein 1	RBMS1	582,990,000	101,720,000	109,470,000	87,943,000	47,975,000	117,990,000	117,880,000	4
Yes		F8VZY9 P01024	Keratin, type I cytoskeletal 18 Complement C3;Complement C3 beta chain	KRT18 C3	508,470,000 484,020,000	182,680,000 0	57,886,000 112,750,000	98,079,000 0	48,183,000 0	67,435,000 371,270,000	54,210,000 0	11 18
Yes Yes		F5H5D3 C9JEU5	Tubulin alpha-1C chain;Tubulin alpha-1B chain Fibrinogen gamma chain	TUBA1C FGG	478,170,000 455,740,000	54,611,000 0	141,340,000 79,865,000	66,825,000 2,023,400	35,734,000 0	118,870,000 368,680,000	60,793,000 5,169,500	7 8
Yes	Yes	P31942-2 A0A286YEY4	Heterogeneous nuclear ribonucleoprotein H3 Ig gamma-2 chain C region	HNRNPH3 IGHG2	453,350,000 432,350,000	48,222,000 114,780,000	34,002,000 109,100,000	131,920,000 83,334,000	77,527,000 18,798,000	103,460,000 68,437,000	58,216,000 37,904,000	7 10
Yes		P06733 E9PGY2	Alpha-enolase	ENO1 DNAAF5	410,010,000 404,800,000	29,654,000	202,800,000 183,310,000	42,689,000	15,683,000	119,190,000 69,246,000	0 65,333,000	12
Yes		E5RHP7	Dynein assembly factor 5, axonemal Carbonic anhydrase 1	CA1	401,260,000	19,772,000	391,980,000	67,144,000	0	9,284,600	0	8
		O43866 O14979-3	CD5 antigen-like Heterogeneous nuclear ribonucleoprotein D-like	CD5L HNRNPDL	377,830,000 365,710,000	69,239,000 19,376,000	55,821,000 5,685,600	96,818,000 198,730,000	44,043,000 94,806,000	63,341,000 32,417,000	48,571,000 14,696,000	7 8
Yes		Q9UNZ2 P01767	NSFL1 cofactor p47 Ig heavy chain V-III region BUT	NSFL1C IGHV3-66	347,920,000 341,860,000	35,893,000 194,310,000	47,043,000 62,905,000	106,430,000 0	50,500,000 45,120,000	26,935,000 39,526,000	81,121,000 0	8
		P06702 E7EQB2	Protein S100-A9 Lactotransferrin;Lactoferricin-H	S100A9 LTF	328,250,000 327,250,000	18,939,000 38,827,000	139,660,000	0 27,766,000	0 5,594,100	309,310,000 60,142,000	0 55,260,000	5 7
Yes		J3QSA3 P35579	Ubiquitin-40S ribosomal protein S27a Myosin-9	UBB MYH9	324,440,000 312,240,000	21,637,000 3.676,700	77,494,000 19,015,000	57,113,000 0	32,248,000 0	60,277,000 289,550,000	75,668,000 0	2 14
Yes		P00488	Coagulation factor XIII A chain	F13A1	309,550,000	38,304,000	144,670,000	49,351,000	0	12,444,000	64,783,000	11
Yes		P16403 P05091	Histone H1.2 Aldehyde dehydrogenase, mitochondrial	HIST1H1C ALDH2	308,980,000 295,420,000	26,941,000 0	14,080,000 295,420,000	6,953,300 0	0	29,397,000 0	231,610,000 0	8 13
Yes	Yes	P31944 P23141-3	Caspase-14;Caspase-14 subunit p17, mature form Liver carboxylesterase 1	CASP14 CES1	292,460,000 287,760,000	41,450,000 0	20,154,000 275,240,000	92,287,000 0	47,890,000 0	24,225,000 12,513,000	66,452,000 0	5 8
Yes		Q13492-3 P08263	Phosphatidylinositol-binding clathrin assembly protein Glutathione S-transferase A1	PICALM GSTA1	280,250,000 276,080,000	0	13,085,000 276,080,000	54,721,000 0	40,016,000 0	68,106,000 0	104,330,000	2 6
Yes		P01709 K7EMS3	lg lambda chain V-II region MGC Keratin, type I cytoskeletal 19	KRT19	272,320,000 271,550,000	194,040,000 43,143,000	27,482,000 35,179,000	0 52,355,000	0 28,751,000	20,496,000 3,693,300	30,296,000 108,430,000	1 8
Yes		P32119 P11142	Peroxiredoxin-2	PRDX2 HSPA8	264,970,000 256,440,000	10,440,000	193,050,000	17,114,000 39 021 000	0	28,665,000	15,708,000	7
Yes		H3BQ34	Heat shock cognate 71 kDa protein Pyruvate kinase;Pyruvate kinase PKM	PKM	253,600,000	21,135,000 157,610,000	64,536,000 12,316,000	26,633,000	7,716,200	87,034,000 41,154,000	44,712,000 8,175,000	12 4
Yes		M0QZK8 P62805	Gamma-glutamylcyclotransferase Histone H4	GGCT HIST1H4A	252,790,000 247,550,000	23,067,000 32,165,000	23,773,000 44,025,000	53,047,000 57,166,000	57,290,000 32,274,000	26,710,000 24,152,000	68,899,000 57,770,000	3
Yes		F8VV32 A0A2R8YGD1	Lysozyme;Lysozyme C Tripeptidyl-peptidase 1	LYZ TPP1	237,840,000 228,720,000	25,942,000 59,580,000	54,297,000 36,930,000	24,124,000 40,003,000	46,944,000 12,722,000	38,336,000 48,382,000	48,197,000 31,107,000	3 2
Yes		A0A286YFJ8 P30086	Ig gamma-4 chain C region Phosphatidylethanolamine-binding protein 1	IGHG4 PEBP1	221,300,000 220,410,000	21,901,000	25,795,000 220,410,000	0	48,084,000 0	94,876,000 0	30,645,000 0	9
Yes		Q8NDC0 E9PSB3	MAPK-interacting and spindle-stabilizing protein-like Eukaryotic translation initiation factor 3 Sub M	MAPK1IP1L EIF3M	219,790,000 204,390,000	0	0	74,677,000 204,390,000	0	55,083,000	90,029,000	1
Yes		P00367	Glutamate dehydrogenase 1, mitochondrial	GLUD1	202,320,000	0	194,820,000	0	0	7,505,800	0	8
Yes Yes		P01040 H0Y755	Cystatin-A;Cystatin-A, N-terminally processed Low affinity immunoglobulin gamma Fc region receptor III-A	CSTA FCGR3A	200,650,000 200,010,000	31,866,000 96,729,000	28,575,000 0	24,874,000 76,577,000	17,883,000 15,235,000	0	97,455,000 11,468,000	3 2
Yes Yes		Q6UWP8 H0YH81	Suprabasin ATP synthase subunit beta,mitochondrial	SBSN ATP5B	199,090,000 192,440,000	23,686,000 0	5,567,100 150,240,000	53,784,000 11,186,000	11,163,000 0	9,392,600 26,174,000	95,502,000 4,835,000	7 3
Yes	Yes	P00738 P05109	Haptoglobin;Haptoglobin alpha chain Protein S100-A8;Protein S100-A8, N-terminally processed	HP S100A8	191,600,000 188,970,000	0 15,112,000	83,217,000 51,461,000	6,955,600	7,752,500	105,830,000 102,410,000	2,547,800 5.286.800	8 4
		P10412 P30101	Histone H1.4 Protein disulfide-isomerase A3	HIST1H1E PDIA3	188,770,000 184,850,000	0 27.987.000	51,503,000 81,404,000	19,340,000 9,267,600	0	38,303,000 52,967,000	79,622,000 13,224,000	7
Yes	Yes	Q60FE5 P59666	Filamin-A Neutrophil defensin 3:HP 3-56:Neutrophil defensin 2	FLNA DEFA3	176,900,000 175,940,000	17,314,000 12,525,000	62,222,000 147,180,000	4,156,600	0	93,211,000	16,235,000	14 4
	res	A0A7I2V4I6	Heterogeneous nuclear ribonucleoproteins A2/B1	HNRNPA2B1	175,770,000	10,611,000	33,709,000	0 28,025,000	3,763,900	47,208,000	52,448,000	8
Yes		C9JZN1 E9PJX3	Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit 2 DC-STAMP domain-containing protein 1	GNB2 DCST1	167,230,000 165,830,000	0 165,830,000	32,409,000 0	0	114,540,000 0	0	20,285,000	3 1
Yes Yes		Q93088 Q08188	Betainehomocysteine S-methyltransferase 1 Protein-glutamine gamma-glutamyltransferase E	BHMT TGM3	156,930,000 151,040,000	0 19,454,000	156,930,000 14,749,000	30,930,000	0 27,901,000	0 11,456,000	0 46,554,000	5 6
Yes		Q5JP53 P00352	Tubulin beta chain;Tubulin beta-2B chain Retinal dehydrogenase 1	TUBB ALDH1A1	148,810,000 147,820,000	0	39,759,000 143,910,000	10,457,000	5,418,600	93,172,000 3,905,500	0	3
		A0A7I2V3H3	Putative elongation factor 1-alpha-like 3	EEF1A1	146,880,000	10,829,000	56,560,000	10,460,000	7,325,300	52,315,000	9,388,600	1
Yes		P29508-2 P47929	Serpin B3 Galectin-7	SERPINB3 LGALS7	144,360,000 142,190,000	34,074,000 14,374,000	0	63,249,000 53,808,000	7,558,700 19,822,000	7,745,700 41,851,000	31,729,000 12,331,000	3 4
Yes Yes		P02730 P25705-2	Band 3 anion transport protein ATP synthase subunit alpha, mitochondrial	SLC4A1 ATP5A1	137,560,000 135,600,000	0 25,045,000	122,820,000 92,411,000	6,434,500 4,146,300	0	0 14,002,000	8,304,400 0	6 9
Yes Yes		P09467 A0A6Q8PFK8	Fructose-1,6-bisphosphatase 1 Heat shock protein beta-1	FBP1 HSPB1	134,090,000 129,770,000	0 6,293,600	112,310,000 23,017,000	0 23,662,000	0 14,009,000	21,781,000 27,850,000	0 34,937,000	4
. 00		P14625 A0A5F9ZHX5	Endoplasmin Chromodomain-helicase-DNA-binding protein 3	HSP90B1 CHD3	128,220,000 126,410,000	0,255,000 0 72,151,000	87,804,000 0	12,003,000	1,880,000	22,276,000	4,253,300 54,262,000	6
.,		D3YTK1	B-cell lymphoma/leukemia 11B	BCL11B	124,710,000	76,098,000	14,068,000	16,701,000	0	0	17,845,000	1
Yes Yes		P07476 P00558-2	Involucrin Phosphoglycerate kinase 1	IVL PGK1	120,360,000 119,430,000	0	106,620,000	0	0	120,360,000 12,816,000	0	6 5
Yes		A0A0G2JRN3 P10599-2	Alpha-1-antitrypsin;Short peptide from AAT Thioredoxin	SERPINA1 TXN	119,420,000 119,320,000	0 32,992,000	7,421,500	0 15,014,000	0 6,942,900	119,420,000 38,357,000	0 18,590,000	2
		A0A087WVQ6	Clathrin heavy chain;Clathrin heavy chain 1	CLTC	118,860,000	7,694,400	39,319,000	4,351,100	5,094,400	27,799,000	34,607,000	5

		P11166	Solute carrier family 2, facilitated glucose transporter member 1	SLC2A1	117,840,000	27,594,000	20,800,000	27,638,000	17,045,000	17,769,000	6,991,000	1
Yes		A0A0A0MSI0 P04843	Peroxiredoxin-1 Dolichyl-diphosphooligosaccharideprotein glycosyltransferase subunit 1	PRDX1 RPN1	117,410,000 114,750,000	0 14,069,000	23,434,000 19,291,000	24,158,000 38,305,000	0	50,913,000 5,918,100	18,908,000 37,166,000	6 5
Yes		Q9BS26 P31040	Endoplasmic reticulum resident protein 44 Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial	ERP44 SDHA	114,410,000 110,870,000	0 21,023,000	19,792,000 29,762,000	0 5.004.900	57,777,000 6,511,700	15,611,000 7,760,200	21,226,000 40,805,000	2
Yes		E9PS23 P00918	Cofilin-1 Carbonic anhydrase 2	CFL1 CA2	105,680,000 103,530,000	0	47,412,000 103,530,000	6,922,800	6,769,200	42,374,000	2,206,100	2
Yes		P40926	Malate dehydrogenase, mitochondrial; Malate dehydrogenase Glutathione S-transferase A2	MDH2	102,110,000	0	102,110,000 101,640,000	0	0	0	0	6
Yes Yes		P09210 P09211	Glutathione S-transferase P	GSTA2 GSTP1	101,640,000 101,360,000	0	24,528,000	0	0	76,833,000	0	2
Yes Yes		P00338-3 P30084	L-lactate dehydrogenase A chain Enoyl-CoA hydratase, mitochondrial	LDHA ECHS1	101,020,000 100,510,000	0	67,486,000 100,510,000	0	0	33,536,000 0	0	4 5
Yes Yes		P00326 P11182	Alcohol dehydrogenase 1C Lipoamide acyltransferase component of branched-chain α-keto acid	ADH1C DBT	99,362,000 98,020,000	0 2,429,500	99,362,000 0	0 88,425,000	7,165,200	0	0	12 6
Yes Yes		P60174 P31995-4	Triosephosphate isomerase Low affinity immunoglobulin gamma Fc region receptor II-c	TPI1 FCGR2C	96,410,000 95,150,000	0	96,410,000 0	0 21,613,000	0 16,029,000	0	0 57.508.000	6
Yes		P81605-2 A0A7I2V2R3	Dermcidin;Survival-promoting peptide;DCD-1 Heterogeneous nuclear ribonucleoprotein A3	DCD HNRNPA3	94,948,000 94,476,000	0	17,310,000 0	24,755,000 40,480,000	14,705,000 18,442,000	27,485,000 11,950,000	10,693,000 23,604,000	8
Yes Yes		Q15828 P04259	Cystatin-M Keratin, type II cytoskeletal 6B	CST6 KRT6B	90,006,000 89,853,000	23,842,000	0 3,936,600	12,469,000 12,262,000	11,616,000 4,134,500	14,124,000 69,520,000	27,955,000	1 56
		K7EQ02	DAZ-associated protein 1	DAZAP1	88,043,000	0	4,283,400	36,199,000	21,232,000	26,328,000	0	2
Yes Yes		P08238 Q13835-2	Heat shock protein HSP 90-beta Plakophilin-1	HSP90AB1 PKP1	87,486,000 87,271,000	9,004,500 14,367,000	43,177,000 4,843,200	0	0 14,614,000	26,031,000 47,376,000	9,274,000 6,070,300	8
Yes		P16401 P21549	Histone H1.5 Serinepyruvate aminotransferase	HIST1H1B AGXT	86,334,000 84,253,000	0	0 84,253,000	0	0	33,838,000 0	52,496,000 0	5 3
Yes Yes		E7EQR4 A8MW49	Ezrin Fatty acid-binding protein, liver	EZR FABP1	83,177,000 80,281,000	11,616,000 0	57,174,000 80,281,000	0	0	0	14,386,000 0	6 3
Yes Yes		Q09666 P06396-2	Neuroblast differentiation-associated protein AHNAK Gelsolin	AHNAK GSN	79,609,000 77,391,000	4,552,900 0	0	0	0	75,056,000 77,391,000	0	8 5
Yes Yes		P08311 P07737	Cathepsin G Profilin-1	CTSG PFN1	75,345,000 73,460,000	0	64,752,000 45,606,000	0	0	10,593,000 27,854,000	0	3
Yes Yes		Q13867 A0A0G2JIW1	Bleomycin hydrolase Heat shock 70 kDa protein 1A;Heat shock 70 kDa protein 1B	BLMH HSPA1A	71,299,000 70,838,000	15,720,000	8,186,000 40,124,000	22,679,000 9.828.700	0	9,475,800 14,307,000	15,237,000 6,577,900	2
Yes		P25311	Zinc-alpha-2-glycoprotein	AZGP1 HSPD1	70,437,000	17,679,000	10,057,000	36,466,000	0	0	6,235,100	6
Yes		A0A7I2YQK6 P30041	60 kDa heat shock protein, mitochondrial Peroxiredoxin-6	PRDX6	70,230,000 70,214,000	ō	41,023,000 70,214,000	0	Ō	29,206,000	0	2
Yes	Yes	P17066 E9PHT9	Heat shock 70 kDa protein 6;Putative heat shock 70 kDa protein 7 Annexin;Annexin A5	HSPA6 ANXA5	69,823,000 69,705,000	7,186,600	31,296,000 4,930,200	5,901,700 11,971,000	4,534,000 16,361,000	18,897,000 5,489,900	9,194,300 23,766,000	4
		P31025 P31930	Lipocalin-1;Putative lipocalin 1-like protein 1 Cytochrome b-c1 complex subunit 1, mitochondrial	LCN1 UQCRC1	68,579,000 66,759,000	17,246,000 0	7,055,500	8,715,500 32,142,000	19,543,000 9,727,500	9,898,400 17,834,000	13,176,000 0	2
Yes Yes		P22735 Q6ZVX7	Protein-glutamine gamma-glutamyltransferase K F-box only protein 50	TGM1 NCCRP1	66,068,000 65,548,000	9,145,000 18,299,000	8,097,100 1,627,800	11,141,000 13,871,000	12,123,000 10,069,000	8,823,300 9,179,600	16,739,000 12,502,000	2 2
Yes		Q92637 P31947-2	High affinity immunoglobulin gamma Fc receptor IB 14-3-3 protein sigma	FCGR1B SFN	65,085,000 65,014,000	14,808,000	24,911,000	0	0	0 65,014,000	25,367,000	2
		M0R3F1 Q9HAU0-6	Heterogeneous nuclear ribonucleoprotein U-like protein 1 Pleckstrin homology domain-6	HNRNPUL1 PLEKHA6	64,921,000 64,712,000	7,997,300 0	41,310,000	15,614,000 0	0 35,710,000	03,014,000	15,006,000	3
Yes		Q16822	Phosphoenolpyruvate carboxykinase [GTP], mitochondrial	PCK2	63,356,000	0	63,356,000	0	0	0	0	6
Yes Yes		P42765 V9GYC1	3-ketoacyl-CoA thiolase, mitochondrial Apolipoprotein A-II;Proapolipoprotein A-II;Truncated apolipoprotein A-II	ACAA2 APOA2	63,130,000 63,025,000	0	63,130,000 0	0	0	0 63,025,000	0	3
Yes		O95954 P01833	Formimidoyltransferase-cyclodeaminase Polymeric immunoglobulin receptor;Secretory component	FTCD PIGR	62,955,000 62,780,000	0 55,565,000	62,955,000 0	0 7,215,700	0	0	0	3 2
Yes Yes		H3BUH7 I3NI03	Fructose-bisphosphate aldolase;Fructose-bisphosphate aldolase A Protein disulfide-isomerase	ALDOA P4HB	61,547,000 61,057,000	0 5,594,500	30,590,000 24,393,000	0 6,481,000	0 4,107,900	30,957,000 14,479,000	0 6,001,800	2
Yes Yes		P04899-4 J3QS36	Guanine nucleotide-binding protein G(i) subunit alpha-2 L-xylulose reductase	GNAI2 DCXR	60,628,000 58,887,000	0	5,045,200 58,887,000	17,245,000 0	6,652,900 0	12,318,000 0	19,367,000	3 4
Yes		D6REM4 P01594	Casein kinase I isoform alpha;Casein kinase I isoform alpha-like Ig kappa chain V-I region AU;Ig kappa chain V-I region AG	CSNK1A1 IGKV1D-33	58,574,000 58,512,000	58,574,000 35,985,000	4,295,800	2,809,900	3,517,000	0 4,290,800	0 7,612,700	1
Yes		A0A0A0MSV6 P69891	Complement C1q subcomponent subunit B Hemoglobin subunit gamma-1	C1QB HBG1	58,010,000 57,351,000	0	0	58,010,000 20,525,000	0 11,885,000	0	24,940,000	2 11
Yes		Q5T6W2	Heterogeneous nuclear ribonucleoprotein K	HNRNPK	56,797,000	0	9,694,800	10,343,000	0	20,754,000	16,006,000	1
Yes Yes		Q6P0N6 P08559-3	Dystonin Pyruvate dehydrogenase E1 component subunit alpha, mitochondrial	DST PDHA1	55,054,000 54,649,000	0	0	0 36,915,000	55,054,000 17,733,000	0	0	2
Yes Yes		P54868 K7EP41	Hydroxymethylglutaryl-CoA synthase, mitochondrial Glucose-6-phosphate isomerase	HMGCS2 GPI	54,294,000 51,787,000	0	54,294,000 28,093,000	0	0	0 23,693,000	0	3 1
Yes		A0A7I2V5R8 P02745	Dipeptidyl peptidase 4 soluble form Complement C1q subcomponent subunit A	DPP4 C1QA	49,250,000 49,029,000	16,947,000 0	0	6,971,900 26,241,000	7,260,800	0	25,332,000 15,527,000	3 1
Yes Yes		H7C131 P14550	3-ketoacyl-CoA thiolase, peroxisomal Alcohol dehydrogenase [NADP(+)]	ACAA1 AKR1A1	49,012,000 48,970,000	0	39,040,000 48,970,000	0	0	9,971,800 0	0	2
Yes Yes		H7BYH4 O75891-2	Superoxide dismutase [Cu-Zn] Cytosolic 10-formyltetrahydrofolate dehydrogenase	SOD1 ALDH1L1	48,641,000 47,334,000	0	36,536,000 47,334,000	0	0	12,105,000 0	0	1
Yes Yes		P16152 Q16762	Carbonyl reductase [NADPH] 1 Thiosulfate sulfurtransferase	CBR1 TST	46,537,000 46,314,000	0	46,537,000 46,314,000	0	0	0	0	3
		P98082-2	Disabled homolog 2	DAB2	46,020,000	7,661,800	4,233,100	4,780,500 0	11,910,000	4,537,100 0	12,898,000	1 3
Yes Yes		A0A2R8Y7L2 F5H5P2	Peroxisomal multifunctional enzyme type 2;Enoyl-CoA hydratase 2 2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial	HSD17B4 BCKDHA	44,462,000 44,336,000	0	44,462,000 0	27,748,000	6,992,100	9,596,700	0	2
		P07910 P01701	Heterogeneous nuclear ribonucleoproteins C1/C2 Ig lambda chain V-I region NEW	HNRNPC IGLV1-51	44,199,000 43,260,000	0 43,260,000	0	19,282,000 0	0	24,917,000 0	0	2 1
Yes Yes		Q16610-2 P80748	Extracellular matrix protein 1 Ig lambda chain V-III region LOI	ECM1 IGLV3-9	43,164,000 39,938,000	16,073,000 39,938,000	0	4,679,200 0	16,017,000 0	0	6,394,400 0	3 2
Yes Yes		P00480 P06727	Ornithine carbamoyltransferase, mitochondrial Apolipoprotein A-IV	OTC APOA4	38,811,000 38,730,000	0	38,811,000 0	0	0	0 38,730,000	0	3 4
	Yes	A0A3B3ISA6 C9J2I0	Complement C4-A;Complement C4 beta chain Arf-GAP domain and FG repeat-containing protein 1	C4B AGFG1	37,477,000 37,463,000	0	0 19,993,000	0	0 17,470,000	37,477,000 0	0	3 1
Yes Yes		P62081 P00505	40S ribosomal protein S7 Aspartate aminotransferase, mitochondrial	RPS7 GOT2	36,563,000 36,173,000	0	36,173,000	0	0	36,563,000	0	1
Yes		Q14669	E3 ubiquitin-protein ligase TRIP12 Plasminogen;Plasmin heavy chain A;Activation peptide;Angiostatin	TRIP12	35,387,000	5,063,600 0	0	0	1,274,500	7,478,400	21,571,000	2
Yes Yes		P00747 A0A5F9ZHD4	Acetyl-CoA acetyltransferase, mitochondrial	PLG ACAT1	35,204,000 34,864,000	0	18,546,000 34,864,000	0	0	16,658,000 0	0	2
Yes Yes		P42357 P08574	Histidine ammonia-lyase Cytochrome c1, heme protein, mitochondrial	HAL CYC1	34,798,000 34,705,000	3,023,300 17,970,000	5,789,400 0	4,315,200 0	4,655,100 3,321,100	3,693,900 6,646,500	13,321,000 6,767,300	1
Yes		A0A7I2V2G2 Q13151	Stress-70 protein, mitochondrial Heterogeneous nuclear ribonucleoprotein A0	HSPA9 HNRNPA0	34,422,000 34,332,000	3,644,700 9,337,700	30,777,000 8,802,000	0 6,967,600	9,225,100	0	0	5 1
Yes		Q00266 B4E1S2	S-adenosylmethionine synthase isoform type-1 Annexin;Annexin A4	MAT1A ANXA4	34,266,000 34,107,000	0	34,266,000 23,248,000	0 7,248,900	0	0	0 3,610,400	3 2
Yes Yes		E7EN95 Q15149-7	Filamin-B Plectin	FLNB PLEC	33,248,000 32,622,000	0	0	0	0	33,248,000 32,622,000	0	4 5
Yes		Q5T750 P29401	Skin-specific protein 32 Transketolase	XP32 TKT	32,441,000 32,236,000	14,229,000	12,308,000 25,916,000	0	5,905,100	0 6,320,100	0	1
Yes Yes		R4GN49 Q14574-2	Protein S100-A2 Desmocollin-3	S100A2 DSC3	32,039,000 31,820,000	0	0	11,287,000	0 9,170,400	32,039,000	11,362,000	2 2
Yes Yes		P07900 K7ESE1	Heat shock protein HSP 90-alpha	HSP90AA1 KRT17	31,748,000 31,444,000	0	0	18,987,000	0 0	12,762,000 31.444.000	0	7
		H7BZJ3	Keratin, type I cytoskeletal 17 Protein disulfide-isomerase A3	PDIA3	31,218,000	10,969,000	Ö	ō	ō	12,027,000	8,221,900	2
Yes		A0A2R8YGX3 A0A1X7SBZ2	Tropomyosin alpha-4 chain Probable ATP-dependent RNA helicase DDX17	TPM4 DDX17	30,416,000 30,189,000	0 11,040,000	0 12,105,000	0	0	30,416,000 7,044,500	0	4 1
Yes Yes		P68133 P31151	Actin, alpha skeletal muscle; Actin, aortic smooth muscle Protein S100-A7	ACTA1 S100A7	28,542,000 28,377,000	0 16,068,000	0	22,625,000 0	0 3,923,400	5,916,600 5,362,900	0 3,022,700	11 1
Yes Yes		O75874 P63104	Isocitrate dehydrogenase [NADP] cytoplasmic 14-3-3 protein zeta/delta	IDH1 YWHAZ	27,456,000 26,529,000	0	27,456,000 0	0 3,983,100	0	0 11,736,000	0 10,810,000	3
Yes Yes		A0A7I2V3U0 C9JEH7	Aconitate hydratase, mitochondrial 40S ribosomal protein S4, X isoform	ACO2 RPS4Y1	26,341,000 26,072,000	26,072,000	7,668,600 0	3,421,200 0	0	7,748,000 0	7,503,500 0	2 3
Yes Yes		D6RHJ7 P21980	Dihydropteridine reductase Protein-olutamine gamma-olutamytransferase 2	QDPR TGM2	25,964,000 25,527,000	0	22,627,000 25,527,000	0	0	3,337,100 0	0	2
Yes	Yes	I3L1P8 E9PP21	Mitochondrial 2-oxoglutarate/malate carrier protein Cysteine and glycine-rich protein 1	SLC25A11 CSRP1	25,396,000 25,181,000	0	19,963,000	9,416,800 5,218,000	0	5,550,200 0	10,429,000	1
Yes		P26641	Elongation factor 1-gamma	EEF1G	25,062,000	8,120,000	0	0	0	16,942,000	0	2
Yes		Q99497 B4DK69	Protein deglycase DJ-1 Aldo-keto reductase family 1 member C2	PARK7 AKR1C2	24,469,000 23,775,000	0	24,469,000 23,775,000	0	0	0	0	2 3
Yes		H3BTX9 P17096	Acyl-coenzyme A synthetase ACSM2B, mitochondrial High mobility group protein HMG-I/HMG-Y	ACSM2B HMGA1	23,403,000 23,239,000	0	23,403,000 0	0	0	0	0 23,239,000	2 1
Yes Yes		O43548 A0A6E1W9L1	Protein-glutamine gamma-glutamyltransferase 5 Zinc finger and BTB domain-containing protein 3	TGM5 ZBTB3	22,931,000 22,345,000	0 5,533,200	0	5,106,200 7,473,000	3,459,400 0	5,197,500 9,338,700	9,168,100 0	1 2
Yes Yes		P07099 A0A7I2YQ74	Epoxide hydrolase 1 UTPglucose-1-phosphate uridylyltransferase	EPHX1 UGP2	21,730,000 21,651,000	0	21,730,000 21,651,000	0	0	0	0	2 3
Yes Yes		P34896-3 P51857-2	Serine hydroxymethyltransferase, cytosolic 3-oxo-5-beta-steroid 4-dehydrogenase	SHMT1 AKR1D1	21,544,000 21,175,000	0	21,544,000 21,175,000	0	0	0	0	2
Yes Yes		H0YCY6 F8VPF3	Bifunctional ATP-dependent dihydroxyacetone kinase; ATP-dependent Myosin light polypeptide 6;Myosin light chain 6B	TKFC MYL6	20,829,000 20,561,000	0	20,829,000	0	0	0 20.561.000	0	3
Yes		P01019	Angiotensinogen; Angiotensin-1; Angiotensin-2; Angiotensin-3; Angiotensin-4	AGT	20,374,000	ő	Ö	Ö	ō	20,374,000	ő	2

Yes		P25325-2	3-mercaptopyruvate sulfurtransferase; Sulfurtransferase	MPST	19,789,000	0	19,789,000		0	0		
Yes Yes		A0A3B3ISY1	3-mercaptopyruvate suiturtransterase; Suiturtransterase Tissue factor pathway inhibitor 2	MPS1 TEPI2	19,789,000	8,176,900	19,789,000	0	8,803,000	2,706,500	0	2
Yes		Q16698-2	2,4-dienoyl-CoA reductase, mitochondrial	DECR1	19,661,000	0,170,300	19,661,000	0	0,000,000	2,700,300	0	2
Yes		C9JV37	Prothrombin;Activation peptide fragment 1	F2	19,349,000	ő	0	ő	ŏ	19,349,000	ő	1
Yes		A0A6Q8PFC6	Glycine amidinotransferase, mitochondrial	GATM	18,900,000	0	18,900,000	0	Ö	0,010,000	0	1
Yes		A0A075B6H9	Immunoglobulin lambda variable 4-69	IGLV4-69	18,184,000	18,184,000	0,300,000	0	0	0	0	i
Yes		V9GYG0	ADP/ATP translocase 3;ADP/ATP translocase 3, N-terminally processed	SI C25A4	17.956.000	0	0	6 886 600	4,931,600	Ö	6,137,900	1
Yes		A0A1W2PP35	Heterogeneous nuclear ribonucleoprotein U	HNRNPU	17,783,000	ő	0	17,783,000	0	Ö	0,107,000	3
Yes		E5RGW4	Nucleophosmin	NPM1	17,763,000	Ö	n	0	Ö	17,763,000	Ö	1
Yes		J3QRN2	Beta-2-alvcoprotein 1	APOH	17,755,000	ő	8,891,500	Ö	Ö	0	8,863,300	1
		E9PRN7	3 beta-hydroxysteroid dehydrogenase/Delta 5>4-isomerase type 2	HSD3B1	17,661,000	Ö	0,001,000	4,061,200	6,881,400	ő	6,718,400	1
Yes		P52758	Ribonuclease UK114	HRSP12	16.603.000	ő	16,603,000	0	0,001,100	ő	0,710,100	1
Yes		Q15084-3	Protein disulfide-isomerase A6	PDIA6	16,371,000	ō	10,683,000	ō	ō	5,687,900	ō	1
Yes		Q5TF55	Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial	ALDH4A1	16.343.000	ō	16,343,000	ō	ō	0	ō	1
Yes		H0Y4K8	Fibronectin;Anastellin;Ugl-Y1;Ugl-Y2;Ugl-Y3	FN1	16,129,000	2,290,000	0	7,354,100	0	0	6,485,400	1
Yes		A0A494C1T2	C-1-tetrahydrofolate synthase, cytoplasmic	MTHFD1	15,674,000	0	15,674,000	0	0	0	0	3
		E7EPM6	Long-chain-fatty-acidCoA ligase 1	ACSL1	15,503,000	0	15,503,000	0	0	0	0	2
Yes		H0YJF9	Dihydrolipoyllysine-residue succinyltransferase/2-oxoglutarate dehydrogen	DLST	14,869,000	0	0	11,035,000	0	3,833,400	0	2
Yes		Q14134-2	Tripartite motif-containing protein 29	TRIM29	14,797,000	0	0	0	0	14,797,000	0	2
Yes		P18206-2	Vinculin	VCL	14,766,000	0	0	0	0	0	14,766,000	1
	Yes	D6R9P3	Heterogeneous nuclear ribonucleoprotein A/B	HNRNPAB	14,544,000	0	0	14,544,000	0	0	0	3
Yes		P10696	Alkaline phosphatase, placental-like; Alkaline phosphatase, placental type	ALPPL2	14,464,000	14,464,000	0	0	0	0	0	1
Yes		H3BRG4	Cytochrome b-c1 complex subunit 2, mitochondrial	UQCRC2	14,346,000	0	14,346,000	0	0	0	0	2
Yes		C9JRL4	Malate dehydrogenase; Malate dehydrogenase, cytoplasmic	MDH1	14,124,000	0	14,124,000	0	0	0	0	1
Yes		P62258	14-3-3 protein epsilon	YWHAE	14,037,000	0	5,850,000	0	0	0	8,187,500	2
Yes		D6RFG5	Annexin;Annexin A3	ANXA3	13,723,000	0	0	0	0	13,723,000	0	1
Yes		O60701-3	UDP-glucose 6-dehydrogenase	UGDH	13,415,000	0	13,415,000	0	0	0	0	2
Yes		B0YIW2	Apolipoprotein C-III	APOC3	13,244,000	0	0	0	0	13,244,000	0	1
Yes		A0A0G2JQH2	40S ribosomal protein S18	RPS18	13,172,000	0	0	0	0	13,172,000	0	1
Yes		P49189	4-trimethylaminobutyraldehyde dehydrogenase	ALDH9A1	13,161,000	0	13,161,000	0	0	0	0	1
Yes		P11277-3	Spectrin beta chain, erythrocytic	SPTB	13,077,000	0	13,077,000	0	0	0	0	3
Yes		Q9HC84	Mucin-5B	MUC5B	12,990,000	0	12,990,000	0	0	0	0	2
Yes		P46783	40S ribosomal protein S10;Putative 40S ribosomal protein S10-like	RPS10	12,790,000	0	6,330,400	0	0	6,459,400	0	1
Yes		P04080	Cystatin-B	CSTB	12,717,000	7,164,000	0	5,552,700	0	0	0	1
Yes		F6RFD5	Destrin	DSTN	12,619,000	0	12,619,000	0	0	0	0	1
Yes		P25786	Proteasome subunit alpha type-1;Proteasome subunit alpha type	PSMA1	12,242,000	0	8,949,000	3,292,900	0	0	0	2
Yes		P16157-14	Ankyrin-1	ANK1	12,173,000	0	12,173,000	0	0	0	0	2
Yes Yes		A0A087WT59 E9PK47	Transthyretin	TTR PYGI	11,910,000 11,862,000	0	0 11,862,000	0	0	11,910,000 0	0	2
Yes			Alpha-1,4 glucan phosphorylase;Glycogen phosphorylase, liver form									
.,		P02808	Statherin	STATH	11,823,000	11,823,000	0	0	0	0	0	1
Yes		P08246	Neutrophil elastase	ELANE	11,630,000	0	11,630,000	0	0	0	0	1
		P52907	F-actin-capping protein subunit alpha-1	CAPZA1	11,591,000	0	0	0	0	11,591,000	0	1
Yes		C9JA05 Q9UG54	Immunoglobulin J chain Mitogen-activated protein kinase kinase kinase 7	JCHAIN DKFZp586F0420	11,558,000 11.510.000	11,510,000	0	0	0	11,558,000	0	1
Yes		P45954-2	Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial	ACADSB	11,392,000	11,510,000	11,392,000	0	0	0	0	1
Yes		P45954-2 B5MD38	Trifunctional enzyme subunit beta, mitochondrial:3-ketoacyl-CoA thiolase	HADHB	11,392,000	0	11,392,000	0	0	0	0	1
Yes		P25815	Protein S100-P	S100P	11,215,000	0	11,320,000	0	0	0	11,215,000	1
Yes		P02549-2	Spectrin alpha chain, erythrocytic 1	SPTA1	10.654.000	0	10 654 000	0	0	0	11,213,000	2
Yes		H0YAG8	Alcohol dehydrogenase class-3	ADH5	10,551,000	0	10,551,000	0	0	0	ő	1
163		A0A087WW87	Ig kappa chain V-II region FR;Ig kappa chain V-II region Cum	IGKV2-40	10,538,000	0	0,001,000	0	0	10,538,000	ő	1
Yes		B1AKI5	Muscleblind-like protein 3;Muscleblind-like protein 2	MBNL3	10,394,000	ō	10,394,000	0	ō	0	Ö	2
Yes		B1AKQ8	Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1	GNB1	10,354,000	0	10,354,000	0	0	0	10,354,000	1
Yes		A0A0J9YXZ5	Ras GTPase-activating-like protein IQGAP1	IQGAP1	10,334,000	0	0	0	0	10,328,000	0 0,004	2
Yes		P13716-2	Delta-aminolevulinic acid dehvdratase	ALAD	10,259,000	0	10,259,000	0	ō	0	ő	2
Yes		Q13404-8	Ubiquitin-conjugating enzyme E2 variant 1	UBF2V1	9.964.900	ő	9.964.900	Ö	Ö	Ö	Ö	1
Yes		M0R0Y6	Heterogeneous nuclear ribonucleoprotein M	HNRNPM	9,627,300	ő	0,001,000	ő	ő	9,627,300	ő	1
		A0A7I2V699	Nucleolin	NCL	9.473.600	0	0	ō	0	9.473.600	0	1
		P05387	60S acidic ribosomal protein P2	RPLP2	9,359,400	3,670,500	ō	ō	ō	5.688.900	ō	2
Yes		Q06520	Bile salt sulfotransferase	SULT2A1	9,347,800	0	9,347,800	0	0	0	0	1
Yes		P21399	Cytoplasmic aconitate hydratase	ACO1	9,273,300	0	9,273,300	0	0	0	0	1
		P27824-3	Calnexin	CANX	9,232,100	0	0	0	0	9,232,100	0	2
Yes		A0A0C4DGA2	Enoyl-CoA delta isomerase 2, mitochondrial	ECI2	9,217,600	0	9,217,600	0	0	0	0	1
		A0A140TA58	Keratin-associated protein 9-9	KRTAP9-9	9,046,100	0	9,046,100	0	0	0	0	2
Yes		J3KRG2	Gasdermin-A	GSDMA	8,582,300	0	3,803,000	0	0	0	4,779,300	2
Yes		F5GZP6	Liprin-beta-1	PPFIBP1	8,376,800	8,376,800	0	0	0	0	0	1
Yes		P32926	Desmoglein-3	DSG3	8,254,400	0	0	0	0	8,254,400	0	2
Yes		A0A0G2JMB2	Ig alpha-2 chain C region	IGHA2	7,976,600	0	7,976,600	0	0	0	0	5
Yes		M0QY85	Tubulin beta-4A chain; Tubulin beta-4B chain	TUBB4A	7,933,700	0	7,933,700	0	0	0	0	2
Yes		Q14117	Dihydropyrimidinase	DPYS	7,893,100	0	7,893,100	0	0	0	0	3
		E9PE82	Short-chain specific acyl-CoA dehydrogenase, mitochondrial	ACADS	7,313,700	0	7,313,700	0	0	0	0	1
		F2Z2W8	Selenium-binding protein 1	SELENBP1	6,229,500	0	6,229,500	0	0	0	0	2
Yes		Q13011	Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial	ECH1	5,760,800	0	5,760,800	0	0	0	0	1
		Q9UBG3	Cornulin	CRNN	5,651,400	0	0	5,651,400	0	0	0	1
		Q08257-2	Quinone oxidoreductase	CRYZ	5,461,300	0	5,461,300	0	0	0	0	1
Yes		P28838-2	Cytosol aminopeptidase	LAP3	5,135,200	0	5,135,200	0	0	0	0	1
Yes		A8MUD9	60S ribosomal protein L7	RPL7	4,984,000	4,984,000	0	0	0	0	0	1
.,		E9PEB5	Far upstream element-binding protein 1	FUBP1	4,190,600	0	0	4,190,600	0	0	0	2
Yes		P09651	Heterogeneous nuclear ribonucleoprotein A1	HNRNPA1	3,752,800	3,752,800	0	0	0	0	0	2
.,		P22314-2	Ubiquitin-like modifier-activating enzyme 1	UBA1	3,748,100	0	3,748,100	0	0	0	0	1
Yes		Q14032	Bile acid-CoA:amino acid N-acyltransferase	BAAT	3,451,500	0	3,451,500	0	0	0	0	1
Yes		G3V5K1 H7C4C8	Protein transport protein Sec23A T-complex protein 1 subunit theta	SEC23A CCT8	2,912,600 2.848.600	0	0 2.848.600	0	0	2,912,600	0	1
		E9PBS1	Multifunctional protein ADE2;Phosphoribosylaminoimidazole carboxylase	PAICS	2,615,600	0	2,848,600	0	0	0	0	1
		ESFESI	mutaturotoriai protein ADEZ,F1105p11011005ylattiitioittiuaZ0le CalD0XylaSe	FAIGS	2,010,000	U	2,010,000	U	U	U	0	

Table 4
Proteins identified in PICALM immunoprecipitations.
Placental extracts U1, R4, Q1, Q4, O1, and N3 were immunoprecipitated in one experiment.

Flacelital extracts 01	, R4, Q1, Q4, O1, and N3 were immunoprecipitated in o	пе ехреппени.		Intensity	Intonoity	Intensity	Intonoitu	Intonoity	Intonoity	
Majority protein ID	Protein	Gene	Total Intensity	Intensity PICALM U1	Intensity PICALM R4	Intensity PICALM Q1	Intensity PICALM Q4	Intensity PICALM O1	Intensity PICALM N3	Peptides
P01857	Ig gamma-1 chain C region	IGHG1		197,890,000	13,091,000,000	789,180,000	14,626,000,000	12,977,000,000	6,715,700,000	23
Q13492 P50995-2	Phosphatidylinositol-binding clathrin assembly prote Annexin A11	PICALM ANXA11	18,858,000,000 15,851,000,000		5,271,000,000 4,529,400,000	657,650,000 433,220,000	3,743,800,000 3,795,300,000		4,217,400,000 3,682,800,000	35 37
P20073-2	Annexin A7	ANXA7	9,130,600,000	666,020,000	2,765,200,000	238,940,000	1,535,100,000	2,049,900,000	1,875,500,000	32
A0A286YES1	Ig gamma-3 chain C region	IGHG3	4,336,300,000 3,056,100,000	33,112,000 0	1,106,600,000	53,173,000 0	927,810,000	812,970,000 0	1,402,600,000	20 1
A0A7I2V378 E7EVS6	Laminin subunit beta-1 Actin, cytoplasmic 1, N-termina	LAMB1 ACTB	2,600,000,000	74,816,000	3,056,100,000 1,747,800,000	140,870,000	230,680,000	217,870,000	187,980,000	19
P01834	Ig kappa chain C region	IGKC	2,165,500,000	19,359,000	221,050,000	1,391,900,000	195,150,000	232,100,000	105,920,000	9
A0A286YFJ8 P0DOY3	Ig gamma-4 chain C region	IGHG4 IGLC3	1,609,600,000	2 691 000	218,830,000 60,706,000	22,468,000 741,050,000	138,990,000 302,850,000	428,050,000	801,270,000	17 9
A0A286YEY1	Immunoglobulin lambda constant 3 Ig alpha-1 chain C region	IGHA1	1,591,000,000 1,335,500,000	2,681,900 23,359,000	584,930,000	130,660,000	252,550,000	240,510,000 139,020,000	243,250,000 204,990,000	14
Q9Y6R7	IgGFc-binding protein	FCGBP	1,098,700,000	9,162,000	128,730,000	9,654,400	38,684,000	824,150,000	88,293,000	30
P01624 P31943	Ig kappa chain V-III region POM Heterogeneous nuclear ribonucleoprotein H;Heteroc	IGKV3D-15 HNRNPH1	1,060,200,000 1,047,700,000	0 10,293,000	124,770,000 217,040,000	613,850,000 24,254,000	116,590,000 289,540,000	205,020,000 295,340,000	0 211,190,000	2 11
P08670	Vimentin	VIM	951,490,000	6,378,400	298,510,000	5,089,400	72,211,000	358,520,000	210,780,000	26
H0YEF7	Phosphatidylinositol-binding clathrin assembly prote	PICALM	874,480,000	16,602,000	212,520,000	57,324,000	467,540,000	68,277,000	52,211,000	14
E9PQV5 A0A4W8ZXM2	Coiled-coil domain-containing protein 37 Immunoglobulin heavy variable 3-72	CCDC37 IGHV3-72	870,490,000 808,240,000	0 44,918,000	0 282,930,000	870,490,000 12,296,000	0 137,660,000	0 204,230,000	0 126,190,000	1
P05783	Keratin, type I cytoskeletal 18	KRT18	760,020,000	44,510,000	231,740,000	8,635,500	185,390,000	187,570,000	146,680,000	17
P07355	Annexin A2;Annexin;Putative annexin A2-like protei	ANXA2	742,370,000	6,496,700	256,760,000	55,166,000	54,726,000	196,500,000	172,720,000	15
P01871 P31942-2	Ig mu chain C region Heterogeneous nuclear ribonucleoprotein H3	IGHM HNRNPH3	722,270,000 681,640,000	105,950,000	12,770,000 133,900,000	0 68,508,000	95,422,000 133,680,000	155,950,000 231,950,000	352,180,000 113,610,000	18 9
Q8NDC0	MAPK-interacting and spindle-stabilizing protein-like	MAPK1IP1L	497,400,000	15,599,000	39,220,000	243,740,000	59,063,000	32,791,000	106,990,000	1
P51512-2	Matrix metalloproteinase-16	MMP16	429,540,000	0	178,440,000	27,390,000	0	223,720,000	0	1
H0Y8G5 E7ETU5	Heterogeneous nuclear ribonucleoprotein D0 RNA-binding motif, single-stranded-interacting prote	HNRNPD RBMS1	409,120,000 391,920,000	0 5,970,500	31,290,000 68,667,000	27,715,000 17,784,000	95,052,000 143,760,000	151,740,000 44,979,000	103,320,000 110,760,000	5 7
Q8WZ42	Titin	TTN	387,820,000	0	0	0	75,928,000	210,050,000	101,840,000	1
P02675	Fibrinogen beta chain; Fibrinopeptide B; Fibrinogen b	FGB	348,580,000	0	343,520,000	2,249,600	0	0	2,806,500	16
A0A0D9SF16 O14979-3	Methyl-CpG-binding domain protein 5 Heterogeneous nuclear ribonucleoprotein D-like	MBD5 HNRNPDL	346,080,000 334,140,000	0 4,097,000	84,425,000	0 6,682,100	346,080,000 92,722,000	0 38,095,000	108,120,000	1 6
P98082	Disabled homolog 2	DAB2	308,620,000	30,904,000	53,571,000	22,044,000	29,573,000	79,395,000	93,129,000	8
A0A286YEY4	Ig gamma-2 chain C region	IGHG2	295,690,000	3,630,700	140,820,000	13,340,000 58,392,000	30,486,000	32,731,000	74,683,000 43,798,000	15
P68871 P11021	Hemoglobin subunit beta;LVV-hemorphin-7;Spinorp 78 kDa glucose-regulated protein	HBB HSPA5	289,630,000 278,720,000	17,601,000 66,634,000	25,216,000 8,224,700	00,392,000	73,808,000 44,577,000	70,816,000 12,509,000	146,770,000	4 14
P04083	Annexin A1;Annexin	ANXA1	264,550,000	7,343,100	128,430,000	38,085,000	12,426,000	24,473,000	53,792,000	13
P01594 O43866	lg kappa variable 1-33 CD5 antigen-like	IGKV1-33 CD5L	258,450,000 258,210,000	2,181,900	6,309,800 64,662,000	167,650,000 0	34,900,000 27,301,000	29,177,000 135,430,000	18,233,000 30,812,000	2 5
F8VV32	Lysozyme;Lysozyme C	LYZ	201,490,000	13,865,000	04,002,000	33,772,000	58,974,000	48,689,000	46,193,000	3
P21980-2	Protein-glutamine gamma-glutamyltransferase 2	TGM2	182,780,000	21,051,000	6,206,000	155,520,000	0	0	0	4
P01615 Q5T749	Immunoglobulin kappa varibable 2D-28 Keratinocyte proline-rich protein	IGKV2D-28 KPRP	157,840,000 156,670,000	0	0 14,536,000	56,727,000 42,583,000	2,124,500 12,523,000	1,244,100 41,980,000	97,746,000 45,045,000	1 8
Q5T7N2	LINE-1 type transposase domain-containing protein	L1TD1	147,570,000	0	33,515,000	51,668,000	0	41,900,000	62,386,000	2
A0A6Q8PGK1	Heat shock protein beta-1	HSPB1	140,170,000	5,102,400	5,175,100	116,740,000	0	9,140,400	4,009,100	4
Q02413 F8VVB9	Desmoglein-1 Tubulin alpha-1B chain;Tubulin alpha-1A chain;Tub	DSG1 TUBA1B	139,520,000 130,470,000	4,467,600 4,960,800	13,159,000 53,076,000	21,449,000 11,800,000	21,775,000 10,998,000	52,035,000 17,150,000	26,635,000 32,482,000	9 4
A0A6Q8PFJ0	Prelamin-A/C;Lamin-A/C	LMNA	126,810,000	51,770,000	36,048,000	0	9,173,200	5,398,800	24,420,000	7
P69905	Hemoglobin subunit alpha	HBA1	120,580,000	8,819,100	32,928,000	0	19,697,000	31,037,000	28,103,000	3
P02671 A0A0B4J231	Fibrinogen alpha chain; Fibrinopeptide A; Fibrinogen Immunoglobulin lambda-like polypeptide 5; Ig lambd	FGA IGLL5	119,010,000 113,780,000	5,765,800 0	89,186,000 823,960	13,712,000	0 51,884,000	1,589,500 45,566,000	8,753,800 15,503,000	6 7
Q9HAU0-6	Pleckstrin homology domain-6	PLEKHA6	100,890,000	0	9,826,200	91,063,000	0 1,004,000	40,000,000	0,000,000	1
Q92945	Far upstream element-binding protein 2	KHSRP	96,813,000	25,823,000	0	0	5,257,900	16,437,000	49,295,000	8
R4GNB1	Acyl-CoA synthetase family member 4	AASDH	94,959,000	0	6,802,400	6,567,300	14,507,000	47,725,000	19,358,000	1
C9JEU5 P04406	Fibrinogen gamma chain Glyceraldehyde-3-phosphate dehydrogenase	FGG GAPDH	90,470,000 89,398,000	63,046,000 4,504,400	15,905,000 74,117,000	3,593,000	10,380,000 1,898,700	5,284,800	1,139,700 0	7 6
K7ERX7	ATP synthase subunit alpha, mitochondrial	ATP5A1	87,648,000	0	49,222,000	0	0	20,992,000	17,434,000	5
E9PPG9	mRNA export factor	RAE1	87,447,000	0	0	0	58,237,000	2,416,200	26,794,000	4
P30101 K7EQ02	Protein disulfide-isomerase A3 DAZ-associated protein 1	PDIA3 DAZAP1	86,682,000 83,974,000	0	34,607,000 11,234,000	0	0 42,826,000	17,446,000 23,140,000	34,628,000 6,774,000	8 2
Q01469	Fatty acid-binding protein, epidermal	FABP5	79,112,000	0	8,010,100	12,771,000	28,053,000	0	30,278,000	1
Q01085	Nucleolysin TIAR; Nucleolysin TIA-1 isoform p40	TIAL1	77,006,000	0	15,592,000	0	14,334,000	18,441,000	28,639,000	4
P21397-2 A6NHN2	Amine oxidase [flavin-containing] A;Amine oxidase Roquin-2	MAOA RC3H2	76,723,000 74,367,000	0	33,332,000	0 50,159,000	16,437,000	0 8,880,000	26,954,000 15,328,000	4 1
P14866	Heterogeneous nuclear ribonucleoprotein L	HNRNPL	68,836,000	0	0	0	0	0	68,836,000	7
Q5JPU3	Pyruvate dehydrogenase E1 component subunit alp	PDHA1	66,908,000	0	12,367,000	0	31,262,000	13,254,000	10,024,000	3
Q8IUC1 Q5JP53	Keratin-associated protein 11-1 Tubulin beta chain	KRTAP11-1 TUBB	65,493,000 64.164.000	0 3.856.400	18,492,000 37.532.000	28,950,000 2.310,200	7.223.200	18,051,000 4,449,300	0 8.792.800	3
C9J2I0	Arf-GAP domain and FG repeat-containing protein 1	AGFG1	59,976,000	4,759,100	12,457,000	0	0	18,719,000	24,041,000	1
P19474 D6R9P3	E3 ubiquitin-protein ligase TRIM21 Heterogeneous nuclear ribonucleoprotein A/B	TRIM21 HNRNPAB	58,811,000 58,548,000	0	6,681,800 7,571,700	0 2,186,500	9,640,700	29,267,000 28,004,000	22,862,000 11,145,000	5 4
Q5T1M5	FK506-binding protein 15	FKBP15	58,396,000	11,484,000	7,571,700	2,180,300	14,598,000	28,004,000	32,314,000	4
E9PGY2	Dynein assembly factor 5, axonemal	DNAAF5	56,016,000	0	0	0	20,626,000	25,326,000	10,064,000	1
P63261 Q9NZT1	Actin, cytoplasmic 2;Actin, cytoplasmic 2, N-termina Calmodulin-like protein 5	ACTG1 CALML5	55,103,000 54,136,000	0	29,965,000 7,928,200	6,910,800 10,694,000	6,077,800	5,127,100 27,905,000	7,022,400 7,608,500	19 1
C9JZN1	Guanine nucleotide-binding protein G(I)/G(S)/G(T) s	GNB2	53,184,000	0	0	45,048,000	8,135,900	0	0	4
A0A7I2YQK6	60 kDa heat shock protein, mitochondrial	HSPD1	50,218,000	1,514,400	15,195,000	0	15,571,000	6,895,200	11,042,000	3
P31040-2 A0A7I2V2R3	Succinate dehydrogenase [ubiquinone] flavoprotein Heterogeneous nuclear ribonucleoprotein A3	SDHA HNRNPA3	49,094,000 48,903,000	0	23,561,000 15,655,000	0	3,205,300 7,296,200	15,958,000 11,237,000	6,369,600 14,714,000	5 2
Q8IWB6-3	Inactive serine/threonine-protein kinase TEX14	TEX14	48,249,000	0	0	ő	0	21,743,000	26,507,000	1
P68371	Tubulin beta-4B chain;Tubulin beta-4A chain	TUBB4B	48,032,000	0	39,150,000	0	4,137,600	0	4,744,800	3
H0YFX9 Q8IUC0	Histone H2A;Histone H2A type 1-J;Histone H2A type Keratin-associated protein 13-1;Keratin-associated protein 13-1;Keratin-asso	H2AFJ KRTAP13-1	45,901,000 44,512,000	12,453,000 0	7,861,100 7,315,500	20,288,000 7,365,500	0	0 29,831,000	5,298,900 0	1 1
A0A087WVQ6	Clathrin heavy chain; Clathrin heavy chain 1	CLTC	44,504,000	21,103,000	0	0	0	0	23,400,000	3
P63267	Actin, gamma-enteric smooth muscle;Actin, alpha s	ACTG2	44,025,000	4 600 500	23,112,000 27,448,000	0	0	8,310,000 11,128,000	12,603,000	12
H7BZJ3 A0A0B4J1V1	Protein disulfide-isomerase A3 Ig heavy chain V-III region JON;Ig heavy chain V-III	PDIA3 IGHV3-21	43,257,000 43,147,000	4,680,500 0	9,064,600	2,411,600	0	22,858,000	0 8,812,900	3 2
H7C582	Integrator complex subunit 1	INTS1	42,661,000	0	0	42,661,000	0	0	0	1
Q9BYR6	Keratin-associated protein 3-3	KRTAP3-3	40,458,000	0	40,458,000 0	0 5 577 900	21.067.000	0 442 200	2 792 200	2
Q13151 H0Y6B2	Heterogeneous nuclear ribonucleoprotein A0 Sushi domain-containing protein 1	HNRNPA0 SUSD1	39,870,000 38,095,000	0	0	5,577,800 22,678,000	21,067,000 8,950,800	9,442,300 6,466,400	3,783,300 0	1 1
A0A1B0GVP4	Ligand-dependent nuclear receptor corepressor	LCORL	36,335,000	0	16,645,000	0	9,411,000	0	10,278,000	1
P14923	Junction plakoglobin	JUP	35,503,000	0	0	4,915,000	19 201 000	21,240,000	9,347,600	6
P01023 A0A7I2V3H3	Alpha-2-macroglobulin Putative elongation factor 1-alpha-like 3;Elongation	A2M EEF1A1	35,281,000 34,691,000	0	0 20,615,000	0	18,291,000 0	0 6,899,500	16,990,000 7,176,500	2
I3L0W5	14-3-3 protein epsilon	YWHAE	34,151,000	0	4,124,200	16,649,000	3,202,500	4,882,900	5,292,400	1
P02787	Serotransferrin	TF	33,379,000	5,509,000	0	4,698,000	8,538,800	1,682,500	12,951,000	3
Q08554-2 E5RGE1	Desmocollin-1 14-3-3 protein zeta/delta	DSC1 YWHAZ	31,458,000 31,118,000	0	0	2,709,100 31,118,000	0	22,304,000	6,444,900 0	2
P06576	ATP synthase subunit beta, mitochondrial;ATP synt	ATP5B	31,113,000	0	31,113,000	0	0	0	0	3
P17931 C9JA05	Galectin-3;Galectin Immunoglobulin J chain	LGALS3 JCHAIN	30,883,000 29,005,000	0 6,597,900	0 8,495,000	30,883,000 8,405,600	0	0	5,506,600	3 1
000,000	sogiobulii o onum	JOHAN	25,005,000	0,001,000	0,400,000	0,400,000	U	U	5,500,000	•

A0A0G2JRN3	Alpha-1-antitrypsin;Short peptide from AAT	SERPINA1	28,649,000	1,644,400	2,510,900	10,667,000	8,084,300	1,831,300	3,911,300	2
P31025	Lipocalin-1;Putative lipocalin 1-like protein 1	LCN1	28,552,000	0	0	2,845,200	0	6,027,100	19,679,000	2
P07237	Protein disulfide-isomerase	P4HB	28,383,000	0	18,574,000	0	0	4,970,100	4,837,900	3
H0Y5H6 Q96CBB	Ubiquitin-associated protein 2-like Integrator complex subunit 12	UBAP2L INTS12	25,709,000 25,627,000	0	0	0	0	8,179,400 25,627,000	17,530,000 0	1 1
S4R460	Ig heavy chain V-III region BRO region DOB	IGHV3OR16-9	24,932,000	0	13,396,000	0	0	6,415,600	5,120,200	3
Q5JTQ6	Alpha-catulin	CTNNAL1	23,896,000	0	0	17,301,000	0	6,594,900	0,120,200	1
P07910	Heterogeneous nuclear ribonucleoproteins C1/C2	HNRNPC	23,699,000	0	15,502,000	0	8,197,000	0,004,000	0	2
E9PEB5	Far upstream element-binding protein 1	FUBP1	23,687,000	0	0 0,002	0	0,107,000	20,589,000	3.098.200	3
Q07065	Cytoskeleton-associated protein 4	CKAP4	23,211,000	0	10,484,000	Ō	0	7,232,200	5,495,600	5
Q9UBG3	Cornulin	CRNN	23,063,000	0	0	23,063,000	0	0	0	3
A0A0C4DH31	Ig heavy chain V-I region V35	IGHV1-18	22,114,000	0	7,494,400	0	0	8,305,200	6,314,800	2
P04843	Dolichyl-diphosphooligosaccharideprotein glycosyl	RPN1	21,647,000	0	6,872,300	0	2,481,300	3,898,300	8,395,600	3
A0A0G2JIW1	Heat shock 70 kDa protein 1A;Heat shock 70 kDa pı	HSPA1A	21,113,000	1,946,300	16,283,000	0	0	2,883,300	0	4
P11142-2	Heat shock cognate 71 kDa protein	HSPA8	20,977,000	14,054,000	0	1,367,200	1,373,400	4,182,300	0	6
Q15365	Poly(rC)-binding protein 1;Poly(rC)-binding protein 3	PCBP1	19,851,000	0	8,243,700	0	0	7,620,100	3,987,300	4
P29401	Transketolase	TKT	19,791,000	2,617,800	17,173,000	0	0	0	0	3
P11166	Solute carrier family 2, facilitated glucose transporte	SLC2A1	19,512,000	0	19,512,000	0	0	0	0	1
M0R3F1	Heterogeneous nuclear ribonucleoprotein U-like pro	HNRNPUL1	19,055,000	0 8,500,000	0 10,370,000	0	0	0	19,055,000	4
P69892 A0A7I2V4I6	Hemoglobin subunit gamma-2;Hemoglobin subunit (Heterogeneous nuclear ribonucleoproteins A2/B1	HBG2 HNRNPA2B1	18,869,000 18,704,000	0,500,000	10,370,000	0	0	12,162,000	6,541,300	4
A0A712V410 A0A5F9ZH78	Arginase-1	ARG1	17,366,000	0	4,850,200	0	0	5,206,700	7,309,200	2
J3KPS3	Fructose-bisphosphate aldolase;Fructose-bisphosph	ALDOA	16,868,000	0	16,868,000	0	0	0,200,700	0 0	3
A0A7I2YQY2	Heterogeneous nuclear ribonucleoprotein A1;Hetero	HNRNPA1	16,360,000	2,149,600	2,573,000	0	7,993,500	3,644,300	0	1
Q9BYQ3	Keratin-associated protein 9-3	KRTAP9-3	16,191,000	0	16,191,000	0	0	0	0	2
Q9BS26	Endoplasmic reticulum resident protein 44	ERP44	16,007,000	0	7,136,300	0	0	7,435,300	1,435,800	3
P15924-2	Desmoplakin	DSP	15,924,000	0	0	6,126,800	0	9,797,400	0	5
P05109	Protein S100-A8; Protein S100-A8, N-terminally proc	S100A8	15,760,000	828,670	4,227,300	10,704,000	0	0	0	1
E9PMZ8	T-lymphoma invasion and metastasis-inducing prote	TIAM2	15,463,000	0	0	15,463,000	0	0	0	1
P01833	Polymeric immunoglobulin receptor;Secretory comp	PIGR	15,458,000	0	11,036,000	0	0	3,208,000	1,214,700	3
H3BQZ7	Heterogeneous nuclear ribonucleoprotein U-like pro		15,173,000	1,669,300	0	0	0	0	13,503,000	1
P55795	Heterogeneous nuclear ribonucleoprotein H2	HNRNPH2	14,987,000	0	4,489,200	0	1,825,300	5,079,900	3,592,900	5
A0A0G2JPP1	Keratin-associated protein 4-8	KRTAP4-8	14,521,000	0	14,521,000	0	0	0	0	1
E9PHT9	Annexin;Annexin A5	ANXA5	12,946,000	0	0	12,946,000	0	0	0	2
A0A6Q8PF87	Apoptosis-inducing factor 1, mitochondrial	AIFM1	12,539,000	0	12,539,000	0	0	0	0	1
M0R1R1	Serine/threonine-protein kinase PAK 4	PAK4	12,509,000	0	0	0	0	0	12,509,000	1
P04040	Catalase	CAT	12,392,000	0	3,717,800	1,498,500	0	3,932,900	3,243,300	1
A0A140TA58	Keratin-associated protein 9-9;Keratin-associated pr	KRTAP9-9	12,125,000	0	12,125,000	0	0	0	0	2
A0A0A0MS98	Band 3 anion transport protein	SLC4A1	12,063,000	2,108,100 0	0	0	3,363,800 0	0	6,591,400	1
P0DP03 P81605	Ig heavy chain V-III region CAM;Ig heavy chain V-II Dermcidin;Survival-promoting peptide;DCD-1	IGHV3-23 DCD	11,962,000 11,727,000	0	0	7,387,600	0	7,237,200 4.338,900	4,724,800 0	1 2
H0YFA4	Cysteine-rich protein 2	CRIP2	11,648,000	0	0	7,587,800	4,060,200	4,336,900	0	2
A0A3B3ITD8	Nuclear pore complex protein Nup98-Nup96;Nuclea	NUP98	11,301,000	0	0	0 000,700	11,301,000	0	0	2
P14625	Endoplasmin	HSP90B1	11,207,000	11,207,000	0	0	0	0	0	4
Q96PK6	RNA-binding protein 14	RBM14	11,150,000	0	0	0	7,074,900	0	4,075,400	1
E7ENL6	Collagen alpha-3(VI) chain	COL6A3	10,671,000	10,671,000	0	0	0	0	0	3
F8WBE5	Transferrin receptor protein 1;Transferrin receptor p	TFRC	10,642,000	3,853,100	0	0	0	0	6,788,600	1
A0A0G2JMB2	Ig alpha-2 chain C region	IGHA2	10,360,000	0	5,177,500	0	0	2,870,900	2,311,700	9
A0A7I2YQJ0	Transitional endoplasmic reticulum ATPase	VCP	10,078,000	10,078,000	0	0	0	0	0	2
B3KVK2	Guanine nucleotide-binding protein G(I)/G(S)/G(T) s	GNB1	9,941,900	0	0	6,870,800	0	3,071,100	0	1
Q9BYR3	Keratin-associated protein 4-4	KRTAP4-4	9,925,900	0	9,925,900	0	0	0	0	1
P52597	Heterogeneous nuclear ribonucleoprotein F;Heterog	HNRNPF	9,850,000	0	3,857,200	0	0	0	5,992,800	3
P01024	Complement C3;Complement C3 beta chain;C3-bet	C3	9,848,400	0	9,848,400 0	0	0	0	0	2
P80723-2 F8W1T6	Brain acid soluble protein 1 RNA-binding motif, single-stranded-interacting prote	BASP1 RBMS2	9,527,100 9,438,700	0	0	0	0	0	9,527,100 9,438,700	2 4
P31944	Caspase-14;Caspase-14 subunit p17, mature form;	CASP14	9,239,700	0	0	5,161,200	0	0	4,078,600	1
P0DP08	Ig heavy chain V-II region NEWM;Ig heavy chain V-	IGHV4-4	9,180,400	0	0	5,161,200	0	5,589,100	3,591,300	1
H3BU13	Pyruvate kinase;Pyruvate kinase PKM	PKM	9,106,300	0	9,106,300	0	0	0,509,100	0,551,500	1
F8WEU2	ATP-dependent 6-phosphofructokinase, liver type	PFKL	9,083,300	9,083,300	0,100,000	0	0	0	0	1
A0A0C4DH25	Immunoglobulin kappa variable 3D-20	IGKV3D-20	8,934,800	0	0	0	Ō	0	8,934,800	1
P52907	F-actin-capping protein subunit alpha-1	CAPZA1	8,912,600	0	8,912,600	0	0	0	0	1
I3L1P8	Mitochondrial 2-oxoglutarate/malate carrier protein	SLC25A11	8,767,800	0	0	8,767,800	0	0	0	1
B4E3S0	Coronin;Coronin-1C	CORO1C	8,702,200	0	4,567,500	0	0	4,134,700	0	1
F8W6D9	Sentrin-specific protease 6	SENP6	8,679,600	0	0	0	0	0	8,679,600	2
P36957-2	Dihydrolipoyllysine-residue succinyltransferase com	DLST	8,276,700	0	5,934,900	0	0	0	2,341,800	1
P31930	Cytochrome b-c1 complex subunit 1, mitochondrial	UQCRC1	8,234,200	0	3,957,100	0	0	0	4,277,000	2
P02808	Statherin	STATH	8,064,100	0	0	8,064,100	0	0	0	1
P16403	Histone H1.2; Histone H1.3	HIST1H1C	7,889,100	0	2,483,600	5,405,500	0	0	0	3 1
K7EMF8 C9JP00	Very long-chain specific acyl-CoA dehydrogenase, r	ACADVL MBNL1	7,844,000	0	7,844,000 0	0	0			
A0A6I8PIN8	Muscleblind-like protein 1	CAPZB	7,830,800 7,662,300	0	0	6,785,600	0	2,369,000 876,710	5,461,800 0	1 1
O95205	F-actin-capping protein subunit beta Muscleblind-like protein 2	MBLL	7,485,300	0	0	0,785,000	0	1,647,200	5,838,000	1
A0A590UK99	Deleted in malignant brain tumors 1 protein	DMBT1	7,481,500	1,749,100	ő	0	3,277,000	0	2,455,300	1
P01766	Ig heavy chain V-III region BRO	IGHV3-13	6,767,800	0	0	0	0,211,000	4,376,000	2,391,900	2
J3KSH9	Integrin beta-4	ITGB4	6,700,000	0	0	0	0	0	6,700,000	1
P55268	Laminin subunit beta-2	LAMB2	6,456,200	6,456,200	0	0	0	0	0	2
P47929	Galectin-7	LGALS7	6,362,600	0	0	1,822,500	0	0	4,540,100	1
E9PFG7	2-oxoglutarate dehydrogenase, mitochondrial	OGDH	6,288,400	6,288,400	0	0	0	0	0	1
E5RK69	Annexin;Annexin A6	ANXA6	6,072,900	0	0	0	0	0	6,072,900	2
E7EQB2	Lactotransferrin;Lactoferricin-H;Kaliocin-1;Lactoferri	LTF	6,032,800	0	3,762,400	2,270,400	0	0	0	3
E9PRN7	3 beta-hydroxysteroid dehydrogenase/Delta 5>4-is	HSD3B1	5,960,500	0	5,960,500	0	0	0	0	1
P17661	Desmin Collagen alpha-1(VI) chain	DES	5,939,400	0	5,939,400 0	0	0	0	0	5 2
A0A087X0S5 P0DP09	Immunoglobulin kappa variable 1-13	COL6A1 IGKV1D-13	5,903,600 5,730,000	5,903,600 0	0	5,730,000	0	0	0	1
P62805	Histone H4	HIST1H4A	5,728,200	0	2,222,200	5,730,000	0	3,506,000	0	2
Q8WVV4	Protein POF1B	POF1B	5,534,300	0	0	0	0	5,534,300	0	1
A0A1W2PP22	Heterogeneous nuclear ribonucleoprotein U	HNRNPU	5,391,800	Ö	ő	0	Ö	0,004,000	5,391,800	1
Q9BW30	Tubulin polymerization-promoting protein family me	TPPP3	5,092,600	5,092,600	Ö	Ö	Ö	0	0	1
P08572	Collagen alpha-2(IV) chain; Canstatin	COL4A2	5,034,400	5,034,400	0	0	0	0	0	1
A0A075B6K5	Ig lambda chain V-III region LOI	IGLV3-9	5,025,200	0	0	2,660,600	0	0	2,364,600	1
H0YJL6	Ena/VASP-like protein	EVL	4,998,300	0	0	4,998,300	0	0	0	1
P59666	Neutrophil defensin 3;HP 3-56;Neutrophil defensin 2	DEFA3	4,545,800	0	0	0	0	4,545,800	0	1
Q9NQP5	Coagulation factor XIII A chain	F13A1	4,473,400	4,473,400	0	0	0	0	0	2
E9PS23	Cofilin-1	CFL1	4,289,600	0	2,251,300	0	2,038,300	0	0	2
B4DU11	Estradiol 17-beta-dehydrogenase 1	HSD17B1	4,274,500	0	2,367,500	1,907,000	0	0	0	1
C9J9S3	Serine/threonine-protein phosphatase;Serine/threon	PPP1CB	4,214,000	0	0	1,916,400	0	0	2,297,500	1
C9JHS9	Vigilin	HDLBP	4,198,300	0	0	0	1,536,900 0	0	2,661,400	1
P05187 F8WEW2	Alkaline phosphatase, placental type;Alkaline phosp Actin-related protein 3	ALPP ACTR3	4,169,700 4,132,700	0	0 4,132,700	0	0	0	4,169,700 0	2 1
Q9ULV0	Unconventional myosin-Vb	MYO5B	4,132,700	2,220,100	4,132,700	0	1,853,000	0	0	2
J3QSA3	Ubiquitin-40S ribosomal protein S27a;Ubiquitin;40S	UBB	4,045,100	1,288,700	0	0	1,655,000	0	2,756,400	1
B8ZZ51	Malate dehydrogenase, cytoplasmic	MDH1	4,029,700	1,200,700	0	4,029,700	0	0	2,730,400	1
E9PQ34	Serpin H1	SERPINH1	4,018,600	Ö	4,018,600	0	Ö	0	Ö	1
I3L245	Nuclear pore complex protein Nup88	NUP88	3,921,000	0	0	0	0	0	3,921,000	1
Q13263-2	Transcription intermediary factor 1-beta	TRIM28	3,569,200	3,569,200	0	0	0	0	0	1
Q9HD89		RETN	3,487,400	0	0	2,254,600	0	1,232,800	0	1
	Resistin									
Q9GZM7-3	Resistin Tubulointerstitial nephritis antigen-like	TINAGL1	3,481,600	0	3,481,600	0	0	0	0	1

P27824-3	Outroude	CANX	0.444.400	•					0.444.400	
	Calnexin		3,444,400	0	0	0	0	0	3,444,400	1
A0A3B3ISA6	Complement C4-A;Complement C4 beta chain;Com	C4B	3,381,500	0	0	0	0	0	3,381,500	1
A6NCI4-3	von Willebrand factor A domain-containing protein 3	VWA3A	3,185,200	0	0	0	3,185,200	0	0	1
Q8WV48-5	Coiled-coil domain-containing protein 107	CCDC107	3,057,000	0	0	3,057,000	0	0	0	1
Q00013-2	55 kDa erythrocyte membrane protein	MPP1	2,911,300	0	2,911,300	0	0	0	0	1
Q14677	Clathrin interactor 1	CLINT1	2,901,400	0	0	0	0	2,901,400	0	1
A6NHR2	39S ribosomal protein L37, mitochondrial	MRPL37	2,898,500	0	0	0	0	2,898,500	0	1
P82663-3	8S ribosomal protein S25, mitochondrial	MRPS25	2,580,800	0	0	0	0	0	2,580,800	1
H7C4C8	T-complex protein 1 subunit theta	CCT8	2,560,000	0	2,560,000	0	0	0	0	1
P16401	Histone H1.5	HIST1H1B	2,527,600	0	0	2,527,600	0	0	0	1
A0A3B3ITI4	Stress-70 protein, mitochondrial	HSPA9	2,413,000	2,413,000	0	0	0	0	0	1
Q8TE68	Epidermal growth factor receptor kinase substrate 8	EPS8L1	2,165,700	2,165,700	0	0	0	0	0	1
Q8TDL5	BPI fold-containing family B member 1	BPIFB1	2,146,600	0	0	0	0	1,170,700	975,880	1
P31146	Coronin-1A	CORO1A	2,123,800	0	0	0	0	2,123,800	0	1
E9PSE0	MAP kinase-interacting S/T-protein kinase 1	MKNK1	1,976,500	0	0	0	1,976,500	0	0	1
A0A1X7SBZ2	Probable ATP-dependent RNA helicase DDX17	DDX17	1.903.300	0	0	0	1.903.300	0	0	1
M0R1B5	Acetolactate synthase-like protein	ILVBL	1.702.000	0	1,702,000	0	0	0	0	1
M0QX10	Nuclear pore glycoprotein p62	NUP62	1.380.100	0	0	0	0	0	1.380.100	1
P09525-2	Annexin A4	ANXA4	1,341,500	0	0	1,341,500	0	0	0	1
O15400-2	Svntaxin-7	STX7	1,329,200	1,329,200	0	0	0	0	0	1
H3BS21	Haptoglobin;Haptoglobin alpha chain;Haptoglobin be	HP	1.311.500	0	1.311.500	0	0	0	0	2
U3KQK0	Histone H2B;Histone H2B type 1-L;Histone H2B typ	HIST1H2BN	1,266,700	0	1,266,700	0	0	0	0	1
K7EJ44	Profilin-1	PFN1	1,249,400	Ō	0	ō	Ō	1,249,400	Ō	1
K7EK06	PhenylalaninetRNA ligase alpha subunit	FARSA	1,246,700	0	1,246,700	0	0	0	0	1
P10412	Histone H1.4	HIST1H1E	1,033,200	0	0	1,033,200	0	0	0	3
A0A087WUX6	Proteasomal ubiquitin receptor ADRM1	ADRM1	993,900	0	993,900	0	0	0	0	1
B1AUU8	Epidermal growth factor receptor substrate 15	EPS15	797.470	797,470	030,500	0	0	0	0	1
O76041	Nebulette	NEBL	651,720	0	0	0	0	0	651.720	1
070041	Hobalotto	HEDE	331,720	U	U	U	U	U	001,720	

Patient				MDMX % of Q1				MEAN
H1		128.4	116.9	116.5	78.2	116.9	141.1	116.3
H2		120.4	19.1	60.8	32.5	18.9	16.0	29.5
H3			8.3	9.0	26.3	17.4	4.2	13.0
I-1		128.8	209.0	114.6	222.2	102.8	146.1	153.9
1-2				57.1	75.4	106.7	51.6	72.7
1-3		123.6	72.5	77.1	84.1	37.8	71.7	77.8
1-4	136.6	88.3	135.7	81.5	58.6	133.1	103.0	94.1
J-1					118.1	130.2	119.1	122.5
J-2					92.9	56.5	58.9	69.5
J-3					84.0	60.8	66.2	70.3
L1			46.6	61.1	72.0	35.8	41.9	51.5
L2					46.3	55.2	31.0	44.2
L3					72.1	69.1	47.5	62.9
L4				11.9	23.9	16.2	8.9	16.3
M1				57.2	57.5	29.7	62.4	51.7
M3						76.8	37.2	57.0
M4				60.1	40.8	42.1	68.7	52.9
N1		60.1	40.8	42.1	68.7	101.6	101.6	115.5
N2		10.2	31.0	45.5	58.0	58.2	6.6	34.9
N3			75.3	167.8	85.8	80.4	68.0	95.5
N4				55.9	52.5	60.4	48.7	54.4
01			57.5	34.5	46.1	101.6	49.8	57.9
Ω2				78.4	82.8	34.4	85.6	70.3
03		77.3	58.3	22.3	42.5	11.0	8.6	36.7
04			72.9	24.9	34.5	25.4	111.4	53.8
O5					244.4	229.0	145.1	206.1
07					167.2	179.6	163.3	170.0
Q1	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Q2		199.7	169.8	211.0	205.4	156.5	144.9	181.2
Q3		90.9	90.1	76.0	75.8	74.2	88.5	82.6
Q4		50.5	86.2	28.6	45.5	62.7	31.5	50.8
R3		28.2	99.6	57.5	20.0	60.2	77.0	54.5
R4			126.7	116.9	93.8	58.6	109.0	101.3
R5					33.6	79.8	48.8	54.1
S1					207.4	128.9	151.4	162.6
S2					202.5	107.1	110.4	140.0
T1				124.8	161.9	155.5	124.5	141.7
T2					115.0	91.3	82.9	96.4
U1					119.7	87.7	103.7	103.7
U2					163.0	175.0	122.9	153.6
V1					75.4	71.1	21.0	55.9
V2					92.8	72.9	99.0	88.2
W1					99.2	72.4	84.0	85.2
W2					261.5	197.7	173.8	211.0

Patient				% of Q1				MEAN
H1					21.3	31.8	34.7	29.3
H2					32.8	31.2	55.6	39.9
H3				126.3	114.0	164.0	120.6	131.2
1-1						59.9	77.3	68.6
1-2						64.9	78.8	71.8
1-3					31.5	28.4	10.5	23.4
1-4			15.7	14.2	2.0	7.1	2.9	8.4
J-1	85.4	122.8	105.8	72.0	126.2	127.1	103.0	106.0
J-2				30.9	21.9	21.6	41.0	28.8
J-3			93.6	118.5	113.6	166.7	101.5	118.8
L1				95.2	122.6	227.4	127.2	143.1
L2					60.2	58.9	91.8	70.3
L3				100.2	102.2	142.1	94.5	109.7
L4					77.4	92.1	115.4	95.0
M1				167.9	156.1	131.4	159.8	153.8
M3					4.6	4.3	4.2	4.4
M4					106.1	78.3	104.0	96.1
N1					42.5	34.5	80.1	52.4
N2				50.7	49.6	87.1	62.5	62.5
N3					72.7	69.7	77.3	73.2
N4				45.2	42.4	43.5	51.3	45.6
01				41.5	43.8	35.3	11.4	33.0
02				96.6	42.9	109.5	117.3	91.6
03				53.7	66.5	45.6	151.3	79.3
04				157.1	63.8	54.9	188.3	116.0
05						153.7	134.3	144.0
07						142.0	216.5	179.2
Q1	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Q2			166.3	186.0	176.6	138.0	140.5	161.5
Q3					115.3	138.5	138.3	130.7
Q4						198.8	188.6	193.7
R3					95.8	208.0	244.3	182.7
R4					83.7	64.9	42.0	63.5
R5						205.3	274.9	240.1
S1				150.9	115.3	97.3	186.9	137.6
S2				192.9	181.9	233.0	216.2	206.0
T1						173.3	169.2	171.3
T2				226.5	181.1	130.8	219.4	189.5
U1					104.2	165.3	217.6	162.3
U2					119.8	122.6	218.0	153.5
V1					147.0	207.3	288.0	214.1
V2					225.3	215.0	251.0	230.4
W1				129.3	200.6	263.6	152.0	186.4
W2		l		l	125.9	125.7	184.5	145.4

				T-R			
Patient			%0	f V1			MEAN
H				31.9	32.6	34.9	33.1
H2				44.6	47.5	54.3	48.8
H3			52.7	53.5	66.5	64.1	59.2
1-1				45.9	44.5	43.4	44.6
1-2	56.0	64.8	43.0	40.5	51.5	35.1	48.5
I-3			43.3	42.7	29.3	32.2	36.9
4				24.3	24.4	18.2	22.3
J-1			78.0	66.2	80.9	83.8	77.2
J-2				64.8	55.1	44.8	54.9
3.3		74.2	64.0	62.4	73.1	87.1	72.2
L1					85.6	77.4	81.5
L2			84.2	80.5	86.5	93.2	86.1
L3			77.8	72.1	61.6	81.6	73.3
L4			79.0	70.5	82.2	82.3	78.5
M1				43.2	37.9	41.8	41.0
M3			22.0	22.3	21.1	18.9	21.1
M4				57.8	42.3	45.7	48.6
N1			73.6	61.4	84.1	88.0	76.8
N2				75.7	80.6	78.6	78.3
N3				102.2	95.9	108.0	102.0
N4			56.3	55.7	76.5	55.9	61.1
01			40.0	61.6	46.1	43.1	47.7
02				81.7	85.7	90.1	85.8
03			67.0	77.0	90.8	93.7	82.1
04		80.5	81.2	84.9	93.8	97.9	87.7
05			100.2	85.9	89.7	95.0	92.7
07				67.1	71.1	79.1	72.4
Q1			83.6	76.2	85.0	99.4	86.1
Q2			93.4	102.4	103.9	119.0	104.7
Q3	69.1	65.4	91.4	67.6	71.4	74.1	73.2
Q4				77.3	70.4	82.6	76.8
R3				117.8	101.2	107.9	109.0
R4			87.2	75.4	84.6	97.8	86.2
R5			80.3	79.4	83.4	122.1	91.3
S1			108.7	99.1	116.1	118.3	110.6
S2		102.9	89.2	116.9	119.2	116.5	108.9
T1		120.1	104.1	113.7	129.4	119.7	117.4
T2			118.7	112.9	127.8	122.0	120.4
U1		84.5	66.8	75.1	126.9	103.6	91.4
U2			107.0	101.2	117.9	112.0	109.5
V1	100.0	100.0	100.0	100.0	100.0	100.0	100.0
V2		111.0	100.6	104.7	117.9	114.4	109.7
W1			102.0	113.8	121.5	118.2	113.9
W2		92.1	107.5	101.6	115.0	96.9	102.6
.,,,		V2.1	107.0	101.0		J-3.5	.02.0

Patient H1			%0				
			,,,,	• • •			MEAN
					27.0	46.7	36.9
H2				51.5	62.7	70.4	61.5
H3					73.0	73.8	73.4
1-1				77.8	61.7	72.6	70.7
1-2					51.4	56.5	53.9
I-3					58.5	69.7	64.1
1-4					56.4	67.2	61.8
J-1			41.2	43.3	54.9	67.6	51.7
J-2					55.3	42.6	48.9
j.				56.8	61.7	75.2	64.5
L1			43.6	57.5	63.6	67.0	57.9
L2				80.4	76.0	91.4	82.6
L3				87.9	87.8	98.6	91.5
L4				87.2	68.3	75.9	77.1
M1				76.4	90.0	87.7	84.7
M3				118.5	80.7	108.1	102.4
M4			43.9	60.7	66.4	63.1	58.5
N1				67.4	79.6	76.5	74.5
N2			65.5	58.4	72.5	81.7	69.5
N3				71.8	70.9	85.2	75.9
N4		30.3	16.9	46.6	46.1	31.8	34.3
01				83.8	60.3	76.4	73.5
02				75.0	72.3	77.4	74.9
03				74.5	72.2	79.3	75.3
04				69.9	51.4	70.2	63.8
O5		49.8	93.2	68.2	85.9	73.6	74.2
07				83.8	73.3	88.3	81.8
Q1			98.8	62.7	98.3	79.8	84.9
Q2		91.1	77.3	102.2	99.7	100.8	94.2
Q3				71.5	62.4	66.2	66.7
Q4	68.5	60.6	96.9	78.0	73.7	82.9	76.7
R3		33.1	64.9	74.7	51.4	74.6	59.7
R4			98.1	81.9	92.3	103.7	94.0
R5			66.6	42.8	72.9	68.6	62.7
S1				95.2	105.6	93.2	98.0
S2				78.4	86.0	99.7	88.0
T1		129.5	91.3	102.2	77.7	100.1	100.2
T2		69.6	73.3	93.1	84.7	95.1	83.2
U1			63.1	51.1	77.3	65.0	64.1
U2				78.1	79.5	87.6	81.7
V1	100.0	100.0	100.0	100.0	100.0	100.0	100.0
V2				93.0	98.1	107.1	99.4
W1			105.0	94.9	91.2	92.2	95.8
W2		111.0	62.2	103.1	99.2	75.4	90.2

Regression coefficients from univariable analysis of MDMX protein band intensity (relative to internal reference individual Q1)

(relative to internal reference marvidual	<u>Q 1 j</u>	
Covariate	Regression Coefficient (95% CI)	P-value
Age	1.94 (-0.79, 4.67)	0.17
Gravidity	9.66 (3.59, 15.70)	3x10 ⁻³
Gestational Age	-1.79 (-12.40, 8.86)	0.74
Body Mass Index in Labor and Delivery		
Suite	0.97 (-0.18, 2.13)	0.11
Race		
White	(REF)	
Black	22.20 (-14.85, 59.26)	0.24
Asian	-32.49 (-133.62, 68.64)	0.53
Unknown	-3.74 (-77.21, 69.73)	0.92
Hispanic	-0.66 (-37.72, 36.39)	0.97
Preeclampsia		
No	(REF)	
Yes	-44.13 (-71.63, -16.64)	3x10 ⁻³
Diabetes		
No	(REF)	
Type II	47.63 (14.27, 90.00)	8x10 ⁻³
GDM	47.91 (5.51, 90.32)	0.03
Mode of Delivery		
SVD	(REF)	
CD prior to onset of Labor	56.16 (24.13, 88.18)	1x10 ⁻³
CD after onset of Labor	34.80 (-4.46, 74.07)	0.09
VBAC	5.55 (-85.70, 96.79)	0.91
Neonate Sex		
Female	(REF)	
Male	5.04 (-24.35, 34.43)	0.74
Neonatal Weight (g)	0.03 (0.01, 0.06)	3x10 ⁻³

Table 7

Regression coefficients from univariable analysis of PICALM protein band intensity (relative to internal reference individual Q1)

ntensity (relative to internal reference individual Q1)				
Covariate	Regression Coefficient (95% CI)	P-value		
Age	3.68 (0.28, 7.08)	0.04		
Gravidity	7.64 (-0.68, 15.95)	0.08		
Gestational Age	6.88 (-6.62, 20.37)	0.32		
Body Mass Index in Labor and Delivery				
Suite	2.06 (0.66, 3.45)	6x10 ⁻³		
Race				
White	(REF)			
Black	17.33 (-24.11, 60.77)	0.44		
Asian	17.49 (-101.07, 136.05)	0.77		
Unknown	-75.81 (-161.94, 10.32)	0.09		
Hispanic	-46.39 (-89.82, -2.95)	0.04		
Preeclampsia				
No	(REF)			
Yes	-35.60 (-73.25, 2.04)	0.07		
Diabetes				
No	(REF)			
Type II	23.28 (-23.57, 70.13)	0.34		
GDM	38.05 (-21.50, 97.60)	0.22		
Mode of Delivery				
SVD	(REF)			
CD prior to onset of Labor	59.96 (19.24, 100.68)	6x10 ⁻³		
CD after onset of Labor	5.69 (-44.23, 55.62)	0.82		
VBAC	-50.27 (-166.29, 65.75)	0.40		
Neonate Sex				
Female	(REF)			
Male	19.10 (-18.16, 56.37)	0.32		
Neonatal Weight (g)	0.03 (7x10 ⁻⁷ , 0.06)	0.06		

Table 8

Regression coefficients from univariable analysis of OT-R protein band intensity (relative to internal reference individual T1)

(relative to internal reference individual 1	1)	
Covariate	Regression Coefficient (95% CI)	P-value
Age	1.56 (0.13, 2.99)	0.04
Gravidity	1.02 (-2.60, 4.64)	0.58
Gestational Age	1.73 (-4.00, 7.45)	0.56
Body Mass Index in Labor and Delivery		
Suite	0.55 (-0.07, 1.17)	0.09
Race		
White	REF	REF
Black	-10.77 (-30.15, 8.61)	0.28
Asian	-6.04 (-58.92, 46.85)	0.82
Unknown	-27.94 (-66.36, 10.49)	0.16
Hispanic	-19.53 (-38.90, -0.15)	0.06
Preeclampsia		
No	REF	REF
Yes	-15.28 (-31.12, 0.54)	0.07
Diabetes		
No	REF	REF
Type 2	24.16 (5.47, 42.85)	0.02
GDM	15.32 (-8.44, 39.07)	0.21
Mode of Delivery		
SVD	REF	REF
CD prior to onset of Labor	21.82 (4.09, 39.55)	0.02
CD after onset of Labor	0.55 (-21.19, 22.29)	0.96
VBAC	-19.308 (-69.60, 31.44)	0.46
Neonatal Sex		
Female	REF	REF
Male	8.56 (-7.11, 24.23)	0.29
Neonatal Weight (g)	0.01 (8.36x10 ⁻⁴ , 0.03)	0.04

Table 9

Regression coefficients from univariable analysis of V1aR protein band intensity (relative to internal reference individual T1)

(relative to internal reference individual i	1/	
Covariate	Regression Coefficient (95% CI)	P-value
Age	0.63 (-0.30, 1.56)	0.19
Gravidity	1.84 (-0.38, 4.07)	0.11
Gestational Age	-0.72 (-4.34, 2.90)	0.70
Body Mass Index in Labor and Delivery		
Suite	0.20 (-0.20, 0.60)	0.34
Race		
White	REF	REF
Black	7.77 (-4.51, 20.04)	0.22
Asian	-15.55 (-49.05, 17.94)	0.37
Unknown	-13.74 (-38.07, 10.60)	0.28
Hispanic	-0.24 (-12.52, 12.03)	0.97
Preeclampsia		
No	REF	REF
Yes	-5.17 (-15.46, 5.12)	0.33
Diabetes		
No	REF	REF
Type 2	11.84 (-0.34, 24.03)	0.06
GDM	7.67 (-7.82, 23.16)	0.34
Mode of Delivery		
SVD	REF	REF
CD prior to onset of Labor	20.36 (10.58, 30.13)	6x10 ⁻³
CD after onset of Labor	-1.05 (-13.04, 10.93)	0.86
VBAC	-9.60 (-18.26, 37.44)	0.50
Neonatal Sex		
Female	REF	REF
Male	-4.53 (-14.46, 5.40)	0.38
Neonatal Weight (g)	5x10 ⁻³ (-3.00x 10 ⁻³ , 0.013)	0.23

Table 10

Regression coefficients from multivariable analysis of MDMX protein band intensity (relative to internal reference individual Q1)

interiors, (resistance to interiors in artificial 4.1)			
Covariate	Regression Coefficient (95% CI)	P-value	
Gravidity	7.19 (1.24, 13.14)	0.02	
Preeclampsia			
No	(REF)		
Yes	-40.61 (-66.18, -15.04)	3x10 ⁻³	
Diabetes			
No	(REF)		
Type II	20.10 (-16.80, 57.00)	0.29	
GDM	31.20 (-8.81, 71.22)	0.14	
Mode of Delivery			
SVD	(REF)		
CD prior to onset of Labor	9.05 (-26.72, 44.83)	0.62	
CD after onset of Labor	27.22 (-8.08, 62.52)	0.14	
VBAC	-15.92 (-93.98, 62.13)	0.69	
Neonatal Weight (g)	0.01 (-0.01, 0.04)	0.37	

Regression coefficients from multivariable analysis of PICALM protein band intensity (relative to internal reference individual Q1)

	· ·	
Covariate	Regression Coefficient (95% CI)	P-value
Age	1.73 (-1.64, 5.09)	0.32
Body Mass Index in Labor and Delivery		
Suite	1.35 (-0.07, 2.77)	0.07
Mode of Delivery		
SVD	(REF)	
CD prior to onset of Labor	40.00 (-3.85, 83.85)	0.08
CD after onset of Labor	0.82 (-48.29, 49.93)	0.97
VBAC	-37.87 (-151.23, 75.48)	0.52

Regression coefficients from multivariable analysis of OT-R protein band intensity (relative to internal reference individual T1)

	· · · · · ,	
Covariate	Regression Coefficient (95% CI)	P-value
Age	0.71 (-0.83, 2.35)	0.39
Diabetes		
No	REF	REF
Type 2	14.0 (-11.14, 37.70)	0.27
GDM	5.64 (-21.43, 32.00)	0.68
	·	
Mode of Delivery		
SVD	REF	REF
CD prior to onset of Labor	13.25 (-7.83, 34.33)	0.23
CD after onset of Labor	-1.04 (-23.92, 21.84)	0.93
VBAC	-0.17 (-68.44, 34.32)	0.52
Neonatal Weight (g)	4.05x 10 ⁻⁴ (-0.02, 0.02)	0.96

Regression coefficients from bootstrapped replicates of univariable analysis of MDMX protein band intensity (relative to internal reference individual Q1)

MUMIX protein band intens	MDMX protein band intensity (relative to internal reference individual Q1)				
	(95% quantiles of point	Percentage of replicates			
Covariate	estimate from bootstrapped	<0.05 (95% quantiles of P-			
	replicates)	value)			
Age	(0.43, 2.90)	1.7% (0.05, 0.77)			
Gravidity	(6.82, 12.15)	95.5% (8x10 ⁻⁴ , 0.06)			
Gestational Age	(-6.88, 1.78)	0% (0.25, 0.97)			
Body Mass Index in Labor					
and Delivery Suite	(0.60, 1.50)	12.6% (0.03, 0.34)			
Race					
White	(REF)				
Black	(5.10, 39.4)	0.9% (0.07, 0.80)			
Asian	(-53.55, -6.43)	0% (0.33, 0.91)			
Unknown	(-30.86, 17.09)	0% (0.46, 0.99)			
Hispanic	(-19.69, 13.18)	0% (0.32, 0.99)			
Preeclampsia					
No	(REF)				
Yes	(-54.91, -28.15)	91.2% (9x10 ⁻⁴ , 0.08)			
Diabetes					
No	(REF)				
Type II	(24.47, 60.41)	60% (2x10 ⁻³ , 0.23)			
GDM	(24.83, 67.47)	44.8% (7x10 ⁻³ ,0.30)			
Mode of Delivery					
SVD	(REF)				
CD prior to onset of Labor	(38.96, 67.36)	98.6% (5x10 ⁻⁴ , 0.04)			
CD after onset of Labor	(17.16, 55.75)	15.5% (0.18, 0.46)			
VBAC	(-25.22, 55.19)	0% (0.28, 0.99)			
Neonate Sex	(=\)				
Female	(REF)	00/ (0.00.00)			
Male	(-10.62, 15.81)	0% (0.32, 0.99)			
Neonatal Weight (g)	(0.02, 0.05)	85.8% (3x10 ⁻⁴ , 0.14)			

Regression coefficients from bootstrapped replicates of univariable analysis of PICALM protein band intensity (relative to internal reference individual Q1)

i loatin protein band intens	ity (relative to internal rele	rence marvidual &1)
	(95% quantiles of point	Percentage of replicates
Covariate	estimate from	<0.05 (95% quantiles of P-
	bootstrapped replicates)	value)
Age	(2.19, 5.17)	41% (7.1x10 ⁻³ , 0.27)
Gravidity	(3.42, 11.80)	22% (0.01, 0.46)
Gestational Age	(1.82, 11.72)	0.1% (0.11, 0.82)
Body Mass Index in Labor		
and Delivery Suite	(1.41, 2.66)	90% (8x10 ⁻⁴ , 0.09)
Race		
White	(REF)	
Black	(-7.10, 40.07)	0% (0.12, 0.97)
Asian	(-40.69,111.00)	0% (0.9, 0.99)
Unknown	(-96.07, -53.30)	2% (0.05, 0.28)
Hispanic	(-64.85, -29.39)	40% (0.01, 0.24)
Preeclampsia		
No	(REF)	
Yes	(-52.30, -18.88)	20.3% (0.01, 0.37)
Diabetes		
No	(REF)	
Type II	(2.82, 45.52)	0.6% (0.08, 0.91)
GDM	(23.35, 56.54)	0.6% (0.08, 0.51)
Mode of Delivery		
SVD	(REF)	
CD prior to onset of Labor	(41.39, 79.89)	88.5% (9x10 ⁻⁴ , 0.08)
CD after onset of Labor	(-17.08, 31.02)	0% (0.26, 0.99)
VBAC	(-82.60, -27.18)	0% (0.22, 0.67)
Neonate Sex		
Female	(REF)	
Male	(3.42, 35.19)	0.3% (0.10, 0.84)
Neonatal Weight (g)	(0.01, 0.05)	35.1% (3x10-3, 0.40)

Regression coefficients from bootstrapped replicates of univariable analysis of OT-R protein band intensity (relative to internal reference individual T1)

OT-R protein band intensity (r	OT-R protein band intensity (relative to internal reference individual 11)			
	(95% quantiles of point	Percentage of replicates		
Covariate	estimate from	<0.05 (95% quantiles of P-		
	bootstrapped replicates)	value)		
Age	(1.17, 2.01)	54.7% (0.01, 0.14)		
Gravidity	(0.15, 2.08)	0% (0.29, 0.93)		
Gestational Age	(-0.00, 3.40)	0% (0.26, 0.96)		
Body Mass Index in Labor				
and Delivery Suite	(0.34, 0.77)	15% (0.02, 0.30)		
Race				
White	REF	REF		
Black	(-17.36, -3.71)	0% (0.09, 0.74)		
Asian	(-13.48, 1.09)	0% (0.62, 0.99)		
Unknown	(-33.74, -21.97)	0% (0.10, 0.30)		
Hispanic	(-24.88, -14.18)	32% (0.02, 0.18)		
Preeclampsia				
No	REF	REF		
Yes	(-20.16, -10.62)	24% (0.02, 0.22)		
Diabetes				
No	REF	REF		
Type 2	(17.21, 31.63)	84% (0.00, 0.10)		
GDM	(8.96, 22.63)	1% (0.07, 0.48)		
Mode of Delivery				
SVD	REF	REF		
CD prior to onset of Labor	(16.54, 27.71)	83% (0.01, 0.09)		
CD after onset of Labor	(-5.28, 6.19)	0% (0.57, 0.99)		
VBAC	(-29.34, -2.46)	0% (0.27, 0.93)		
Neonatal Sex				
Female	REF	REF		
Male	(4.20, 13.13)	0% (0.11, 0.62)		
Neonatal Weight (g)	(0.01, 0.02)	49% (0.01, 0.17)		

Regression coefficients from bootstrapped replicates of univariable analysis of V1aR protein band intensity (relative to internal reference individual T1)

viak protein band intensity (relative to internal reference individual 11)			
	(95% quantiles of point	Percentage of replicates	
Covariate	estimate from	<0.05 (95% quantiles of P-	
	bootstrapped replicates)	value)	
Age	(0.17, 1.12)	6% (0.03, 0.74)	
Gravidity	(0.48, 3.04)	14% (0.02, 0.71)	
Gestational Age	(-2.20, 0.98)	0% (0.30, 0.98)	
Body Mass Index in Labor			
and Delivery Suite	(-0.03, 0.43)	2% (0.07, 0.93)	
Race			
White	REF	REF	
Black	(1.07, 14.58)	3% (0.04, 0.88)	
Asian	(-32.74, -3.26)	0% (0.09, 0.87)	
Unknown	(-24.28, -1.85)	0% (0.09, 0.89)	
Hispanic	(-7.10, 7.06)	0% (0.26, 0.99)	
Preeclampsia			
No	REF	REF	
Yes	(-11.01, 0.40)	2% (0.07, 0.94)	
Diabetes			
No	REF	REF	
Type 2	(5.78, 19.09)	23% (9x10 ⁻³ , 0.41)	
GDM	(-4.01, 18.40)	4% (0.04, 0.95)	
Mode of Delivery			
SVD	REF	REF	
CD prior to onset of Labor	(14.50, 26.60)	100% (4x10 ⁻⁵ , 2x10 ⁻²)	
CD after onset of Labor	(-7.93, 5.70)	0% (0.26, 0.99)	
VBAC	(-7.09, 23.62)	0% (0.16, 0.97)	
Neonatal Sex			
Female	REF	REF	
Male	(-9.92, 0.86)	0% (0.11, 0.93)	
Neonatal Weight (g)	(1.0x 10 ⁻³ , 9.0x 10 ⁻³)	2% (0.05, 0.82)	

Regression coefficients from bootstrapped replicates of multivariable analysis of MDMX protein band intensity (relative to internal reference individual Q1)

indinix protein band intensity (relative to internal reference marviadal & 1)			
	(95% quantiles of point	Percentage of replicates	
Covariate	estimate from	<0.05 (95% quantiles of P-	
	bootstrapped replicates)	value)	
Gravidity	(4.17, 9.81)	44% (0.01, 0.28)	
Preeclampsia			
No	REF		
Yes	(-54.42, -22.05)	80% (1x10 ⁻³ , 0.17)	
Diabetes			
No	(REF)		
Type II	(-7.15, 35.26)	1% (0.10, 0.97)	
GDM	(7.02, 50.01)	5% (0.04, 0.78)	
Mode of Delivery			
SVD	(REF)		
CD prior to onset of Labor	(-7.87, 27.66)	0% (0.22, 0.98)	
CD after onset of Labor	(7.62, 49.52)	8% (0.03, 0.69)	
VBAC	(-45.98, 36.55)	0% (0.32, 0.86)	
Neonatal Weight (g)	(-0.002, 0.03)	2% (0.07, 0.96)	

Regression coefficients from bootstrapped replicates of multivariable analysis of PICALM protein band intensity (relative to internal reference individual Q1)

	(95% quantiles of point Percentage of replicates	
Covariate	estimate from	<0.05 (95% quantiles of P-
	bootstrapped replicates)	value)
Age	(0.09, 3.35)	1% (0.07, 0.93)
Body Mass Index in Labor		
and Delivery Suite	(0.55, 2.11)	26% (0.008, 0.54)
Mode of Delivery		
SVD	REF	
CD prior to onset of Labor	(17.36, 62.80)	20% (0.02, 0.48)
CD after onset of Labor	(-23.42, 26.23)	0% (0.31, 0.99)
VBAC	(-70.1712.72)	0% (0.29, 0.84)

Regression coefficients from bootstrapped replicates of multivariable analysis of OT-R protein band intensity (relative to internal reference individual T1)

<u> </u>		<u> </u>
	(95% quantiles of point	Percentage of replicates
Covariate	estimate from	<0.05 (95% quantiles of P-
	bootstrapped replicates)	value)
Age	(0.27, 1.17)	0% (0.17, 0.76)
Diabetes		
No	REF	REF
Type 2	(6.09, 21.30)	0% (0.10, 0.65)
GDM	(-1.66, 14.21)	0% (0.32, 0.99)
Mode of Delivery		
SVD	REF	REF
CD prior to onset of Labor	(7.33, 19.97)	0% (0.09, 0.51)
CD after onset of Labor	(-6.97, 4.89)	0% (0.55, 0.99)
VBAC	(-27.20, -0.44)	0% (0.32, 0.98)
Neonatal Weight (g)	(-4x 10 ⁻³ , 5x 10 ⁻³)	0% (0.52, 0.99)

Table 20 Autoantigens listed by Neiman et al. among the proteins in VEGFR2, MDMX, and PICALM immunoprecipitations (IP).

	Uniprot	Gene	Protein name	Autoimmune disease
VEGFR2 IP	P01023	A2M	Alpha-2-macroglobulin (Alpha-2-M)	Sjögren's syndrome
	E7EVS6	ACTB	Actin, cytoplasmic 1 (Beta-actin)	Autoimmune hemolytic anemia
	P07355	ANXA2	Annexin A2 (Annexin II) (Annexin-2)	Antiphospholipid syndrome
	P08758	ANXA5	Annexin A5 (Anchorin CII)	Antiphospholipid syndrome
	P11182	DBT	Lipoamide acyltransferase BCOADC-E2	Primary biliary cholangitis
	P17661	DES	Desmin	Sjögren's syndrome
	P10515	DLAT	PDC-E2	Primary biliary cirrhosis
	Q02413	DSG1	Desmoglein-1	Pemphigus foliaceus
	P19474	TRIM21	E3 ubiquitin-protein ligase TRIM21	Sjögren's syndrome; Systemic Lupus Erythematosus
	Q8WZ42	TTN	Titin	Myasthenia gravis
	P08670	VIM	Vimentin	Rheumatoid arthritis
MDMX IP	P01023	A2M	Alpha-2-macroglobulin (Alpha-2-M)	Sjögren's syndrome
	P68133	ACTA1	Actin, alpha skeletal muscle	Autoimmune hemolytic anemia; myashenia gravis
	P07355	ANXA2	Annexin A2 (Annexin II) (Annexin-2)	Antiphospholipid syndrome
	P08758	ANXA5	Annexin 5	Antiphospholipid syndrome
	P11182	DBT	Lipoamide acyltransferase BCOADC-E2	Primary biliary cirrhosis
	Q6P0N6	DST	Dystonin	Bollous pemphigoid
	P06733	ENO1	α-Enolase	Multiple sclerosis
	P35579	MYH9	Myosin-9	Multiple sclerosis
	P08559	PDHA1	Pyruvate dehydrogenase E1-A type 1	Primary biliary cholangitis
	P21980	TGM2	Isopeptidase TGM2	Celiac's disease
	Q08188	TGM3	Transglutaminase-3	Dermatitis herpetiformis
	P29401	TKT	Transketolase	Multiple sclerosis
	P19474	TRIM21	E3 ubiquitin-protein ligase TRIM21	Sjögren's syndrome; Systemic Lupus Erythematosus
	P18206	VCL	Vinculin	Myasthenia gravis
PICALM IP	P01023	A2M	Alpha-2-macroglobulin (Alpha-2-M)	Sjögren's syndrome
	E7EVS6	ACTB	Actin, cytoplasmic 1 (Beta-actin)	Autoimmune hemolytic anemia
	P63261	ACTG1	Actin, cytoplasmic 2/γ-actin	Autoimmune hemolytic anemia; myashenia gravis
	P63267	ACTG2	Alpha-actin-2	Autoimmune hemolytic anemia; myashenia gravis
	P07355	ANXA2	Annexin A2 (Annexin II) (Annexin-2)	Antiphospholipid syndrome
	P08758	ANXA5	Annexin A5 (Anchorin CII)	Antiphospholipid syndrome
	P17661	DES	Desmin	Sjögren's syndrome
	P36957	DLST	2-oxoglutarate dehydrogenase E2	Pernicuous anemia
	Q08554	DSC1	Desmocollin-1	IgA pemphigus
	Q02413	DSG1	Desmoglein-1	Pemphigus foliaceus
	Q02413			i ciripingus ioliaceus
	Q9Y285		•	Schizophrenia
			Phenylalanyl-tRNA synthetase α-subunit	· · · · · · · · · · · · · · · · · · ·
	Q9Y285	FARSA OGDH	Phenylalanyl-tRNA synthetase α-subunit 2-oxoglutarate dehydrogenase E1	Schizophrenia Pernicuous anemia
	Q9Y285 Q02218	FARSA OGDH	Phenylalanyl-tRNA synthetase α-subunit	Schizophrenia
	Q9Y285 Q02218 Q5JPU3	FARSA OGDH PDHA1	Phenylalanyl-tRNA synthetase α-subunit 2-oxoglutarate dehydrogenase E1 Pyruvate dehydrogenase E1-A type 1	Schizophrenia Pernicuous anemia Primary biliary cholangitis
	Q9Y285 Q02218 Q5JPU3 P21980	FARSA OGDH PDHA1 TGM2 TKT	Phenylalanyl-tRNA synthetase α-subunit 2-oxoglutarate dehydrogenase E1 Pyruvate dehydrogenase E1-A type 1 Isopeptidase TGM2 Transketolase	Schizophrenia Pernicuous anemia Primary biliary cholangitis Celiac's disease Multiple sclerosis
	Q9Y285 Q02218 Q5JPU3 P21980 P29401	FARSA OGDH PDHA1 TGM2 TKT TRIM21	Phenylalanyl-tRNA synthetase α-subunit 2-oxoglutarate dehydrogenase E1 Pyruvate dehydrogenase E1-A type 1 Isopeptidase TGM2 Transketolase E3 ubiquitin-protein ligase TRIM21	Schizophrenia Pernicuous anemia Primary biliary cholangitis Celiac's disease Multiple sclerosis Sjögren's syndrome; Systemic Lupus Erythematosus
	Q9Y285 Q02218 Q5JPU3 P21980 P29401 P19474	FARSA OGDH PDHA1 TGM2 TKT TRIM21	Phenylalanyl-tRNA synthetase α-subunit 2-oxoglutarate dehydrogenase E1 Pyruvate dehydrogenase E1-A type 1 Isopeptidase TGM2 Transketolase	Schizophrenia Pernicuous anemia Primary biliary cholangitis Celiac's disease Multiple sclerosis

Table 21Patient demographics

Clinical characteristics	Study subjects (n=44)	% of n
Maternal Age		
18-34	40	91%
≥35	4	9%
BMI		
Underweight (<18.5)	0	0%
Normal (18.5-24.9)	3	7%
Overweight (25-29.9)	9	20%
Obesity I (30-34.9)	12	27%
Obesity II (35-35.9)	5	11%
Extreme Obesity (≥40)	15	34%
Parity		
Nulliparous	11	25%
Multiparous	33	75%
Gestational Age at Delivery		
< 37 weeks	4	9%
≥ 37 weeks	40	91%
Race		
White	17	39%
African American	12	27%
Hispanic	12	27%
Other	3	7%
Diabetes	14	32%
Type 1	0	0%
Type 2	9	20%
Gestational	5	11%
Chronic Hypertension	6	14%
Normotensive	28	64%
Preeclampsia	16	36%
Preeclampsia and Diabetes	4	9%